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Summary 
  
 Preclinical mouse models of Alzheimer’s disease capture cognitive impairments which can 
be attributed to β-amyloid (Aβ) pathology. Aβ pathology may also be an antecedent of depressive 
symptoms in these mouse models, though this has been less rigorously investigated. This thesis 
reports a longitudinal investigation of both the depressive symptom of anhedonia (a reduction in 
pleasurable reactions), and memory of specific object-location associations, in the Tg2576 mouse 
model of Alzheimer’s disease. The effectiveness of sub-anaesthetic ketamine, largely as an anti-
depressant treatment, was also examined in anhedonic and cognitively impaired Tg2576 mice. 
Possible biochemical underpinnings of these deficits were then investigated, namely the glutamate, 
serotonin and opioid signalling systems. Tg2576 mice displayed an age-dependent reduction in 
hedonic reactions, consistent with an Aβ-related deficit. While object-in-place testing did not 
explicitly reveal an age-dependent dysfunction, Tg2576 mice were only impaired later in life, 
consistent with aging and Aβ underlying their diminished performance. An additional T-maze task 
revealed that aged Tg2576 mice retained a preference for spatial novelty. 
 While ketamine treatment increased expression of measures relating to the AMPA receptor 
GluR1 subunit, it did not improve hedonic or cognitive dysfunction in Tg2576 mice. Tg2576 mice 
displayed a relative reduction in Y1472 phosphorylation of the NMDA receptor NR2B subunit in the 
hippocampus, suggesting an NMDAR-mediated dysfunction underlying their object-in-place deficit. 
Investigation of the opioid system in Tg2576 mice revealed elevations of cortical kappa and 
hippocampal mu receptor expression. An unbalanced opioid system may therefore diminish hedonic 
tone in Tg2576 mice. Tg2576 mice also displayed elevated cortical serotonin transporter expression, 
though the relation of this to behavioural deficits was less clear. This thesis demonstrates that Aβ 
and its potential effects on the glutamate and opioid systems can underlie both amnesic and 
affective symptoms in Tg2576 mice, though an attempt to remedy these impairments was 
unsuccessful.
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Chapter 1: Introduction 
 
1.1 Alzheimer’s disease 
1.1.1 Background 
Alzheimer’s disease, first described in 1906 by Alois Alzheimer, is the commonest form of 
dementia, making up ~62% of dementia cases in the UK (Alzheimer’s Society, 2014), and 
characterised by the presence of β-amyloid (Aβ) plaques and neurofibrillary tau tangles in the brain 
(Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). Dementia is a syndrome comprising various 
symptoms, characterised by a marked cognitive decline that is sufficient to impede the independent 
activities of daily living (Sachdev et al., 2014). Dementia is both a devastating and costly disease 
syndrome, with no curative treatment currently available. Patients progressively deteriorate over 
years or decades until death, with a societal cost estimated financially as £26 billion in the UK each 
year, and $817 billion globally (Alzheimer’s Research UK, 2017). The number of people living with 
dementia is projected to rise from 50 million in 2018 to 152 million in 2050, meaning effective 
therapies will only become more and more vital (World Health Organisation, 2017). Causes of 
dementia including Alzheimer’s disease place an immense personal and financial burden on 
caregivers of dementia patients (Förstl & Kurz, 1999; Haro et al., 2014). 
Alzheimer’s disease is largely an age-related phenomenon; its prevalence rises with age, 
notably so after the age of 65 (Mayeux & Stern, 2012). Between 60 and 85 years of age, prevalence 
increases almost 15-fold, and estimates suggest that the incidence rate of Alzheimer’s disease 
roughly doubles every 5 years after the age of 60 (Launer et al., 1999; Mayeux & Stern, 2012). In the 
absence of effective interventions, the burden of late-onset dementia (the majority of which is due 
to Alzheimer’s disease) is projected to worsen in the UK (Lewis & Torgerson, 2017). Alzheimer’s 
disease is thus a medical condition in urgent need of investigation, an urgency which is only set to 
increase with time. 
The onset of Alzheimer’s disease can be early (under the age of 65) or late (at or over 65); 
early-onset cases tend to be more severe and progress rapidly in comparison to late-onset 
Alzheimer’s disease (Reitz, Brayne, & Mayeux, 2011). While not all the causes of early-onset 
Alzheimer’s disease are known, one underlying cause is inherited autosomal dominant mutations 
with a high penetrance, in cases referred to as familial Alzheimer’s disease (Reitz et al., 2011). Cases 
of Alzheimer’s disease which do not result from heritable high penetrance genetic mutations are 
known as sporadic Alzheimer’s disease. Familial and sporadic Alzheimer’s disease share a similar 
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clinical presentation (Duara et al., 1993), and the same underlying neuropathology (accumulated Aβ 
and tau formations) (Lippa et al., 1996). Familial Alzheimer’s disease cases make up roughly 5% of all 
Alzheimer’s disease cases, and the causative autosomal dominant genetic mutations can occur at 
three genetic loci – amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) 
(Bekris, Yu, Bird, & Tsuang, 2010). These genetic mutations either lead to an increase in total Aβ 
production, or increase production of Aβ42 relative to Aβ40 (Bekris et al., 2010; Citron et al., 1997; 
Potter et al., 2013; Scheuner et al., 1996). Sporadic Alzheimer’s disease cases comprise the majority 
of Alzheimer’s disease patients, with genetic and other risk factors being the underlying causes, 
most likely due to their affecting either the production or clearance of Aβ. The most significant 
genetic risk factor is the ε4 polymorphism of the apolipoprotein E (APOE) gene (Corder et al., 1993; 
Liu, Liu, Kanekiyo, Xu, & Bu, 2013); two copies of the APOEε4 allele confer a greatly increased risk of 
developing Alzheimer’s disease (Liu et al., 2013). Genes associated with a smaller degree of risk 
include TREM2, PICALM, ABCA7 and BIN1 (Jonsson et al., 2013; Tanzi, 2012). Outside of genetics, 
biological changes that occur with aging may increase the risk of Alzheimer’s disease, such as poorer 
clearance or degradation of the Aβ protein with age (Silverberg et al., 2010), diminished blood-brain 
barrier integrity in the elderly (Marques, Sousa, Sousa, & Palha, 2013), or other factors. 
 
1.1.2 Symptoms of Alzheimer’s disease 
Alzheimer’s disease exhibits a wide range of symptoms, which typically worsen with disease 
progression, with the cardinal and most well-known being memory decline. In addition to this well-
recognised memory impairment, Alzheimer’s disease patients exhibit a number of psychiatric 
symptoms, including psychosis and depression (Lopez et al., 2003). While the linkage between 
disease pathology and impaired memory has been the focus of much research (see, for example, 
Section 1.1.6), it remains unclear how the pathological processes underlying Alzheimer’s disease 
could cause depression or certain symptoms thereof. The pathological cascade leading to 
Alzheimer’s disease is thought to begin with Aβ (see Section 1.1.4), and a major aim of this thesis is 
to investigate whether the accumulation of Aβ is sufficient to induce depressive behaviour in a 
mouse model of Alzheimer’s disease. The memory-related symptoms of Alzheimer’s disease are 
discussed immediately below, and the depressive symptoms of Alzheimer’s disease are discussed in 
Section 1.2.2. 
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1.1.2.1 Memory decline in Alzheimer’s disease 
In its clinical presentation, Alzheimer’s disease typically manifests initially with impairments 
in anterograde episodic memory (Galton, Patterson, Xuereb, & Hodges, 2000), and (to some extent) 
semantic memory (Hodges & Patterson, 1995). Memory degradation in early Alzheimer’s disease 
leads to difficulties in performing activities of daily living, as the planning and organising of tasks 
becomes compromised, leading to the individual requiring some type of support system (Förstl & 
Kurz, 1999). As the course of the disease progresses, impairments in recent memory worsen, with 
even early biographical memories being lost by the time the disease reaches the advanced stages 
(Förstl & Kurz, 1999). 
 The decline in episodic memory (the conscious recollection of previous experiences (Tulving, 
2002)) appears to begin several years prior to diagnosis, in the pre-clinical stage of the disease 
(Grober et al., 2008; Mickes et al., 2007), and progressively worsens up to and beyond clinical 
diagnosis (Grober et al., 2008). Other aspects of cognition, including executive function, verbal IQ, 
and visuospatial ability display sharp declines closer to the time of diagnosis, and also continue to 
worsen throughout the disease (Grober et al., 2008; Johnson, Storandt, Morris, & Galvin, 2009). One 
crucial site of pathology thought to contribute to the memory decline in Alzheimer’s disease is the 
temporal lobe (see Section 1.1.6). 
 
1.1.3 Neuropathology of Alzheimer’s disease 
The primary pathological hallmarks of Alzheimer’s disease are plaques and neurofibrillary 
tangles (NFTs).  Plaques are composed of insoluble Aβ, and NFTs are formed from 
hyperphosphorylated and misfolded tau protein (Serrano-Pozo et al., 2011). The presence of both 
these proteinopathies is required for a definitive post-mortem diagnosis of Alzheimer’s disease, and 
each lesion has a characteristic topographical progression through distinct regions of the brain, 
allowing for staging of neuropathological severity to be established (Braak & Braak, 1991; Thal, Rüb, 
Orantes, & Braak, 2002). In brief, Aβ plaques are deposited first in the neocortex, then allocortical 
regions including the hippocampal formation, and eventually reach brainstem nuclei and cerebellum 
(Thal et al., 2002). In contrast, NFTs begin in the transentorhinal region, and eventually spread to the 
hippocampal formation and then isocortical association areas (Braak & Braak, 1991). These major 
features of Alzheimer’s disease neuropathology, along with other commonly observed aspects, will 
be discussed below. 
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1.1.3.1 Amyloid plaques 
Aβ plaques are extracellular deposits of fibrillary, insoluble, Aβ peptide, typically comprising 
the two common Aβ species Aβ40 and Aβ42, of which the latter is the major plaque component 
(Mann et al., 1996). Plaques can be characterised as ‘diffuse’ or ‘dense core’; it is the ‘dense core’ Aβ 
plaques, typically associated with neuritic dystrophy, reactive astrocytes, activated microglia and 
synapse loss, which are indicative of Alzheimer’s disease (Serrano-Pozo et al., 2011). Whilst 
diagnostically essential, Aβ plaques in and of themselves do not seem to be critical to the 
pathological process, as they are not the best correlate of cognitive impairment in Alzheimer’s 
disease (Terry et al., 1991), and preclinical rodent research has shown Aβ can be synaptotoxic in the 
absence of plaque deposition (Hsia et al., 1999; Mucke et al., 2000). It is currently thought that pre-
plaque Aβ species (i.e. soluble Aβ oligomers) are critical to the disease process (see Section 
1.1.4.3.2). Whilst not the principal contributor to the pathological process, Aβ plaques may still have 
some impact. As plaques can sequester soluble forms of Aβ, it has been speculated that they may 
represent a protective structure (Esparza, Gangolli, Cairns, & Brody, 2018). However, it has also been 
found that plaques may act as a reservoir of damaging soluble Aβ (Koffie et al., 2009). Aβ plaques 
are therefore diagnostically highly useful, and may indirectly affect the disease process in 
Alzheimer’s disease, but are not thought to be a critical pathological event in their own right.  
 
1.1.3.2 Tau tangles 
Tau tangles (or NFTs) are intra-neuronal inclusions of microtubule-associated tau filaments 
which have undergone misfolding and abnormal hyperphosphorylation (Serrano-Pozo et al., 2011). 
NFT presence is thought to lead to axonal and dendritic degradation, and NFTs can be graded as 
diffuse, mature or extra-neuronal (in order of ascending severity) (Serrano-Pozo et al., 2011). NFT 
burden provides a better correlate of dementia severity than Aβ plaque burden (Arriagada, 
Growdon, Hedley-Whyte, & Hyman, 1992; Bierer et al., 1995), though this may simply reflect the fact 
that tau pathology is proposed to be downstream of Aβ in the disease process (see Section 1.1.4). As 
with Aβ plaques, current research now suggests that soluble, pre-tangle, forms of tau may be the 
overtly damaging species (see Section 1.1.5.2), with NFTs themselves perhaps simply serving as a 
marker of already inflicted neuronal damage, or potentially representing a protective mechanism 
(Gendreau & Hall, 2013). In light of this newer focus on soluble forms of tau, NFTs themselves are 
useful for post-mortem diagnostic purposes, but may not have the most relevance to the 
pathological events underlying Alzheimer’s disease symptoms. 
 
5 
 
1.1.3.3 Other features 
A major feature of Alzheimer’s disease is synapse loss (Serrano-Pozo et al., 2011). While not 
diagnostically necessary, loss of synapses appears to be the best correlate of cognitive decline in 
Alzheimer’s disease (Terry et al., 1991), to the extent that Alzheimer’s disease been characterised as 
a synaptic failure (Selkoe, 2002). Synapse loss contributes to disconnectivity in the brain (Scheff & 
Price, 2006), and occurs even in early Alzheimer’s disease, in areas such as the hippocampus, a 
region critical to memory (Zola-Morgan, Squire, & Amaral, 1986). Importantly, soluble forms of both 
Aβ and tau have various deleterious effects at the synapse (see Sections 1.1.4.3.2 and 1.1.5.2). To 
the extent that Alzheimer’s disease is a failure of synapses, soluble Aβ and tau are sensible 
candidates to examine in terms of mechanistic understanding and therapeutic interventions. 
Neuronal loss is another major feature (or consequence) of Alzheimer’s disease 
neuropathology (Serrano-Pozo et al., 2011). The pattern of neuronal loss parallels NFT appearance, 
but correlates with dementia severity better than NFTs (though not as well as synapse loss) 
(Serrano-Pozo et al., 2011). Neuronal loss, like synapse loss, contributes to impaired connectivity in 
the brain (deToledo-Morrell, Stoub, & Wang, 2007), and causes tissue atrophy, resulting in loss of 
volume in key brain structures such as the hippocampus (De Leon et al., 1997). Neuronal loss is 
essentially the terminal event in the sequence of Alzheimer’s disease pathology, and as such is 
unlikely to be the most productive stage for targeting interventions. 
The inflammatory component of Alzheimer’s disease is another important facet of pathology 
(Heppner, Ransohoff, & Becher, 2015), and involves the microglia and astrocytes of the immune 
system (Prokop, Miller, & Heppner, 2013; Verkhratsky, Olabarria, Noristani, Yeh, & Rodriguez, 2010). 
Pro-inflammatory cytokines, such as tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β), 
appear to be raised in Alzheimer’s disease (Blum-Degen et al., 1995; Tarkowski, Andreasen, 
Tarkowski, & Blennow, 2003), though this is not a consistent finding (Brosseron, Krauthausen, 
Kummer, & Heneka, 2014). The innate immune system has been implicated in the development of 
Alzheimer’s disease, as mutated genes encoding for TREM2 (Jonsson et al., 2013), CD33 (Naj et al., 
2011), and CR1 (Lambert et al., 2009) are associated with an increased risk. Potential mechanisms 
underlying inflammatory and immune contributions in Alzheimer’s disease include production of 
inflammatory cytokines via Aβ binding to microglial receptors (El Khoury et al., 2003), as well as 
potential loss of normal microglial function (Krabbe et al., 2013). Interestingly, an inflammatory 
‘footprint’ can also be found in at least some cases of depression (Raison & Miller, 2011), and 
microglia have been suggested as a point of connection between depression and Alzheimer’s disease 
(Santos, Beckman, & Ferreira, 2015). 
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1.1.4 Amyloid cascade hypothesis of Alzheimer’s disease 
1.1.4.1 History of the hypothesis 
After the Aβ protein was identified from brain tissue of Alzheimer’s disease patients 
(Glenner & Wong, 1984), the initial hypothesis was that deposition of insoluble Aβ was the critical 
pathological event in Alzheimer’s disease (Hardy & Allsop, 1991). The ‘cascade’ of events ending in 
neurodegeneration and dementia was said to begin with Aβ deposition, with Aβ plaques leading to 
both neuronal damage in their own right, and to NFTs with their own damaging effects on neurons 
(Hardy & Allsop, 1991). This seemed to be supported by APP mutations causing Aβ overproduction in 
familial Alzheimer’s disease, and Aβ plaques appearing before NFTs and tissue atrophy in Down’s 
syndrome (in which chromosome 21, harbouring the APP gene, is triplicated). However, since the 
initial formulation of the amyloid cascade hypothesis, it has become understood that Aβ deposition 
itself is unlikely to begin the pathological cascade; more recent research suggests that soluble Aβ 
oligomers are the relevant species (Hayden & Teplow, 2013), and the hypothesis has been revised in 
light of this (Selkoe & Hardy, 2016). The characterisation of the secretase enzymes and presenilins, 
and the study of the interplay between Aβ and tau, have also helped refine the amyloid cascade 
hypothesis. Before discussing the amyloid cascade hypothesis in more detail, some of the basic 
biology around APP and Aβ will be examined. 
 
1.1.4.2 APP and Aβ 
Aβ is the product of a series of enzymatic cleavage processes, and is ultimately derived from 
the parent molecule APP. APP is a type I transmembrane glycoprotein comprising a large N-terminal 
ectodomain (lying outside the cell membrane), a transmembrane region and a short C-terminal 
domain (the cytoplasmic tail) (Ling, Morgan, & Kalsheker, 2003). APP is genetically encoded in 
humans by one gene found on chromosome 21; 18 exons encode for APP, of which exons 7, 8 and 15 
(encoding for extracellular domain regions) allow for alternative splicing (Ling et al., 2003). Thus APP 
isoforms of varying amino acid lengths can exist, the 3 most common being the 695, 751 and 770 
amino acid forms, the former being mainly expressed in the central nervous system (Selkoe, 1998). 
For Aβ to be generated, APP is first cleaved by β-secretase at the N-terminal ectodomain to 
liberate a secreted molecule, sAPPβ (Haass, Kaether, Thinakaran, & Sisodia, 2012). The 99 amino 
acid APP C-terminus (C99) is then cleaved by γ-secretase in the cell membrane lipid bilayer, 
generating a liberated extracellular Aβ40 or Aβ42 peptide, depending upon the cleavage site, as well 
as the cytoplasmic APP intracellular domain (AICD) (Haass et al., 2012). There is also a non-
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amyloidogenic enzymatic pathway, in which α-secretase cleaves APP within the Aβ domain to 
release sAPPα and retain the C83 C-terminal fragment, following which γ-secretase activity produces 
the p3 peptide, AICD, and no Aβ (Selkoe, 1998). These two APP processing pathways are illustrated 
in Figure 1.1. 
 
Figure 1.1. APP Processing and Aβ production (Haass, Kaether, Thinakaran, & Sisodia, 2012).  
 
There is some variability in the generation of Aβ by γ-secretase cleavage, resulting in a range 
of Aβ peptides with differing C-terminals; the Aβ40 species comprises most of the output, with Aβ42 
constituting most of the remaining peptides (Thinakaran & Koo, 2008). Of these, it is the Aβ42 
peptide which is thought to be the most relevant to Alzheimer’s disease, as it is more prone to 
aggregation (Mann et al., 1996; Suzuki et al., 1994) and forms a number of damaging oligomers (see 
Section 1.1.4.3.2). APP and Aβ are also thought to serve physiological functions under normal 
conditions (Dawkins & Small, 2014; Pearson & Peers, 2006), but the focus of this thesis is the 
pathological effects of Aβ. 
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1.1.4.3 Evaluation of the amyloid cascade hypothesis 
1.1.4.3.1 Genetics 
The major evidence in favour of the amyloid cascade hypothesis is principally genetic: all 
known genetic mutations conferring autosomal dominant familial Alzheimer’s disease relate either 
to APP or presenilins, both of which are involved in Aβ production (Tanzi, 2012). Bolstering this are 
the facts that duplication of the APP gene also leads to Alzheimer’s disease (Rovelet-Lecrux et al., 
2006), and Down’s syndrome (trisomy 21) includes Alzheimer’s disease neuropathology and 
cognitive deterioration among its consequences (Mrak & Griffin, 2004). There is even a version of 
trisomy 21 in which the chromosomal segment containing the APP gene is not repeated; individuals 
with this mutation do not go on to develop Alzheimer’s disease (Prasher et al., 1998). In addition, 
there is a coding mutation (A673T) in the APP gene which confers robust protection against 
developing Alzheimer’s disease (Jonsson et al., 2012). Though the relevance of other APP fragments 
cannot be definitively ruled out, Aβ is the common molecule linking all known genetic causes of 
Alzheimer’s disease, and as such represents the most likely initiator of the disease. In addition to the 
convincing genetic evidence, biomarker modelling of the pathological cascade in Alzheimer’s disease 
indicates that accumulation of Aβ42 is the earliest event to occur (Jack et al., 2013). 
 
1.1.4.3.2 Pathological relevance of Aβ 
Since being first isolated, a number of toxic effects of Aβ have been identified. Early studies 
identified a number of ways in which Aβ was broadly toxic to neurons (see Mattson, 1997 for 
review). For example, Aβ decreases neuronal survival (Yankner, Duffy, & Kirschner, 1990), and 
damages neurons in a number of ways, including: apoptosis (Loo et al., 1993; Nakagawa et al., 2000), 
sensitisation to glutamatergic neurotoxicity (Mattson et al., 1992), impairing glucose transport 
(Mark, Pang, Geddes, Uchida, & Mattson, 1997), oxidative stress (Behl, Davis, Lesley, & Schubert, 
1994; Bruce, Malfroy, & Baudry, 1996), and plasma membrane interaction (Hertel et al., 1997). 
While somewhat informative, these initial toxicity studies used a variety of different Aβ species and 
aggregation states, concentrations, exposure times, and various primary and secondary cell cultures 
derived from different species. The absolute physiological relevance of these studies is not clear, 
though they make the point that Aβ, under certain conditions, can be harmful to neurons. The 
mechanisms by which Aβ is damaging at the cellular level, in ways which could contribute to the 
cognitive, and potentially mood, symptoms of Alzheimer’s disease, are now understood to a more 
detailed extent. These are thought to relate primarily to soluble Aβ oligomers, which have a variety 
of disruptive effects on neurons. 
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Aβ oligomers of various sizes are thought to be the molecular culprit responsible for 
memory dysfunction in early Alzheimer’s disease (Gong et al., 2003; Lacor et al., 2004). An important 
site of Aβ oligomer activity is the synapse, where interactions with a number of receptors, including 
α7-nicotinic acetylcholine (α7-nACh) and NMDA receptors, could contribute to synaptic dysfunction 
and impaired memory (Dinamarca, Ríos, & Inestrosa, 2012). For instance, naturally secreted human 
Aβ oligomers induce a reduction in dendritic spine density and synapse loss in rat hippocampal 
slices, through a mechanism which includes NMDA receptor inhibition (Shankar et al., 2007). Aβ 
oligomers also block hippocampal long-term potentiation (LTP), a synaptic plasticity-based 
experimental paradigm for learning and memory (Bliss & Collingridge, 1993), as shown in a number 
of studies. For example, human Aβ oligomers from cultured cells block LTP when administered to 
rats (Walsh et al., 2002), and Aβ trimer-enriched culture-medium fractions are potent inhibitors of 
LTP in mouse hippocampal slices (Townsend, Shankar, Mehta, Walsh, & Selkoe, 2006). Extracts 
containing soluble Aβ oligomers taken from human Alzheimer’s disease brain also impair LTP in 
mouse hippocampus, an effect not seen when the extracts are depleted of Aβ (Shankar et al., 2008). 
Soluble cortical extract from human Alzheimer’s disease brain is also able to disrupt memory 
processing in vivo, as administration to rats worsened performance in a step-through passive 
avoidance task, compared against Aβ-depleted extract (Shankar et al., 2008). A specific Aβ 
oligomeric formation, the Aβ dodecamer (termed Aβ*56), has been identified in transgenic mouse 
brain (Lesné et al., 2006), and correlates negatively with performance on a spatial memory task. 
When extracted from transgenic mouse brain and administered to young rats, Aβ*56 impaired 
performance on probe trials in the Morris water maze task (Lesné et al., 2006). 
Taken together, these findings demonstrate that naturally occurring Aβ oligomers, including 
those derived directly from human Alzheimer’s disease brain, are capable of disrupting synaptic 
function in electrophysiological studies, as well as memory performance in living animals. 
Particularly damaging Aβ oligomeric formations may include trimers and dodecamers. These various 
Aβ assemblies are thus a crucial target in the disease process of Alzheimer’s disease, as they could 
underlie early memory symptoms, and represent an early event in the pathological cascade (Selkoe 
& Hardy, 2016). In addition to their relevance to the memory symptoms of early Alzheimer’s disease, 
Aβ oligomers could theoretically contribute to symptoms of depression. As depressive symptoms 
appear early in the course of Alzheimer’s disease (see Section 1.2.2), this would be consistent with 
the idea that Aβ oligomers may play a role in the mood disturbances common in Alzheimer’s disease 
also. 
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1.1.4.3.3 Aβ as a therapeutic target 
Pre-clinical studies using transgenic mice provide a useful platform for testing therapies, and 
have demonstrated that, in principle, anti-amyloid therapies can reverse memory deficits (Götz et 
al., 2004; Lee et al., 2006; Morgan et al., 2000; Wilcock et al., 2004). However, this has yet to 
translate to a fully proven therapy for humans. A lingering criticism of the amyloid cascade 
hypothesis is that it has so far failed to provide a beneficial treatment for Alzheimer’s disease in 
humans. Some of the clinical trials investigating anti-amyloid agents were halted due to adverse 
reactions (Orgogozo et al., 2003), and others failed to show clinical benefit (Doody et al., 2013). 
However, as Alzheimer’s disease is thought to have a protracted pre-clinical phase during which Aβ 
levels accumulate (Jack et al., 2013), an explanation of this failure is that therapies were given too 
late in the disease course to have a clinical impact. This defence appears to have merit, as results 
from a phase 2 clinical trial of an anti-Aβ protofibril monoclonal antibody (BAN2401) in early 
Alzheimer’s disease patients show a slowing of cognitive decline (Swanson et al., 2018), consistent 
with the centrality of Aβ to Alzheimer’s disease. Though it may be too early to reach definitive 
conclusions, this may well address the major remaining criticism of the amyloid cascade hypothesis. 
Thus Aβ is not only a critical peptide to target in Alzheimer’s disease, but would appear to require 
addressing as early as possible in order to produce tangible clinical benefits. Beyond its relevance to 
cognitive decline, as Aβ could contribute to depressive symptoms in Alzheimer’s disease (see Section 
1.2.2), therapies targeting Aβ could potentially address mood alterations also. 
 
1.1.5 Tau in Alzheimer’s disease 
1.1.5.1 Fibrillar tau 
Fibrillar tau aggregates arise from hyperphosphorylated tau self-assembling into paired 
helical filaments (Alonso, Grundke-Iqbal, & Iqbal, 1996). These paired helical filaments coalesce to 
form NFTs, one of the two major lesions used in post mortem diagnosis of Alzheimer’s disease 
(Serrano-Pozo et al., 2011). NFT count provides a better correlate of cognitive decline than Aβ 
plaque load (Arriagada et al., 1992), thus it was suspected that fibrillar tau assemblies were 
damaging to neurons. However, the role of fibrillar tau formations in Alzheimer’s disease is now 
disputed, with some researchers suggesting certain tau aggregates could be protective rather than 
damaging (Cowan & Mudher, 2013). Evidence from animal studies questions the toxicity of NFTs: a 
manipulation that increases tau aggregation in a rat tauopathy model decreases neuronal loss 
(d’Orange et al., 2018), and the presence of NFTs in neurons does not cause gross neuronal 
dysfunction in a transgenic mouse model (Kuchibhotla et al., 2014). Thus despite NFTs being 
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diagnostically necessary, insoluble fibrillar forms of tau may not be the most relevant to the disease 
process in Alzheimer’s disease. 
 
1.1.5.2 Soluble tau 
Pre-fibrillar, soluble species of tau, known to occur in Alzheimer’s disease brain (Lasagna-
Reeves, Castillo-Carranza, Sengupta, Sarmiento, et al., 2012; Maeda et al., 2006), are under 
investigation as formations which could contribute to pathology in Alzheimer’s disease (Kopeikina, 
Hyman, & Spires-Jones, 2012). Transgene suppression in a transgenic tauopathy mouse model, for 
example, reduces soluble tau but not NFTs, restoring neuronal responsiveness to environmental 
stimuli and reducing hippocampal neuron loss (Fox et al., 2011). Soluble human tau has also been 
found to reduce synapse number in mouse dentate gyrus, and impair performance in a cognitive 
task (Bolós et al., 2017). Soluble tau oligomers extracted from human Alzheimer’s disease brain 
induce both LTP disruption and memory impairment in rodents (Lasagna-Reeves, Castillo-Carranza, 
Sengupta, Guerrero-Munoz, et al., 2012). Studies such as these suggest that soluble tau species are 
more pathologically relevant than fibrillar tau, and are more likely to contribute to the symptoms of 
Alzheimer’s disease. 
 
1.1.5.3 Synergistic effects of Aβ and tau 
 The chain of pathological events in Alzheimer’s disease is thought to begin with the 
occurrence of Aβ oligomers, which are then able to induce toxic tau species by promoting tau 
hyperphosphorylation (De Felice et al., 2008; Jin et al., 2011). The interplay between Aβ and tau is an 
important facet of Alzheimer’s disease, as at least some of the disturbances Aβ can cause at the 
synapse appear to depend on the co-occurrence of tau (Ittner & Götz, 2011; Spires-Jones & Hyman, 
2014). In addition, presence of Aβ and tau biomarkers points to a synergistic effect between the two 
in driving the conversion from mild cognitive impairment (MCI) (the pre-clinical precursor of 
Alzheimer’s disease) to Alzheimer’s disease (Pascoal, Mathotaarachchi, Shin, et al., 2017), and in 
causing metabolic decline in the brains of cognitively normal elderly (Pascoal, Mathotaarachchi, 
Mohades, et al., 2017). The view that Aβ and tau are both critical players in Alzheimer’s disease 
pathology is thus a sensible one, and the precise relation of each to both the disease process and 
one another are important topics. However, it remains the case that Aβ is the molecule which 
appears to be the initiator of the pathological process, and as such potentially represents the most 
appropriate intervention point in the disease cascade. 
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1.1.6 The hippocampus in Alzheimer’s disease 
 The hippocampus is a structure located in the medial temporal lobe, a brain region known to 
be vital to mnemonic processes since the 1950s, when a patient with bilateral medial temporal lobe 
removal was found to exhibit profound anterograde amnesia (Scoville & Milner, 1957). Later studies 
demonstrated that organic damage localised to the hippocampus in humans was sufficient to cause 
pronounced and persistent memory impairment (Victor & Agamanolis, 1990; Zola-Morgan et al., 
1986), revealing the importance of the hippocampus per se to memory. The importance of the 
hippocampus to functional memory holds true in non-human primates and rodents, as well as 
humans (Squire, 1992). 
One important site of pathology in Alzheimer’s disease is the hippocampus, which is known 
to both accumulate small Aβ species (Funato, Enya, Yoshimura, Morishima-Kawashima, & Ihara, 
1999), and contain deposited Aβ plaques and NFTs (Price, Davis, Morris, & White, 1991). The 
hippocampus is compromised early in the course of Alzheimer’s disease, experiencing synapse loss 
which correlates with lowered performance on tests of cognition (Scheff, Price, Schmitt, DeKosky, & 
Mufson, 2007; Scheff, Price, Schmitt, & Mufson, 2006). Early in Alzheimer’s disease, the 
hippocampus also displays decreased activation after stimulus presentation (Small, Perera, DeLaPaz, 
Mayeux, & Stern, 1999). Beyond these early changes, the hippocampus undergoes frank 
neurodegeneration in Alzheimer’s disease, with neuronal loss leading to tissue atrophy and volume 
reduction (Barnes et al., 2009; Seab et al., 1988; Simić, Kostović, Winblad, & Bogdanović, 1997). 
Pathological changes in Alzheimer’s disease also impair hippocampal connectivity with other brain 
areas, such as cortical and limbic regions (Allen et al., 2007; Hyman, Van Hoesen, Damasio, & Barnes, 
1984). 
Notably, the hippocampus is a structure rich in NMDA and cholinergic receptors (Breese et 
al., 1997; Rubboli et al., 1994; Ułas, Brunner, Geddes, Choe, & Cotman, 1992). Both of these receptor 
types are important to cognition and memory (Hasselmo, 2006; Morris, 2013), are affected by Aβ 
(Oz, Lorke, Yang, & Petroianu, 2013; Shankar et al., 2007), and are altered in Alzheimer’s disease 
(Kuhl et al., 1996; Mishizen-Eberz et al., 2004; Nordberg, 2001; Ułas et al., 1992). NMDA and 
cholinergic receptors are also the targets of licensed medications used in Alzheimer’s disease (see 
Section 1.1.7); the fact that these medicines provide partial relief from the memory symptoms of 
Alzheimer’s disease suggests the contribution of these receptors to impaired memory. Given that 
synapse loss in the hippocampus correlates with diminished cognitive performance, that the 
hippocampus accumulates Aβ, and that Aβ both perturbs synapses and acts on receptors known to 
subserve memory function, the hippocampus is an important site of pathology in Alzheimer’s 
disease, and is likely to contribute to its amnesic symptoms. 
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1.1.7 Treatment of Alzheimer’s disease 
 Currently licensed therapies for treating Alzheimer’s disease are limited to two classes of 
compounds: cholinesterase inhibitors, and NMDA receptor antagonists. The cholinesterase 
inhibitors include the drugs donepezil, galantamine and rivastigmine, all of which are recommended 
in the UK for use in mild to moderate Alzheimer’s disease (National Institute for Health and Care 
Excellence, 2018b). These agents provide some degree of improvement in cognitive function versus 
placebo (Birks, Chong, & Grimley Evans, 2015; Birks & Harvey, 2018; Loy & Schneider, 2006), though 
they do not halt disease progression, and patients still decline over time (Johannsen, 2004). Broadly 
speaking, the mechanism of action of donepezil and galantamine is inhibition of the enzyme 
acetylcholinesterase, reducing the breakdown of acetylcholine, increasing acetylcholine levels and 
improving nicotinic cholinergic neurotransmission (Shinotoh et al., 2001; Woodruff-Pak, Vogel, & 
Wenk, 2001). Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase to improve 
cholinergic neurotransmission (Eskander, Nagykery, Leung, Khelghati, & Geula, 2005; Kaasinen et al., 
2002). The facilitation of cholinergic neurotransmission appears to be the major mechanism by 
which cholinesterase inhibitors provide clinical benefit, though other mechanisms such as increasing 
nicotinic receptor density have been suggested (Wilkinson, Francis, Schwam, & Payne-Parrish, 2004). 
The NMDA receptor antagonist class of therapies currently comprises one agent, 
memantine, which is recommended in the UK for moderate and severe Alzheimer’s disease 
(National Institute for Health and Care Excellence, 2018b). Memantine has a small beneficial effect 
on cognitive function in moderate to severe Alzheimer’s disease (McShane, Sastre, & Minakaran, 
2006), and acts as a non-competitive antagonist of the NMDA receptor (Parsons, Danysz, & Quack, 
1999). The utility of this antagonism is thought to depend upon the NMDA receptor occupancy 
profile of memantine; it is thought to block the NMDA receptor channel under background 
pathological conditions, such as synaptic presence of Aβ oligomers, whilst still leaving the channel 
when a strong pre-synaptic signal arrives, better allowing the synaptic plasticity underpinning 
learning and memory to occur (Danysz & Parsons, 2012). As with cholinesterase inhibitors, 
memantine does not arrest the disease process itself, and while patients display an initial cognitive 
improvement from baseline, they still decline over time (Atri et al., 2015). 
In addition to improving cognitive symptoms, cholinesterase inhibitors provide a small 
benefit in alleviating neuropsychiatric or behavioural symptoms in Alzheimer’s disease (Trinh, 
Hoblyn, Mohanty, & Yaffe, 2003; Wang et al., 2015). Whether these agents address depression 
specifically is less clear: donepezil may fully or partially resolve depression in a number of 
Alzheimer’s disease patients, though this is based on a secondary analysis with no placebo 
comparison group (Cummings, McRae, & Zhang, 2006). A pooled analysis of galantamine studies did 
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not reveal any difference from placebo in changing depression score on the Neuropsychiatric 
Inventory (Herrmann, Rabheru, Wang, & Binder, 2005), and rivastigmine use produced a poorer 
depression subscale score when compared with a historical control cohort (Frankfort et al., 2006), 
though an open-label study has suggested rivastigmine may alleviate depression in mild Alzheimer’s 
disease (Spalletta et al., 2013). Memantine may also provide a small benefit in improving 
behavioural symptoms of Alzheimer’s disease (Matsunaga, Kishi, & Iwata, 2015), although this may 
be due to its effect on symptoms such as agitation and irritability, rather than depression 
(Grossberg, Pejović, Miller, & Graham, 2009). As these symptomatic treatments of Alzheimer’s 
disease are not clearly effective in reducing depression, other agents with antidepressant activity 
should be investigated (see Section 1.2.4). 
 
1.2. Depression and anhedonia in Alzheimer’s disease 
1.2.1 Defining depression and anhedonia 
Depression is a heterogeneous mood disorder, comprising varying combinations of 
psychological and physical signs and symptoms, central to which are depressed mood and 
anhedonia (a loss of interest or pleasure from events normally found enjoyable) (American 
Psychiatric Association, 2013). The constellation of the other signs and symptoms of depression can 
include weight or appetite changes, insomnia or hypersomnia, loss of energy/fatigue, feelings of 
guilt or worthlessness, psychomotor retardation or agitation, impaired concentration, and thoughts 
of death or suicidal ideation or attempts (American Psychiatric Association, 2013). From the late 
1950s through to the 1970s, depression was sub-classified into various forms (Raskin & Crook, 1976), 
though arguably the most significant division was that of distinguishing ‘bipolar depression’ from 
‘unipolar depression’ (Depue & Monroe, 1978). The term depression from this point onwards will 
refer to ‘unipolar’ rather than ‘bipolar’ depression. Depression can also be categorised by its 
responsiveness to treatment: depression that remits following antidepressant therapy is treatment-
responsive, whereas depression that fails to remit given an appropriate antidepressant agent is 
considered treatment-resistant (at least as the term is commonly understood) (Fava, 2003). 
While the prominent diagnostic guidelines for depression vary in symptom number and 
duration required for a clinical diagnosis, anhedonia is a core theme in them all. For example, in the 
Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5), depressed mood and/or 
anhedonia are essential for a major depressive disorder diagnosis (American Psychiatric Association, 
2013), and the 10th iteration of the International Classification of Diseases (ICD-10) considers loss of 
enjoyment or interest to be one of the typical depression symptoms (World Health Organization, 
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1992). In the United Kingdom, clinical guidance issued by the National Institute for Health and Care 
Excellence on recognising and managing depression in adults uses the previous DSM (DSM-4) 
guidance for diagnosis (National Institute for Health and Care Excellence, 2018a). Under DSM-4 
guidance, core symptoms of a depressive episode are either depressed mood or significant 
diminishment of pleasure or interest in most or all activities. (American Psychiatric Association, 
1998). Some guidelines cleave depression into major or minor episodes, the former comprising 5 or 
more symptoms and the latter comprising between 2 and 4 symptoms; both entities must feature 
either depressed mood or loss of interest or pleasure (O’Connor, Whitlock, Gaynes, & Beil, 2009). 
Regardless of the specific clinical diagnostic guidance implemented, it is clear that a loss or decrease 
in experiential pleasure (anhedonia) is a major component of depression. 
Hedonic deficits feature in various psychiatric conditions, including depression and 
schizophrenia (Pelizza & Ferrari, 2009), as well as neurodegenerative conditions such as Alzheimer’s 
disease and Parkinson’s disease (Lemke, Brecht, Koester, Kraus, & Reichmann, 2005; Lopez et al., 
2003). In the context of depression, anhedonia appears to be fairly prevalent amongst depressed 
individuals (Balsis & Cully, 2008; Haarasilta, Marttunen, Kaprio, & Aro, 2001; Pelizza & Ferrari, 2009), 
and predictive of a poorer outcome (Spijker, Bijl, de Graaf, & Nolen, 2001). Questionnaire-based 
studies have found that depressed patients taking antidepressants still report feeling reduced 
positive emotions, including less enjoyment from hobbies, interests and music (Goodwin, Price, De 
Bodinat, & Laredo, 2017; Price, Cole, & Goodwin, 2009). Whether this represents a side effect of 
common antidepressants as some have suggested (Price et al., 2009), or simply a failure of these 
drugs to improve hedonic deficits, the point remains that conventional antidepressant treatments 
may not be particularly suitable for addressing anhedonia, a core component of depression. In 
treatment-resistant depression, the presence of anhedonia is predictive of longer time to remission, 
fewer depression-free days, and minimal response to transcranial magnetic stimulation (Downar et 
al., 2014; McMakin et al., 2012). Again, this suggests that anhedonia is a highly important and 
clinically meaningful aspect of depression, which warrants deeper investigation and targeted 
treatment. 
 
1.2.2 Depressive symptoms in Alzheimer’s disease 
Symptoms of depression appear early in the course of Alzheimer’s disease, including in mild 
cognitive impairment (Gabryelewicz et al., 2004; Visser, Verhey, Ponds, Kester, & Jolles, 2000), and 
appear to be relatively persistent, at least over a 12-16 month time frame (Garre-Olmo et al., 2003; 
Starkstein et al., 1997). The early appearance of depression in Alzheimer’s disease is noteworthy, 
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suggesting that early pathological events are sufficient to produce depressive symptoms, and 
pointing towards the relevance of Aβ as a potential antecedent. The symptom profile of depression 
in Alzheimer’s disease is broadly similar to that of elderly depressed patients (e.g. sadness, guilt, loss 
of interest) (Chemerinski, Petracca, Sabe, Kremer, & Starkstein, 2001). 
The prevalence of depression in Alzheimer’s disease is unclear and ranges from the fairly low 
(Newman, 1999; Weiner, Doody, Sairam, Foster, & Liao, 2002), to moderately high (Ballard, 
Bannister, Solis, Oyebode, & Wilcock, 1996; Migliorelli et al., 1995). This uncertainty is likely due to, 
among other things, the use of different diagnostic criteria, and the study of differing patient 
populations (e.g. home residence versus nursing home residence, mixing possible and probable 
Alzheimer’s disease patients, etc.). Despite this lack of clarity from individual studies, a meta-analysis 
has found that the prevalence of depression in Alzheimer’s disease is roughly 40% (Chi et al., 2015). 
Both major and minor depression exist in Alzheimer’s disease  (Lyketsos et al., 1997; Starkstein, 
Jorge, Mizrahi, & Robinson, 2005); when these groups are combined, it appears that roughly 50% of 
Alzheimer’s disease patients experience some level of depression. 
Thus depression in Alzheimer’s disease appears to be present in the population and emerges 
early in the disease, is similar in appearance to ‘typical’ depression in elderly patients, and relatively 
persistent. The significance of this depression will now be considered. 
 
1.2.3. Significance of depression in Alzheimer’s disease 
Addressing the non-cognitive features of Alzheimer’s disease (sometimes called 
neuropsychiatric symptoms (NPS) (Lyketsos et al., 2011), or behavioural and psychological symptoms 
of dementia (BPSD) (Cerejeira, Lagarto, & Mukaetova-Ladinska, 2012)) is an important component of 
treating Alzheimer’s disease. Depression in Alzheimer’s disease carries a number of additional 
negative outcomes (Lyketsos & Olin, 2002), including: an increase in mortality (Burns, Lewis, Jacoby, 
& Levy, 1991); faster decline in cognition (Zahodne, Ornstein, Cosentino, Devanand, & Stern, 2015); 
reduced quality of life (González-Salvador et al., 2000); lower ability to perform activities of daily 
living (Lyketsos et al., 1997); increased likelihood of aggressive behaviour (Lyketsos et al., 1999); 
increased likelihood of discharge from an assisted living facility to nursing home or hospital (Kopetz 
et al., 2000); and increased burden and depression for caregivers (Bozgeyik, Ipekcioglu, Yazar, & 
Ilnem, 2018; Neundorfer et al., 2001). 
In principle, depression in Alzheimer’s disease could simply be a reactive occurrence due to 
the distressing and unpleasant reality of living with a neurodegenerative condition. However, early 
studies suggest – unlike what might be expected if depression is a reaction to dementia and its 
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symptoms – that the level of insight into cognitive decline does not seem to be associated with an 
increased occurrence of depression (Cummings, Ross, Absher, Gornbein, & Hadjiaghai, 1995; 
Migliorelli et al., 1995; Ott et al., 1996; Verhey, Rozendaal, Ponds, & Jolles, 1993). However, a more 
recent study has suggested that greater insight in Alzheimer’s disease is predictive of greater 
depression severity (Horning, Melrose, & Sultzer, 2014). Regardless, emotional reactivity is unlikely 
to be the only explanation of depression in Alzheimer’s disease, because disclosure of diagnosis is 
associated with worsening depressive symptoms in only a minority of patients (Mormont, Jamart, & 
Jacques, 2014). It could therefore be the case that an enhanced awareness of one’s condition could 
be a source of an additional depressive burden, but there is more to depression in Alzheimer’s 
disease than simply a reaction to the negative consequences of the disease itself.  
Beyond these externally observed consequences, post mortem examination has revealed 
that among Alzheimer’s disease subjects with a lifetime history of depression, those with concurrent 
depression at the onset of Alzheimer’s disease have a greater Aβ plaque and neurofibrillary tangle 
burden in the hippocampus than those without (Rapp et al., 2006). Given the manifold problems 
caused by depression in Alzheimer’s disease, improvements in identification and treatment of this 
depression are a major issue in need of addressing. To the extent that depression in Alzheimer’s 
disease is not purely ‘reactive’, it may represent a common (though not universal) consequence of 
the disease process itself. If properly explored, these possibilities could yield valuable insights into 
underlying mechanisms and thus therapeutic targets which could alleviate this depression. Before 
considering how the pathological processes of Alzheimer’s disease could potentially give rise to 
depression and anhedonia, their diagnosis and treatment in Alzheimer’s disease will be described. 
 
1.2.4 Diagnosis and treatment of depression and anhedonia in Alzheimer’s disease 
As with depression in the general population, depression in Alzheimer’s disease is 
recognised by means of a clinical survey or questionnaire. Prior to the creation of rating scales or 
diagnostic criteria which were specific to depression in Alzheimer’s disease, clinicians would use 
methods which generally relied upon patient interview or self-report. Given the fact that memory 
and communication abilities are impaired in Alzheimer’s disease (especially as the disease 
progresses), then it is clear that interview and self-report measures may not be particularly suitable 
for use in this specific population. In 1988 the Cornell Scale for Depression in Dementia was 
introduced, designed to specifically gauge depression in patients with dementia, being administered 
to both the patient and a reliable informant (Alexopoulos, Abrams, Young, & Shamoian, 1988). 
Additionally, in 2002 a National Institute of Mental Health-sponsored working group issued 
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provisional criteria for diagnosing depression in Alzheimer’s disease, modifying DSM-IV style criteria 
for this specific patient population (Olin et al., 2002). Interestingly, these specific instruments for 
gauging or diagnosing depression in Alzheimer’s disease tend to produce higher estimates of 
depression prevalence (Müller-Thomsen, Arlt, Mann, Maß, & Ganzer, 2005; Teng et al., 2008), which 
may explain the varying prevalence estimates in the literature, and suggests that perhaps depression 
in Alzheimer’s disease may be more prevalent than once suspected. 
Specific anhedonia measurement scales have yet to be applied to Alzheimer’s disease, and 
as they rely upon self-report they would have questionable applicability, though could potentially be 
used in early stages of the disease. A consequence of this is the true extent of anhedonia as a 
feature of Alzheimer’s disease is still unknown. However, the 2002 provisional diagnostic criteria do 
consider a decrease in positive affect or pleasure to be a core feature of depression in Alzheimer’s 
disease (Olin et al., 2002). A cross-sectional study of psychiatric symptoms in probable Alzheimer’s 
disease found that, while major depression was less common as dementia advanced, anhedonia 
became more common, and was present in 72% of individuals with severe cognitive impairment 
(Lopez et al., 2003). This suggests that anhedonia specifically may be both prevalent in Alzheimer’s 
disease and a particular by-product of the disease process itself. 
There are no evidence-based guidelines on how best to treat depression in Alzheimer’s 
disease. Several randomised controlled trials have taken place comparing an antidepressant against 
either placebo or another antidepressant in this population (Banerjee et al., 2011; Lyketsos et al., 
2003; Rosenberg et al., 2010; Weintraub et al., 2010), along with less robustly designed studies (G. 
M. Petracca, Chemerinski, & Starkstein, 2001; G. Petracca, Tesón, Chemerinski, Leiguarda, & 
Starkstein, 1996; Reifler et al., 1989). Unfortunately many studies of antidepressants in Alzheimer’s 
disease (and dementia more broadly) have utilised small sample sizes, the largest of which found no 
difference between either sertraline or mirtazapine and placebo at 13 and 39 weeks (Banerjee et al., 
2011), while another trial of sertraline found it was not superior to placebo at 12 and 24 weeks 
(Rosenberg et al., 2010; Weintraub et al., 2010). Thus the best available evidence from the largest 
and most recent individual trials is that commonly used classes of antidepressants (selective 
serotonin reuptake inhibitors (SSRIs) in the case of sertraline, and serotonin and noradrenaline 
reuptake inhibitors (SNRIs) in the case of mirtazapine) do not appear to be effective in treating 
depression in Alzheimer’s disease. The lack of clear benefit of antidepressants in Alzheimer’s disease 
and dementia is also borne out in meta-analyses investigating this topic (Dudas, Malouf, McCleery, & 
Dening, 2018; Orgeta, Tabet, Nilforooshan, & Howard, 2017). 
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In sum, the evidence suggests that antidepressants have little or no beneficial effect on 
depression in Alzheimer’s disease. Importantly, traditional antidepressants do appear to be effective 
in treating depression in adults and the elderly (Arroll et al., 2005; Kok, Heeren, & Nolen, 2011; 
Wilson, Mottram, Sivananthan, & Nightingale, 2001), raising the possibility that there is something 
about Alzheimer’s disease (e.g. sites of disease pathology or transmitter systems affected) that 
renders conventional antidepressants ineffective. Larger high quality studies are needed to 
strengthen the evidence base before firm conclusions can be drawn either way, but it is apparent 
that novel antidepressant agents urgently require investigation in the context of Alzheimer’s disease. 
Given that anhedonia is both prevalent and a core component of depression in Alzheimer’s disease, 
a predictor of poorer outcome in depression generally, and may be unaddressed by conventional 
antidepressants, treatments that could target this specific facet of depression merit particular 
investigation. The underlying biology of anhedonia in Alzheimer’s disease is thus a key issue to be 
studied in aid of identifying targeted therapies (see Section 1.2.5.2). In the next section, the key 
pathological changes manifesting during the course of Alzheimer’s disease are discussed, in light of 
how they may account for depression in Alzheimer’s disease. 
 
1.2.5 Biology of depression and anhedonia in Alzheimer’s disease 
1.2.5.1 Biology of depression in Alzheimer’s disease 
 The most influential biological theory of depression is the monoamine hypothesis of 
depression (Schildkraut, 1965). This has led to the development of various classes of antidepressant 
drugs, and holds that a deficiency in monoaminergic neurotransmitters (e.g. serotonin and 
noradrenaline) is the underlying biochemical state of depression, restoration of which should relieve 
depression, though this has since been refined (Krishnan & Nestler, 2008; Nutt, 2002). While 
conventional antidepressant agents that target the monoamine transmitter systems are effective in 
both adults (Arroll et al., 2005), and the elderly (Kok et al., 2011; Wilson et al., 2001), this does not 
appear to be the case for depression in Alzheimer’s disease (Dudas et al., 2018; Orgeta et al., 2017). 
The lack of clear benefit from antidepressants in Alzheimer’s disease could hypothetically be due to 
altered monoamine or other transmitter systems in Alzheimer’s disease, in a manner distinct from 
‘typical’ depression. 
A single class of molecules is unlikely to provide a full explication of depression, however, 
and a number of other molecular hypotheses of depression have been proffered, including 
glutamatergic (Sanacora, Treccani, & Popoli, 2012), GABAergic (Luscher, Shen, & Sahir, 2011), 
cytokine (Schiepers, Wichers, & Maes, 2005), and corticosteroid receptor (Holsboer, 2000), as well 
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as an excitatory synapse hypothesis of depression (Thompson et al., 2015). Importantly, many of 
these molecular systems (and synapses themselves) are altered during the course of Alzheimer’s 
disease; it would not be unreasonable to speculate that one or more of these narrower hypotheses 
of depression may be more relevant to depression in Alzheimer’s disease. There is no single unified 
hypothesis providing a comprehensive account for the occurrence of depression in Alzheimer’s 
disease. What have been noted, however, are neurodegenerative consequences of Alzheimer’s 
disease which could contribute to depression (Šimić et al., 2017), as well as biological endpoints 
shared by depression and Alzheimer’s disease which could explain the former emerging in the latter 
(Caraci, Copani, Nicoletti, & Drago, 2010). 
 Firstly, the serotonergic and noradrenergic system appear to be compromised in Alzheimer’s 
disease. Markers of serotonergic neurons, such as serotonin (5-hydroxytryptamine; 5HT), its primary 
metabolite 5-HIAA, and 5HT uptake are reduced in the temporal cortex relative to control brain 
(Garcia-Alloza et al., 2005; Palmer et al., 1987). The dorsal raphe nucleus, a major source of 
serotonergic innervation to the forebrain, displays Aβ plaques and NFTs in Alzheimer’s disease brain, 
as well as a loss of large neurons and a decrease in large neuron density (Halliday et al., 1992; 
Yamamoto & Hirano, 1985). Noradrenaline levels are also decreased in regions of Alzheimer’s 
disease brain, including frontal cortex, temporal cortex and hippocampus (Reinikainen et al., 1988). 
Aβ plaques and NFTs occur in the locus coeruleus, a major source of noradrenergic neurons, in 
Alzheimer’s disease brains (Cole, Neal, Singhrao, Jasani, & Newman, 1993; German, White, & 
Sparkman, 1987), along with a substantial loss of noradrenergic neurons themselves (Iversen et al., 
1983). The degradation of the serotonergic and noradrenergic systems in Alzheimer’s disease may 
account for the lack of clear effectiveness of antidepressants in this population. It could be the case, 
for example, that for conventional antidepressants such as SSRIs and SNRIs, which act upon 
serotonin and noradrenaline reuptake sites, a relatively intact population of serotonergic and 
noradrenergic neurons is required for their effectiveness. The substantial damage done to these 
monoaminergic systems in Alzheimer’s disease could limit the utility of standard antidepressant 
agents, and provides a rationale for investigating drugs which target other receptor classes. 
There are also a number of biochemical states observed in depression which are also seen in 
Alzheimer’s disease, including alterations in glucocorticoids, inflammatory mediators and 
neurotrophic factors (Caraci et al., 2010). Depressed patients show, for example, raised salivary 
cortisol after waking (Bhagwagar, Hafizi, & Cowen, 2005), and atypical cortisol trajectories following 
stress exposure (Burke, Davis, Otte, & Mohr, 2005). Alzheimer’s disease patients also show raised 
cortisol levels (Popp et al., 2009, 2015), which are associated with a more rapid cognitive decline 
when present in the pre-clinical stage of the disease (Popp et al., 2015). The precise relevance of 
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raised cortisol to depression in Alzheimer’s disease is unclear, as plasma cortisol level following 
dexamethasone suppression testing has been found to positively correlate with number of total and 
major depression symptoms (Greenwald et al., 1986), while CSF cortisol does not appear to differ 
between depressed and non-depressed Alzheimer’s disease patients (Hoogendijk, Meynen, Endert, 
Hofman, & Swaab, 2006). Similarly, the increase of certain pro-inflammatory cytokines appears to 
play a role in depression (Schiepers et al., 2005), and Alzheimer’s disease also exhibits a profile of 
raised cytokines (Swardfager et al., 2010), which could in principle contribute to depression 
pathogenesis in Alzheimer’s disease. The neurotrophic factor BDNF is lowered in depressed patients 
(Sen, Duman, & Sanacora, 2008), and the Val66Met BDNF genetic polymorphism confers an 
increased risk of depression in Alzheimer’s disease (Borroni et al., 2009).   
While the above phenomena are interesting and merit further study, there is another aspect 
of depression in Alzheimer’s disease that remains relatively neglected. In light of anhedonia being a 
critical facet of depression, and a prevalent occurrence in Alzheimer’s disease, the functionality of 
the reward system in Alzheimer’s disease is an important topic. Reward circuitry in the brain which 
underlies pleasurable reactions could plausibly be a site of pathology in Alzheimer’s disease, leading 
to anhedonia. This could theoretically occur by loss of structural integrity or volume, or by more 
subtle events including alterations in neurotransmitter or receptor function, or both. 
 
1.2.5.2 Biology of anhedonia in Alzheimer’s disease 
Given that anhedonia is known to occur in Alzheimer’s disease, and that dysfunction within 
the reward system could give rise to this anhedonia, the integrity of the reward system in 
Alzheimer’s disease merits close inspection. In brief, this reward system includes cortical structures 
such as the orbitofrontal cortex, insula and anterior cingulate cortex, as well as limbic structures 
such as the nucleus accumbens and ventral pallidum, and brainstem structures such as the 
parabrachial nucleus (Berridge & Kringelbach, 2013). Brain imaging studies of the sort used to 
investigate depressed patients, aimed at the reward system during reward-based tasks, are lacking 
in Alzheimer’s disease patients. However, there are several post mortem studies which have 
investigated reward-related sites in the brain, in the context of the pathological lesions, neuronal 
loss and neurodegeneration of Alzheimer’s disease. In Alzheimer’s disease patients, Aβ plaques and 
NFTs are present in the striatum generally (Braak & Braak, 1990), the nucleus accumbens specifically 
(Suenaga, Hirano, Llena, Yen, & Dickson, 1990), the orbitofrontal cortex (Van Hoesen, Parvizi, & Chu, 
2000), and parabrachial nucleus (German et al., 1987; Parvizi, Van Hoesen, & Damasio, 1998), 
demonstrating that pathological Aβ accumulation and NFT formation occur in recognised sites of the 
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reward system (Berridge & Kringelbach, 2015). In addition to the presence of pathological lesions, 
one MRI study has shown volume reduction in the nucleus accumbens in Alzheimer’s disease 
(Pievani et al., 2013), and gross structural changes to the orbitofrontal cortex have been reported 
post mortem (Van Hoesen et al., 2000). Cholinergic neuron loss in the ventral striatum and ventral 
pallidum is also seen in Alzheimer’s disease (Lehéricy et al., 1989; Lehéricy, Hirsch, Hersh, & Agid, 
1991), although it is not clear how this relates to hedonic processing. 
While these findings do not conclusively demonstrate impaired hedonic processing circuitry 
in Alzheimer’s disease, they do show that the brain structures involved in a functional reward system 
are affected by Alzheimer’s disease pathology. It is not an unreasonable assumption, therefore, that 
changes such as these could produce anhedonia in Alzheimer’s disease. Furthermore, to the extent 
that anhedonia could emerge early in the course of Alzheimer’s disease, its antecedents are unlikely 
to include widespread neuronal loss or tissue atrophy, as these are later occurrences in the 
pathological chain of events. Events which would better explain anhedonia early in Alzheimer’s 
disease may include either some direct action of Aβ in impairing hedonic processing, or a 
downstream effect on some particular neurotransmitter or signalling pathway, or both. Given that 
Aβ is particularly active at synapses and this is thought to contribute to early memory symptoms in 
Alzheimer’s disease (Gong et al., 2003; Lacor et al., 2004), the synapse may also be a sensible 
location for investigating an early depressive symptom such as anhedonia. Opioidergic 
neurotransmission is one particularly important mechanism underlying the generation of reward 
sensations (Castro & Berridge, 2014, 2017), and may merit inspection in the context of anhedonia in 
early Alzheimer’s disease. What would be needed to investigate this in sufficient detail, and to allow 
for a potential therapy to be trialled, would be a biological system which recapitulated, to some 
extent, the early (i.e. Aβ-focused) phase of Alzheimer’s disease. Mouse models of Alzheimer’s 
disease harbouring human APP mutations offer such a system, and will be explained in the next 
section.  
 
1.3 Mouse models of Alzheimer’s disease 
1.3.1 Modelling Alzheimer’s disease in rodents 
Genetics-based mouse models of Alzheimer’s disease first appeared in the mid-1990s, and 
initially incorporated mutated forms of APP from human familial Alzheimer’s disease, which were 
overexpressed throughout the central nervous system and beyond (Games et al., 1995; Hsiao et al., 
1996). Later genetic alterations to these mouse models included the addition of human presenilin 
mutations to induce a more rapid Aβ accumulation (Radde et al., 2006), and human tau mutations to 
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reproduce a fuller tau pathology and NFTs (Oddo et al., 2003). These various mouse models serve as 
a platform for studying many facets of Alzheimer’s disease, such as the relative contributions of Aβ 
and tau to cognitive impairment, and the time course over which cognitive impairment may emerge. 
Mouse models of Alzheimer’s disease also offer the opportunity to investigate whether 
neuropsychiatric symptoms of Alzheimer’s disease, such as depression, may manifest, and to test 
potential therapeutic compounds to address both cognitive and neuropsychiatric symptoms. An 
approach to modelling the early pathological changes of Alzheimer’s disease, which could potentially 
account for the emergence of anhedonia, is the use of mice overexpressing mutant APP. 
 
1.3.2 APP overexpressing models 
 The first successful mouse models of Alzheimer’s disease featured overexpression of 
mutated human APP genes, under the control of various promoters. The first of these was the 
PDAPP mouse model (Games et al., 1995), which was followed by the Tg2576 model (Hsiao et al., 
1996) (and see Section 1.3.2.1), and then by others, such as the APP23 and J20 models (Mucke et al., 
2000; Sturchler-Pierrat et al., 1997). The presence of APP mutations in these mice leads to the 
accumulation of soluble Aβ species in the brain, deposition of Aβ plaques in several brain regions, 
and the presence of reactive astrocytes and microglia in the vicinity of Aβ plaques, all of which 
recapitulate aspects of Alzheimer’s disease in humans. These mouse models do not, however, 
capture the full repertoire of pathological changes seen in human Alzheimer’s disease; they do not 
display overt tau pathology in the form of NFTs (Spires & Hyman, 2005), and they do not feature 
widespread atrophy or neuronal loss (Irizarry, McNamara, Fedorchak, Hsiao, & Hyman, 1997). This 
incomplete pathological profile demonstrates that these mouse models are not complete or perfect 
models of Alzheimer’s disease. However, because they show synaptic loss and synaptic disturbances 
due to Aβ oligomers, along with memory impairments, it has been suggested that they provide a 
model of early or pre-clinical Alzheimer’s disease (Zahs & Ashe, 2010). Consequently, therapies 
found to be beneficial, either biochemically or behaviourally, in these mouse models should be 
viewed in this context; useful in a model of early, rather than advanced, Alzheimer’s disease. 
APP overexpressing mouse models provide a useful platform for investigating both memory 
and depressive symptoms of early Alzheimer’s disease. They display memory deficits across a range 
of cognitive tasks, including the Morris water maze (Kelly et al., 2003; Müller-Schiffmann et al., 2016; 
Puoliväli et al., 2002; Trinchese et al., 2004), radial arm maze (Balducci et al., 2010; Wright et al., 
2013), and other behavioural assays (Karl, Bhatia, Cheng, Kim, & Garner, 2012; Pozueta et al., 2013). 
In addition to impaired memory, APP overexpressing mice also display depressive behaviour. This 
has been demonstrated using conventional behavioural tests of depression, including the forced 
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swim test (Abdel-Hafiz et al., 2018; Filali, Lalonde, & Rivest, 2009), tail suspension test (Iascone et al., 
2013), and sucrose preference test (Romano et al., 2015). The appropriateness of these tests for 
depression, and a novel alternative which may be more suitable for gauging anhedonia, will be 
discussed briefly in Section 1.3.3, and at more length in Sections 2.2.1 and 3.4. Given that an APP 
overexpressing mouse model is a useful tool for investigating early depressive symptoms of 
Alzheimer’s disease, such as anhedonia, a generally representative mouse model needs to be 
selected. This thesis will use the Tg2576 mouse model, which is discussed next. 
 
1.3.2.1 The Tg2576 mouse model 
 The Tg2576 model was first reported in 1996 (Hsiao et al., 1996), and features a human APP 
double mutation (K670N/M671L), found in a Swedish family with familial Alzheimer’s disease (the 
‘Swedish’ mutation; APPSwe) (Mullan et al., 1992). This APP double mutation is expressed in Tg2576 
mouse brain at an approximately 5 to 6 times greater level than endogenous mouse APP, under 
control of the hamster prior promoter (Hsiao et al., 1996). Tg2576 mice display a marked rise in 
soluble Aβ40 and Aβ42 brain levels beginning around 8 months of age, along with appearance of 
early Aβ plaques from 7-8 months of age (Kawarabayashi et al., 2001), with Aβ deposition occurring 
in, but not limited to, frontal, temporal and entorhinal cortex, and the hippocampus (Hsiao et al., 
1996). Aβ plaques in Tg2576 mouse brain are eventually associated with microglial and astrocytic 
involvement, and dystrophic neurites (Hsiao et al., 1996). Despite exhibiting Aβ pathology, NFT 
formation and extensive neuronal loss are not seen in Tg2576 mice (Irizarry et al., 1997; Spires & 
Hyman, 2005), though synaptic disturbances, such as decreases in dendritic spine density, are seen 
from 4 months of age (Dong, Martin, Chambers, & Csernansky, 2007; Jacobsen et al., 2006; Spires-
Jones et al., 2007). Thus neuropathologically, Tg2576 mice are a good model of the early changes 
seen in Alzheimer’s disease. 
Tg2576 mice show impaired learning and memory abilities across a range of testing 
paradigms, and potentially show some type of depressive behaviour. Tg2576 mice display memory 
deficits in the Morris water maze and Y-maze (Hsiao et al., 1996), a T-maze task, (Chapman et al., 
1999), and in contextual fear conditioning (Jacobsen et al., 2006), similar to other APP 
overexpressing models. An aspect of memory in Tg2576 mice that has been investigated in multiple 
studies is object-in-place memory, that is, the preference for exploring spatially switched objects in 
an arena (Dix & Aggleton, 1999). Tg2576 mice, at 14 months of age, display intact object novelty and 
object recency preferences, but show an impairment in their preference for exploring spatially 
switched objects (Hale & Good, 2005), a deficit also found at 10-12 and 21 months of age (Good & 
Hale, 2007; Good, Hale, & Staal, 2007). In addition to impaired memory, Tg2576 mice potentially 
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display some type of depressive behaviour, though this is based on just one study, which found that 
Tg2576 mice fail to develop a preference for a location paired with chocolate, and consume less 
chocolate than wild-type mice (Nobili et al., 2017). This was taken to indicate a deficiency in reward 
processing in Tg2576 mice, suggestive of a ‘depression-like’ behaviour. This finding could indeed 
represent some dysfunction of reward processing, though reduced consumption does not 
necessarily imply a lack of reward (see Section 1.3.3). Behaviourally too, then, Tg2576 mice are 
representative of APP overexpressing models, displaying memory deficits and some degree of 
depressive behaviour. 
Tg2576 mice are thus a sensible choice for examining anhedonia in pre-clinical Alzheimer’s 
disease. That the depressive behaviour of Tg2576 mice has only been examined in one study, 
suggests that there is a need for further investigation, and with a technique more sensitive to the 
core depression symptom of anhedonia. In addition to this, Tg2576 mice offer the opportunity to 
capture when depressive symptoms might emerge relative to memory impairments, i.e. prior to, 
alongside, or after a cognitive deficit manifests. This type of dual hedonic-cognitive profile could be 
informative in many ways. For example, an early anhedonic phenotype relative to cognitive 
impairment could imply a particular vulnerability of the reward circuitry underlying anhedonia to the 
damaging presence of soluble Aβ species, over that of hippocampal circuitry. Conversely, a hedonic 
deficit that emerged relatively late might suggest a certain robustness of reward pathways in the 
presence of Aβ. The timing of the two deficits could potentially help to clarify the earliest symptoms 
of pre-clinical Alzheimer’s disease; a depressive symptom such as anhedonia occurring prior to a 
cognitive deficit could lend weight to the suggestion that depression is an important part of 
prodromal Alzheimer’s disease (Sun et al., 2008). A finding such as this, if widely replicated and 
confirmed in humans, could potentially aid in the diagnosis of Alzheimer’s disease. The inclusion of a 
cognitive test will also allow the investigation of whether a therapeutic compound can benefit 
cognition, as well as mood, in Tg2576 mice. The issue of testing for depression in rodents, and a 
novel method for investigating anhedonia, will briefly be discussed next. 
 
1.3.3 Testing for depression in rodents 
The commonly used assays of depression are not necessarily appropriate for detecting 
anhedonia, and in some cases may not be the most appropriate tests for depression in general. 
Forced swim and tail suspension tests are thought to capture a state of despair (Porsolt, Brossard, 
Hautbois, & Roux, 2001), which is neither a core component of depression nor related to anhedonia. 
Sucrose preference testing, in which preference for a sucrose solution over water is calculated based 
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on amount of each fluid consumed, is presented as sensitive to hedonic changes (Willner, Towell, 
Sampson, Sophokleous, & Muscat, 1987). However, sucrose preference is a measure derived from 
amount consumed, and it has been demonstrated that amount of a sweet solution consumed can 
decrease, while positive hedonic reactions to that solution, when it is experienced, can remain intact 
(Pelchat, Grill, Rozin, & Jacobs, 1983). Thus a decrease in sucrose preference, which derives from the 
amount consumed, is not necessarily evidence of anhedonia. A novel method for investigating 
depressive behaviour, which is sensitive to anhedonia and not derived from gross consumption, is 
lick cluster analysis (Dwyer, 2012). This is based on objective recordings of the lick microstructure of 
rodents when consuming palatable solutions (Davis & Smith, 1992), and is thought to capture the 
hedonic reactions to those solutions, regardless of the precise amount consumed (Dwyer, 2012). 
This approach is based on the idea that a measurably reduced response to something which is 
normatively pleasurable would by definition be an example of an anhedonic reaction, and therefore 
this task should be sensitive to an aspect of anhedonia-related behaviour in rodents. A similar 
phenomenon of reduced hedonic reactions to a sweet stimulus has been observed in dementia 
patients (Perl et al., 1992), though reduced palatability has not been observed within depression per 
se (Scinska et al., 2004, Swiecicki et al., 2015). Thus lick cluster analysis is an ideal method for the 
longitudinal assessment of anhedonia in Tg2576 mice. 
There has been relatively little investigation of the neurobiology responsible for lick cluster 
size in response to palatable substances. This has, however, been better characterised in the 
separate but conceptually similar task of taste reactivity testing, in which reward sites such as the 
nucleus accumbens, orbitofrontal cortex and ventral pallidum, and neurotransmitters such as 
opioids and endocannabinoids are involved. This material is discussed further in Sections 3.1 and 5.1. 
This is a relatively brief justification for using lick microstructure analysis; more details are presented 
in Section 2.2.1, and an evaluation of lick cluster analysis relative to other behavioural tests for 
depression can be found in Section 3.4. 
 
1.4. Proposal for thesis of the PhD 
Depression is a common and early problem in Alzheimer’s disease, with multiple negative 
consequences, and an important component of this depression is anhedonia. A major aim of this 
thesis is to investigate whether the early pathological event of Aβ build-up could be one cause of 
anhedonia in Alzheimer’s disease. Given that conventional antidepressants do not appear 
particularly effective in Alzheimer’s disease, another aim of the thesis is to investigate whether an 
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alternative antidepressant agent could reduce Aβ-dependent anhedonia. To this end, the use of an 
antidepressant thought to target anhedonia will be of particular interest. 
A good way to model the early, Aβ-related, pathological changes of Alzheimer’s disease is 
the use of APP overexpressing mice, of which Tg2576 mice are a representative model. Tg2576 mice 
can thus be used to investigate the contribution of Aβ accumulation to anhedonia. As Aβ levels in 
Tg2576 mice are initially low and increase with age, a sensible investigation of anhedonia would be 
the longitudinal profiling of anhedonia as these mice age. Standard behavioural tests used in 
assessing depression in rodents either do not measure anhedonia, or are not necessarily indicative 
of anhedonia; a novel method of gauging anhedonia known as lick cluster analysis will thus be used 
for the longitudinal assessment of anhedonia in Tg2576 mice. 
An additional aim of this thesis is to profile memory impairment in Tg2576 mice alongside 
the longitudinal measurement of anhedonia. The object-in-place memory deficit in Tg2576 mice has 
been replicated, and appears to be robust and stable, as its presence has been demonstrated over a 
range of several months. This would suggest that object-in-place testing is appropriate for 
characterising the memory decline in Tg2576 mice. A longitudinal profile of this deficit has not been 
previously characterised, and will be a novel finding in its own right. In addition, this could provide 
further behavioural context into which a potential anhedonic profile of Tg2576 mice can be placed. 
In summary, the aims of this thesis are to longitudinally investigate anhedonia and memory 
impairment in Tg2576 mice, by the use of lick cluster analysis and object-in-place testing, 
respectively, and to trial a novel antidepressant agent whose activity may reduce anhedonia. The 
biochemical bases of any hedonic or cognitive deficits, or antidepressant effects, will also be 
investigated. In particular, opioidergic and NMDA receptor-related changes, which may relate to 
hedonic or cognitive behavioural changes, respectively, will be examined.
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Chapter 2: Methods 
 
2.1 Housing, breeding and genotyping of Tg2576 mice 
2.1.1 Housing of Tg2576 mice 
All mice were housed in a dedicated holding room in the Behavioural Neuroscience 
Laboratory, Cardiff School of Psychology. Housing conditions included a 12 hour light/dark cycle 
(08:00 – 20:00), and regulated temperature (21 ± 2°C) and humidity (55% ± 10%). Holding cages of 
dimensions 48×15×13 cm (D×W×H) contained sawdust and cotton squares for bedding, and 
environmentally enriching items (wooden chew sticks and cardboard tubes). Standard mouse chow 
and a bottle of clean drinking water were freely available to caged mice, except when noted 
otherwise (i.e. food restriction as part of an experimental design). The health and well-being of mice 
were regularly monitored by JBIOS animal unit technicians and the Named Animal Care and Welfare 
Officer. Mouse cages were cleaned, and fresh chow and water provided, on a weekly basis. All 
behavioural testing occurred in the light phase of the light/dark cycle, and all experiments were 
conducted in accordance with the Animals (Scientific Procedures) Act 1986. 
 Tg2576 and wild-type mice forming the experimental cohorts were initially housed in groups 
of between 2 and 5. However, by around 4-5 months of age, aggression between mice was often 
seen. As a result, many mice were eventually separated and single-housed. By the end of 
behavioural testing the majority of mice were single-housed, such that it affected both genotypes to 
a roughly equal extent. Where this was not the case at the start of behavioural testing, further 
separation was carried out in order that one genotype was not disproportionately affected over the 
other. Two colonies of Tg2576 and wild-type mice were generated for behavioural experiments, 
numbering 42 transgenic and 41 wild-type mice at the start of behavioural testing, and spaced 
roughly 6 weeks apart in date of birth. This provided both a populous sampling group for the initial 
lick cluster studies, in which group numbers typically number a minimum of 16 each (Lydall, Gilmour, 
& Dwyer, 2010; McNamara, Davis, Dwyer, John, & Isles, 2016), and allowed for a between-subjects 
drug manipulation after the lick cluster age profile had been obtained, even with some degree of 
cohort attrition. 
 
2.1.2 Breeding schedule and weaning 
The Tg2576 line was acquired by the Cardiff School of Psychology in 1998, and was initially 
founded by a C57Bl/6j x SJL F3, then crossed twice into C57Bl/6j (Hsiao et al., 1996). Further 
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generations were crossed to C57Bl/6j × SJL F1 (Chapman et al., 1999). Since acquisition, Tg2576 mice 
have been maintained at the Cardiff School of Psychology, generally as follows. Adult male 
heterozygous Tg2576 mice (up to 10-12 months of age) derived from in-house breeding were paired 
with 8-10 week old female BL6SJL mice acquired from Jackson laboratories. The female BL6SJL mice 
had acclimated to the Cardiff Behavioural Neuroscience Laboratory housing conditions over a 2 
week period, after which they were paired one to one with male Tg2576 mice in a dedicated 
breeding room, under housing conditions as previously described. The paired male and female mice 
were separated after a 2 week period, with male Tg2576 mice being returned to their cages, and 
female BL6SJL mice remaining in the breeding room to give birth. Once litters were born, the 
offspring were monitored and eventually separated between 21 and 28 days of age, dependent on 
their level of development. Offspring were initially group-housed in cages containing between 2 and 
5 mice. Due to the additional variability the oestrus cycle of mammals can introduce to behavioural 
and biochemical results, only male offspring were retained when creating the experimental cohorts 
of mice. These male mice were ear clipped for identification purposes, with the resultant ear tissue 
being used to genotype the mice. 
 
2.1.3 Genotyping 
 Mouse ear tissue was collected in 1.5mL nuclease-free microcentrifuge tubes, and kept on 
dry ice immediately prior to DNA extraction. DNA extraction and genotyping were carried out using 
the Phire Tissue Direct PCR Master Mix kit (Thermo Scientific). Each ear tissue sample was mixed 
with 20µL Dilution Buffer and 0.5µL DNARelease Additive, vortexed and briefly centrifuged, then left 
to react for 5 minutes at room temperature. Three further vortex and centrifugation cycles were 
carried out, punctuated by two periods of heating at 98°C (lasting 3 and 2 minutes, respectively). 
Samples were then stored at -20°C until being genotyped. 
 Genotyping samples were prepared in 0.5mL nuclease-free PCR tubes at 4°C. Each sample 
comprised 3µL extracted DNA sample and 20µL master mix (made up of nuclease-free water, Phire 
Tissue Direct PCR Master Mix, and 3 oligonucleotide primers). Primer sequences for amplifying 
endogenous murine prion protein, present in all mice, were 1501 (5’-
AAGCGGCCAAAGCCTGGAGGGTGGAACA-3’, 50pmol/µl) and 1502 (5’-
GTGGATAACCCCTCCCCCAGCCTAGACCA-3, 10pmol/µl).  Primer sequences for amplifying APPSwe, 
the transgene specific to Tg2576 mice, were 1502 and 1503b (5’-CTGACCACTCGACCAGGTTCTGGGT-
3’, 10pmol/µl). All primers were sourced from Eurofins Genomics. A positive control sample (known 
transgenic Tg2576 mouse), negative control sample (known wild-type mouse) and water blank 
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(nuclease free water in master mix) were also made. Samples were then heated via a PCR thermal 
cycling machine, as described in Table 2.1. 
 
Step Temperature Time 
1 98°C 5 minutes 
2 92°C 5 seconds 
3 72°C 5 seconds 
4 72°C 3 minutes 
Repeat steps 2-4 x39 
5 72°C 5 minutes 
6 4°C ∞ (until electrophoresis) 
Table 2.1. PCR thermal cycling programme used for genotyping Tg2576 and wild-type mice. 
 
After thermal cycling completion, 20µL of sample was mixed with 4µL Novel Juice 
(GeneDireX), which contains 3 tracking dyes to visualise DNA bands and migration (Bromophenol 
Blue, Xylene Cyanol FF and Orange G). Samples and Novel Juice were mixed on aluminium foil 
cleaned with 100% ethanol. 20µL of each sample-Novel Juice mixture was then loaded onto a 1% 
agarose gel (TopVision Agarose, Thermo Scientific) made with, and submerged in, diluted Tris-
acetate-EDTA 50X buffer (Thermo Scientific). To confirm the base pair number of DNA bands, 10µL 
of a 50 base pair DNA ladder (GeneDireX) was mixed with 2µL Novel Juice and loaded on to the gel. 
The loaded samples were electrophoresed at 100 volts applied for 1 hour, and the gel was then 
visualised using a Syngene G:BOX Chemi XX6. Samples from transgene-positive Tg2576 mice 
produced two bands of approximately 300 and 600 base pairs, while transgene-negative wild-type 
mice produced one band of approximately 600 base pairs (see Figure 2.1 below for an exemplar 
image). 
 
Figure 2.1. Tg2576 mouse genotyping gel electrophoresis image. Lanes 1 - 4 and 8 represent wild-type mice. 
Lanes 5 - 7 and 9 - 11 represent transgenic Tg2576 mice. Lanes 12, 13, 14 and 15 represent transgene-positive 
Tg2576 control, transgene-negative wild-type control, water blank and 50bp ladder, respectively. 
300 bp 
600 bp 
1200 bp 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
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2.2 Lick microstructure analysis. 
2.2.1 Background 
The measuring of lick cluster size in this thesis involves recording the licking behaviour of 
mice when given access to a palatable solution. This approach builds on pioneering research by J.D. 
Davis and others, who found that rats consume fluids in rhythmic runs (or clusters) of licks, 
separated by pauses (Davis & Smith, 1992). A lick cluster is defined as a sequence of licks separated 
by an inter-lick interval (ILI) of no more than a given interval, where an ILI exceeding this number 
signifies the beginning of a new lick cluster. ILIs are distributed regularly within a lick cluster, but are 
irregularly distributed between lick clusters; in rat studies, a pause criterion of 0.5s effectively 
cleaves ILIs into those falling within and without lick clusters (Davis & Perez, 1993; Davis & Smith, 
1992). Though the microstructure of the licking behaviour of mice has not been characterised to the 
extent it has been in rats, it appears largely similar, albeit mice tend to have shorter ILIs within 
clusters (Boughter, Baird, Bryant, St John, & Heck, 2007). The significance of this is that a shorter 
pause criterion for grouping ILIs into within clusters and between clusters, such as 0.33s, is probably 
more appropriate (though this would not materially alter conclusions drawn from lick cluster size 
much of the time, as most ILIs longer than 0.33s will also be longer than 0.5s). 
The mean number of licks in a cluster (or lick cluster size) is not an arbitrary figure, but is 
lawfully related to the nature of the ingested solution: lick cluster size generally increases 
monotonically with the concentration of palatable solutions (e.g. sucrose) and decreases 
monotonically as the concentration of unpalatable solutions (e.g. quinine) increases (Davis & Smith, 
1992; Hsiao & Fan, 1993). Conditioned taste aversion experiments have shown that when a 
palatable solution is paired with lithium chloride (which induces gastric malaise), lick cluster size is 
reduced as a consequence (Dwyer, 2009). Moreover, lick cluster size is not merely a proxy for 
consumption, because the two measures can dissociate (for a review see Dwyer, 2012). In addition, 
drug manipulations which enhance hedonic responses in humans (e.g. benzodiazepines), also 
augment lick cluster size (Higgs & Cooper, 1998). These findings relating to changes in lick cluster 
size derive from rat studies and, while this level of investigation has yet to occur in mice, lick cluster 
size seems to behave similarly in the latter species. For example, increases in sucrose concentration 
produce increases in lick cluster size in mice (Clarkson, Dwyer, Flecknell, Leach, & Rowe, 2018; 
Davies et al., 2015), and the dissociation between consumption and hedonics seen in rats can also be 
observed in mice (Davies et al., 2015). In general, pleasant substances produce higher lick cluster 
sizes, and unpleasant substances produce lower lick cluster sizes. Importantly, the fact that lick 
cluster size can change without the solution changing suggests that it reflects the animal’s reaction 
to the solution rather than being a fixed property of the solution itself. Given this, a lower lick cluster 
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size in response to a normatively positive substance would represent a diminished reaction to that 
pleasant substance, analogous to anhedonia. This has been observed in mice (Austen, Sprengel, & 
Sanderson, 2017; McNamara et al., 2016). 
Interpreting lick cluster analysis does depend on the measuring of other behavioural 
variables which can influence lick cluster size, such as the ILI and the amount consumed per lick. An 
interpretation in favour of a hedonic deficit can be made if inter-lick interval and amount per lick can 
be discounted as, or are unlikely to be, major influences on lick cluster size. Overall amount 
consumed is another response to palatable solutions which can be recorded in lick cluster studies, 
which can dissociate from the hedonic reaction to that solution (as described in Chapter 1).  
 
2.2.2 Experimental details 
 Lick cluster analysis necessarily requires some minimum level of consumption to occur. In 
order to incentivise consumption to obtain a reliable measure of lick cluster size, mice were mildly 
food-deprived prior to pre-training and testing sessions, except where noted. Food was removed in 
the morning and returned roughly 6-8 hours later, after testing had finished. Mice were weighed 
each pre-training and testing day; baseline weight was recorded at the time of food deprivation, and 
post-deprivation weight was recorded immediately prior to behavioural testing. Any mouse whose 
body weight fell below 85% of its initial baseline weight and did not recover, had access to food 
immediately restored, though this was a rare occurrence. Outside of the 6-8 hour food deprivation 
period, animals had access to food and water ad libitum. In addition, when testing at 16 months of 
age, mice alternated between food-deprived days and free-feeding days, in order to examine 
whether deprivation itself influenced lick cluster size (Section 3.2.4.5). 
The material conditions of testing occurred as described in previous lick cluster studies 
(Davies et al., 2015; Lydall et al., 2010). Briefly, testing occurred in a room housing 16 drinking 
chambers, which were semi-translucent plastic boxes with dimensions of 30×13×12.8 cm (D×W×H), 
metal grid floors and metal lids. Sucrose solutions were presented in 50mL plastic cylinders with 
stainless steel drinking spouts, which were inserted into the right side of a drinking chamber at the 
start of each experimental session. A touch-sensitive lickometer noted the time of each lick to the 
nearest 0.01 second; this was recorded via MED-PC software (Med Associates Inc., St. Alban’s, VT, 
USA) on a Windows-enabled PC. 
At all time points, a pre-training period occurred prior to experimental drinking sessions, in 
which mice were given access to an 8% w/w sucrose solution, and of sufficient length (4-10 days) for 
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consistent levels of consumption to be reached. Following this pre-training period, experimental 
sessions occurred in two phases of equal length (see Chapter 3 for precise details); in the first phase, 
roughly half of each genotype received 4% sucrose, with the other half receiving 16%; in the second 
phase, animals which had received 4% sucrose in phase 1 received 16% sucrose, and vice versa. All 
drinking sessions were started approximately 3 hours after the animals’ food was first removed, and 
all sucrose solutions were made on the day of testing, using deionised water. Pre-training and 
experimental drinking sessions lasted 10 minutes, during which time the experimenter was absent 
from the testing room. The weight of fluid consumed by each animal per session was determined by 
weighing its drinking bottle before and after that session. As well as recording baseline weight, 
weight change following food restriction, and sucrose consumption each day, average ILI within 
clusters and amount consumed per lick were also derived from the recorded data. Data were 
aggregated across all test days at each concentration, except days where there was evidence of 
failure of either lick recording or drinking spout, or where extremely little drinking occurred (i.e. less 
than 50 licks in a session). Any mouse with less than two days’ drinking data at one or both phases 
was also removed from analysis, as this could not be taken as a reliable measure of its behaviour. 
For information on cleaning of data at each time point, see Chapter 3. Data were analysed using 
0.33s as the pause criterion for defining a new cluster beginning, though data were also collected 
using 0.25s, 0.5s, 0.66s and 1s pause criteria (the pattern of results was not materially different 
between pause criteria, and thus the data at criteria other than 0.33s will not be presented or 
discussed further). 
 
2.3 Object-in-place testing 
2.3.1 Background 
For the purposes of this thesis, the object-in-place cognitive test has several advantageous 
features over other test paradigms and object-based assays. Other conventional approaches to 
testing rodent memory include the Morris water maze, radial arm maze and T- or Y-mazes (Vorhees 
& Williams, 2014). The Morris water maze features an aversive element as it involves placing rodents 
in water (Morris, 1984), and, although this is not procedurally or environmentally identical to the 
forced swim test (Porsolt, Le Pichon, & Jalfre, 1977), repeated water maze tests will likely still 
produce some level of distress. Given that a major aim of this thesis is to profile a depression-related 
behaviour over time, interpreting results of lick cluster studies would be complicated by the 
repeated use of a distressing task, which could in its own right potentially contribute to or influence 
a depressive phenotype. Maze tests typically include an appetitive component such as sucrose 
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reward (Vorhees & Williams, 2014); both reward and satiety processing may be aberrant in Tg2576 
mice (Ishii, Wang, Racchumi, Dyke, & Iadecola, 2014; Nobili et al., 2017), both of which may alter 
motivation towards and consumption of such rewards. As Tg2576 mice may not experience 
rewarding substances in the same way as wild-type mice, a test of cognition which does not include 
reward is preferable. In addition, appetitive maze tasks typically involve some degree of food 
deprivation to ensure animals are motivated towards finding food rewards (Vorhees & Williams, 
2014). Pre-existing reward or satiety processing alterations in Tg2576 mice may mean that food 
deprivation produces unequal motivational states in Tg2576 and wild-type mice, which could 
complicate interpretation of results. A cognitive test that does not rely on food deprivation to induce 
motivation is thus also preferable. Object-related cognitive tests provide such an assay, as they rely 
on the natural tendency of rodents to spontaneously explore objects, in a non-aversive, non-
rewarded, and non-deprived setting (Dix & Aggleton, 1999; Ennaceur & Delacour, 1988). 
There are a number of possible object exploration-based tests which could be used to profile 
cognition in Tg2576 mice. These tests broadly investigate recognition memory, that is, the 
remembering that an item or event has been previously encountered (Mandler, 1980). Specifically, 
recognition memory tests can investigate object novelty per se (Ennaceur & Delacour, 1988), objects 
in novel locations (Ennaceur, Neave, & Aggleton, 1997), and specific object-location associations (Dix 
& Aggleton, 1999), among other manipulations. Typically, rodents will display a preference for 
exploring novel objects, locations, and specific object-location associations in the previously 
mentioned tests. Importantly, these facets of recognition memory have all been investigated in 
Tg2576 mice (Good & Hale, 2007). Tg2576 mice display an intact preference for exploring novel 
objects, and familiar and novel objects in new locations, yet are unable to integrate specific object-
location associations, showing a diminished recognition of objects that exchange positions in a 4 
object array (Good & Hale, 2007). This deficit in object-in-place memory has been detected at 10-12 
(Good, Hale, et al., 2007), 14 (Hale & Good, 2005), and 16 and 21 months of age (Good & Hale, 
2007), and appears to be of a roughly similar magnitude at these time points. Given that this deficit 
appears robust and has been revealed in multiple studies, the object-in-place task is a suitable 
choice for profiling cognitive decline in the Tg2576 mouse. This deficit and its potential neural 
underpinnings will be discussed in more detail in Chapter 4. The methodology used for the object-in-
place task in this thesis is discussed below, and in Chapter 4. 
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2.3.2 Experimental details 
Testing occurred in a well-lit and quiet room, featuring distinct visual cues of different 
shapes and colours on the walls. A Perspex arena (60×60×40cm), with a grey floor and transparent 
walls covered with white paper, was positioned in the centre of the room and at just below waist 
height. Activity in the arena was watched and recorded via a camera directly above, at ceiling height, 
which was connected to a monitor and a Philips DVDR recorder. All objects chosen for habituation 
and object-in-place experiments had been used in previous experiments, were composed of non-
porous material, and built so as to withstand the investigative behaviour of mice. During all 
habituation and test sessions, contact with objects was defined as a mouse oriented towards an 
object within a distance of 1cm, and sniffing or otherwise investigating the object. Climbing or sitting 
atop an object was not recorded as contact time. Object contact was manually recorded using 
stopwatches, with the experimenter sitting out of sight of the mice in the arena. Prior to all 
habituation and test sessions, between mice, and between sample and test phases, objects and the 
arena were wiped clean with 70% isopropyl alcohol wipes, in order to remove odour cues, urine and 
excrement. 
Mice were run in separate squads for object-in-place testing, in which each squad went 
through a habituation phase then a test phase, which were taken from a prior PhD thesis which 
investigated visuospatial memory in Tg2576 mice (Hale, 2007). The habituation protocol was as 
follows: at the first time point, mice spent 10 minutes on 2 consecutive days in the empty arena, 
followed by 10 minutes on 2 consecutive days with 2 identical objects placed 10cm apart in the 
arena centre, which they could freely explore. At every time point thereafter, habituation consisted 
solely of the latter object-presenting portion. A new pair of identical objects was used for 
habituation at each time point. The test phase consisted of a sample trial in which mice could freely 
explore an array of 4 objects, a 2 minute inter-trial interval, and a 10 minute test trial in which 2 of 
the 4 previously encountered objects exchanged positions (mismatched objects), along a diagonal 
plane (see Figure 2.2 for a diagrammatic example). Objects in the sample and test trial were placed 
in the centre of the arena, approximately 15cm apart. The sample trial was 10 minutes for transgenic 
mice, and of variable length (up to 10 minutes) for wild-type mice, as a yoked protocol was adopted 
in order to match object sampling time between genotypes (described in more detail below). At 
each time point, every mouse was tested on 2 separate and distinct 4 object arrays on 2 consecutive 
days; object set and diagonal shift (top right-bottom left versus top left-bottom right) were 
counterbalanced across genotype and day. Further counterbalancing details are included in Chapter 
4. 
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As prior experiments have revealed that Tg2576 mice tend to display lower contact times 
with objects than wild-type mice (Good & Hale, 2007; Hall et al., 2016), a yoking procedure was 
employed in the object-in-place sample trials. Each wild-type mouse was yoked to a Tg2576 mouse, 
and was allowed to accumulate the same amount of total object contact time in the sample phase 
that its transgenic counterpart had accumulated over 10 minutes. Yoking was achieved by the 
experimenter manually timing the total object contact a wild-type mouse accumulated in the sample 
phase, and ending the sample phase once total object contact time had reached that of the prior 
Tg2576 mouse. Yoking was only applied to the sample phase of object-in-place testing; there was no 
criterion set for object contact times mice needed to accumulate in the test phase, outside of the 
minimum level of exploration noted below. If a wild-type mouse happened to display less contact 
time than its transgenic counterpart, then it was given the full 10 minute sample phase. While the 
yoking procedure used may lower the performance of wild-type mice in absolute terms, it ensures 
that the sampling of objects is equivalent between genotypes, and that any deficits seen are not 
simply due to differences in overall levels of exploration in the sample phase. 
Test phase data were initially collected as raw contact times, and also converted to 
discrimination ratios, by the following formula: mismatched object exploration (sec)/(familiar object 
exploration (sec) + mismatched object exploration (sec)). Discrimination ratios significantly greater 
than 0.5 indicate a preference for exploring mismatched objects, while ratios not significantly 
different from, or lower than, 0.5 indicated no discernible preference for exploring mismatched 
objects. Data were averaged to mean contact times over the 2 test days, and mean discrimination 
ratios over the 2 test days, prior to analysis. Any mouse showing low contact times (either <1s total 
object contact or no exploration of either familiar or mismatched objects) had that day’s data 
removed. The specific details of data cleaning at each time point are covered in Chapter 4. 
 
 
 
 
 
 
 
 
 
  
Inter-trial interval 
(2 minutes) 
Sample trial                 
10 minutes (TG)              
Matched contact (WT) 
 
Test trial                       
10 minutes (TG & WT)               
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Figure 2.2. Schema representing object-in-place testing protocol, displaying a 4 object array in an arena, within 
which two objects exchange locations in the test trial. TG = Tg2576 mice, WT = wild-type mice. 
 
A schema illustrating the full behavioural testing schedule which both mouse cohorts underwent is 
shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schema illustrating the behavioural testing schedule the mouse cohorts passed through. Initial numbers reflect 
the numbers of each genotype entered into each behavioural test; bracketed numbers are the numbers of mice 
in each genotype analysed after data cleaning. 
 
2.4 Tissue collection and sample preparation 
Mice were killed by cervical dislocation, and the brain was removed. Left and right 
hippocampi and the surrounding left and right cortical tissue were dissected, collected separately in 
0.5mL tubes, and snap-frozen in liquid nitrogen. Samples were then stored at 80°C until sample 
preparation occurred. 
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42 (42)       
wild-type: 
40 (40)   
 
8 months  
Tg2576:     
42 (42)       
wild-type: 
39 (37)   
 
8-9 months   
Tg2576:     
42 (38)       
wild-type: 
38 (38)   
12 months   
Tg2576:     
40 (40)        
wild-type:  
38 (38)  
12-13 
months       
Tg2576:     
40 (37)        
wild-type: 
38 (38)  
Sacrifice 
for 
brain 
tissue 
16 months      
Tg2576:     
34 (33)        
wild-type: 
37 (36)  
16-17 
months       
Tg2576:     
34 (30)        
wild-type: 
37 (35)  
19 months      
Tg2576:     
32 (31)        
wild-type: 
32 (31)  
19-20 
months       
Tg2576:     
31 (26)        
wild-type: 
31 (31)  
19-20 
months       
Tg2576:     
31 (30)        
wild-type: 
31 (30)  
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Right hippocampus and cortex were used for human Aβ ELISAs. Samples underwent 
extractions that isolated first soluble Aβ, then insoluble Aβ. During these extraction procedures, 
samples were kept cool at 4°C. Frozen tissue samples were transferred to pre-weighed 2mL 
homogenisation tubes (Precellys CK28, 03961-1-002), re-weighed and the tissue weight was 
calculated. 2% SDS containing a protease inhibitor cocktail (set III EDTA-free, Calbiochem) at a 1:100 
ratio was added to the tissue samples at 75mg of tissue per mL of solution. Samples were 
homogenised at 6000 RPM using a Precellys 24-Dual homogeniser for two 30 second periods 
separated by a 30 second pause, then transferred to polycarbonate centrifuge tubes. Samples were 
centrifuged using a Beckman Optima Ultracentrifuge, at 100,000 x g for 1 hour at 4°C. After 
centrifugation, the supernatant (containing soluble Aβ) was transferred to a new 1.5mL 
microcentrifuge tube. 5µL of this fraction was retained for use in a protein assay, and the remaining 
fraction was aliquoted into microcentrifuge tubes, and diluted 1:5 with EC sodium buffer (20mM 
Na2HPO4/NaH2PO4, 0.2mM EDTA, 0.4M NaCl, 0.2% (w/v) bovine serum albumin (BSA), 0.05% (w/v) 
CHAPS, 0.05% (w/v) NaN3 at pH 7). Soluble fraction samples were then stored at -20°C until used in 
ELISAs. The remaining pellet was re-suspended in 70% formic acid (Sigma-Aldrich) at 150mg of tissue 
per mL of solution, and centrifuged as described previously. The supernatant (containing insoluble 
Aβ) was transferred to a new 1.5mL microcentrifuge tube, then aliquoted into microcentrifuge 
tubes, and diluted 1:20 with a neutralising buffer (1M Tris, 0.5M Na2HPO4, at pH 11). Insoluble 
fraction samples were then stored at -20°C until used in ELISAs. 
Left hippocampus and cortex were used for Western blot experiments. As synaptic receptor 
expression was of particular interest, samples underwent a synaptic protein extraction procedure. 
During this extraction procedure, samples were kept cool at 4°C. Frozen tissue samples were 
transferred to pre-weighed 1.5mL microcentrifuge tubes, re-weighed and the tissue weight was 
calculated. Syn-PERTM Synaptic Protein Extraction Reagent (Thermo Scientific) containing a protease 
inhibitor cocktail (set III EDTA-free, Calbiochem) at a 1:100 ratio, and a phosphatase inhibitor cocktail 
(set V 50X, Millipore) at a 1:50 ratio, was added to the tissue samples at a volume of 10µL per mg of 
tissue. The tissue was then homogenised using 10-15 strokes of a micropestle (Sigma-Aldrich). 
Samples were then centrifuged at 1200 x g for 10 minutes at 4°C, the supernatant was transferred to 
a new tube, and the pellet was discarded. The supernatant was then centrifuged at 15,000 x g for 20 
minutes at 4°C, and the resultant supernatant (the cytosolic fraction) was removed and stored at       
-20°C. The remaining synaptosome pellet was re-suspended in Syn-PERTM/inhibitor cocktail mixture, 
at a volume of 1.5µL per mg of original tissue weight, and mixed by pipetting. 5µL of this 
synaptosomal sample was retained for use in a protein assay. The remaining synaptosomal sample 
was diluted with 3X sample buffer, in a 2:1 sample:buffer ratio, for Western blotting (see Table 2.2 
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for sample buffer details). Samples were then stored at -20°C until used in Western blot 
experiments. 
 
Sample buffer ingredient 1X sample buffer 3X sample buffer 
Tris base 0.38g 1.14g 
SDS 2g 6g 
Glycerol 5mL 15mL 
Β-mercaptoethanol 2.5mL 7.5mL 
Bromophenol blue 0.5mL 1.5mL 
dH2O To 50mL To 50mL 
Table 2.2. Sample buffer composition. 
 
Protein quantification of samples was carried out for both ELISA and Western blot samples, 
using the PierceTM bicinchoninic acid (BCA) Protein Assay Kit (Thermo ScientificTM). In brief, a linear 
range of protein standards (BSA 2mg/mL – 0.007mg/mL) were prepared via serial dilution using 
distilled H2O. 25µL of standards or distilled H2O standard blank and 1µL of samples (including a 
sample blank made of the relevant buffer solution) were pipetted, in duplicate, into a 96-well 
SterilinTM Clear MicrotiterTM plate (Thermo ScientificTM). 200µL of working reagent (BCA Reagent A 
with BCA Reagent B in a 50:1 ratio) were added to these wells, and the plate was incubated at 37°C 
for 20 minutes. The plate was then read at 540nm, and the averaged standard blank value was 
subtracted from the averaged standard values to produce a corrected standard curve. The averaged 
sample blank value was subtracted from the averaged sample values, and the protein concentration 
of the corrected sample values was calculated using GraphPad Prism software. 
 
2.5 ELISA details 
Invitrogen human Aβ40 and Aβ42 sandwich ELISA kits (ThermoFisher Scientific) were used to 
quantify soluble and insoluble Aβ40 and Aβ42 levels. Prior to Aβ quantification, plates were 
optimised to find the appropriate sample dilution factor, in line with the manufacturer’s instructions. 
Aβ standards and samples were then prepared and/or diluted, pipetted into plate wells, and 
incubated with detection antibody for 3 hours, as per the manufacturer’s instructions. Wells were 
then aspirated, washed 5 times with 1X wash buffer from the manufacturer’s kit, and incubated for 
30 minutes with anti-rabbit IgG HRP as directed. Wells were aspirated and washed again as 
previously described, then incubated with Stabilised Chromogen for 30 minutes in the dark, after 
which Stop Solution was added. The plate was read at 450nm, standard and sample values were 
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corrected via blank substitution, and a standard curve was generated using GraphPad Prism. Sample 
Aβ values were generated from the standard curve, corrected by the dilution factor used, and 
normalised to protein concentration to give pg/mg tissue values. 
 
2.6 Western blot details 
2.6.1 Gel preparation 
 All Western blotting experiments used a 5% sodium dodecyl sulphate polyacrylamide (SDS-
PAGE) stacking gel, and a 10% SDS-PAGE separating gel (ingredients and volumes in Table 2.3), which 
were prepared in Invitrogen™ Novex™ 1.0mm cassettes (Fisher Scientific) with 12 or 15 well combs. 
 
Ingredient Manufacturer 10% separating 
gel 
5% stacking 
gel 
Distilled H2O n/a 52.7% 57% 
Alfa Aesar™ 
Acrylamide/Bisacrylamide 
37.5:1, 30% solution 
Fisher 
Scientific 
10% 
(acrylamide) 
5% 
(acrylamide) 
3M Tris.HCl Fisher 
Scientific 
12.5% n/a 
0.5M Tris.HCl/0.4% SDS 
(w/v) 
Fisher 
Scientific 
n/a 25% 
10% SDS (w/v) Fisher 
Scientific 
0.1% n/a 
10% Ammonium 
persulfate (w/v) 
Bio-Rad 0.05% 0.5% 
TEMED Sigma-Aldrich 0.05% 0.08% 
Table 2.3. Components (stated in final concentrations) of separating and stacking gels. 
 
2.6.2 Sample loading, electrophoresis and transfer 
 Samples were initially heated at 90°C for 40 minutes in a heating block, and on any 
subsequent use at 70°C for 5 minutes. Heated samples were briefly vortexed and centrifuged, then 
20µg of sample was loaded into each well and gels were run in an InvitrogenTM NovexTM XCell 
SureLock system containing tank buffer (25mM Tris base, 190mM glycine, 0.05% SDS, pH 8.3). 10μL 
of a protein standard (Precision Plus Protein™, Bio-Rad) was also loaded, to aid in identifying the 
molecular mass of any bands. Samples were stacked at 45V for 25 minutes on ice and then run at 
135V for a duration sufficient for protein separation. After separation, samples were transferred to a 
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0.45μm nitrocellulose membrane (Amersham Protran) with semi-dry transfer buffer (48mM Tris 
base, 39mM glycine, 0.038% SDS, 20% methanol) at 38mA for 1 hour. 
After protein transfer to the nitrocellulose membrane was complete, the membrane was 
rinsed in Tris-buffered saline with Tween20 (TBST: 20mM Tris base, 150mM NaCl, 0.1% Tween20, pH 
7.5) for 2 minutes to remove any remaining semi-dry transfer buffer. The membrane was cut into 
distinct sections if necessary (i.e. when investigating two different proteins of distant molecular 
weights from the same membrane), then blocked for 1 hour in 5% Blotto solution (fat-free dried milk 
5% w/v, in TBST), except when probing for the 5HT1B receptor protein when 5% BSA in TBST was 
used. 
  
2.6.3 Antibody incubation, washing, and imaging 
Following blocking, membranes were incubated overnight in a primary antibody solution at 
5°C on a tube roller. After primary antibody incubation, membranes were washed with TBST 
(1x5min, 2x15min, discarded and replaced after each wash) on a rocker, then incubated with a 
secondary antibody. Secondary antibodies were incubated for 1 hour at room temperature, on a 
tube roller. Full details of primary and secondary antibodies are listed in Table 2.4; all antibodies 
were diluted in 1% Blotto except where otherwise noted. Following secondary antibody incubation, 
membranes were washed in TBST as previously described. Membranes were then briefly placed on 
tissue paper to remove any excess TBST, then incubated with an enhanced chemiluminescence (ECL) 
solution for 5 minutes in the dark. This imaging reagent comprised equal parts of solutions A and B 
from the PierceTM ECL Western Blotting Substrate (Thermo ScientificTM), or Luminol and Stable 
Peroxide Buffer from the SuperSignalTM West Dura Extended Duration Substrate (Thermo 
ScientificTM), as per Table 2.4. After the 5 minute incubation time, membranes were imaged with a 
Syngene G:BOX Chemi XX6 using the program GeneSys G:BOX Chemi-XX6 (v1.6.1.0) to capture 
images, which were analysed as described below. 
 In certain cases the membranes were stripped of primary and secondary antibodies after 
imaging and reprobed, either for a second protein, or for β-actin. Where membrane stripping 
occurred, the membrane was washed in TBST for 2 minutes to remove any imaging reagent, then 
incubated in RestoreTM PLUS Western Blot Stripping Buffer (Thermo ScientificTM) for 7 minutes and 
the membrane was re-washed in TBST for 2 minutes. After this stripping procedure, membranes 
were re-incubated with a primary antibody solution for a new protein, or incubated with an anti-β-
actin antibody directly conjugated to peroxidase (Table 2.4) for 40 minutes at room temperature and 
imaged as above. 
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Protein Primary antibody Dilution 
factor 
Secondary 
antibody 
Dilution 
factor 
Imaging 
reagent 
5HT1B Anti-5HT1B 
Receptor Antibody 
(ab13896, Abcam) 
Host: Rabbit 
Blocked with 5% 
BSA 
1:1000 
in 1% 
BSA  
HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:15000 
in 1% 
BSA 
ECL 
SERT Anti-Serotonin 
Transporter 
(AB9726, Merck 
Millipore) 
Host: Rabbit 
1:5000 
in 5% 
Blotto  
HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:10000 
in 5% 
Blotto  
ECL 
5HT4 Anti-5HT4 Receptor 
(HTR4) 
(extracellular) 
Antibody (ASR-036, 
Alomone Labs) 
Host: Rabbit 
1:500 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:10000 West 
Dura 
NR1 Anti-NMDAR1 
(556308, BD 
Biosciences) 
Host: Mouse 
1:500 HRP Horse Anti-
Mouse IgG 
Antibody 
(Peroxidase) (PI-
2000, Vector 
Laboratories) 
1:10000 West 
Dura 
NR2B Anti-NMDAR2B 
Antibody 
(AB1557P, Merck 
Millipore) 
Host: Rabbit 
1:500 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:15000 West 
Dura 
p-NR2B Anti-NMDAR2B 
Antibody, 
phosphoTyr 1472 
(AB5403, Merck 
Millipore) 
Host: Rabbit 
1:750 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:15000 West 
Dura 
GluR1 Anti-Glutamate 
Receptor 1 (AMPA 
subtype) antibody 
(ab31232, Abcam) 
Host: Rabbit 
1:2500 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:10000 ECL 
p-GluR1 Anti-Glutamate 
Receptor 1 (AMPA 
1:1000 HRP Goat Anti-
Rabbit IgG 
1:10000 West 
Dura 
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subtype) (phospho 
S845) antibody 
(ab3901, Abcam) 
Host: Rabbit 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
PSD95 Anti-PSD95 
antibody (ab18258, 
Abcam) 
Host: Rabbit 
1:1000 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:15000 ECL 
Mu Anti-µ-Opioid 
Receptor (OPRM1) 
(extracellular) 
Antibody (AOR-
011, Alomone Labs) 
Host: Rabbit 
1:500 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:15000 West 
Dura 
Kappa  Anti-κ-Opioid 
Receptor (OPRK1) 
(extracellular) 
Antibody (AOR-
012, Alomone Labs) 
Host: Rabbit 
1:500 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:12500 West 
Dura 
Delta Anti-δ-Opioid 
Receptor 
(extracellular) 
Antibody (AOR-
014, Alomone Labs) 
Host: Rabbit 
1:200 HRP Goat Anti-
Rabbit IgG 
Antibody 
(Peroxidase) (PI-
1000, Vector 
Laboratories) 
1:10000 West 
Dura 
β-actin Anti-β-
Actin−Peroxidase 
antibody 
(A3854, Sigma-
Aldrich) 
Host: Mouse 
1:20000 Included in 
primary 
antibody 
solution. 
N/A ECL 
Table 2.4. Primary and secondary antibodies, dilution factors, and chemiluminescence reagents.  
 
2.6.4 Image analysis 
TIF images of membranes were analysed using the program ImageJ (v.1.52a, National 
Institutes of Health, USA). The intensity of sample bands was measured by framing each band in a 
box of equal dimensions (see Figure 2.4A for an exemplar image), which was then converted into a 
series of curves (see Figure 2.4B). The area under the curve was calculated using ImageJ (v.1.52a, 
National Institutes of Health, USA), and the values were imported into Microsoft Excel. 
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Figure 2.4. A: Framing of β-actin bands to produce a series of curves. B: Curves representing band intensity, 
derived from 2A.   
 
 Values for proteins were normalised to β-actin values for each sample (i.e. expressed as a 
proportion of the β-actin value). As the sample size for Western blot experiments was too large for 
all samples to be loaded onto one gel, multiple gels were used for each protein of interest. To 
account for inter-membrane variance, an internal control sample (generally a vehicle-treated wild 
type mouse in aged mice, and a wild-type mouse in young mice) was loaded across all gels for a 
given protein. β-actin-normalised sample values were then normalised to the internal control on 
each gel. This internal control sample was not included in the dataset for statistical analysis. 
 
2.7 Statistical analysis 
 Two statistical approaches were taken in this thesis, for both of which JASP 0.8.0.0 was used. 
Conventional null hypothesis significance testing was used for all behavioural and biochemical data, 
as described in Chapters 3, 4 and 5. Where assumptions of sphericity were not met for ANOVAs, 
Greenhouse-Geisser corrections were used, and where assumptions of equal variance were not met 
for Student’s t-tests, Welch’s t-tests were used. In factorial ANOVAs simple effects analyses were 
carried out where results were of conceptual importance. An alpha level of .05 was used as the 
threshold of significance throughout the empirical work. In addition, a supplementary Bayesian 
analysis was conducted where null results were of material consequence, because conventional 
significance testing fails to distinguish between a genuine absence of effect or simply uninformative 
data (Dienes, 2014). Bayesian statistics provides a ratio of the probability of observed data under 
various models, e.g. a model of the null hypothesis relative to a particular alternative model. The 
output of this analysis comes in the form of Bayes factors, which can be interpreted using a 
A B 
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convention suggested by Harold Jeffreys (Jeffreys, 1998). A Bayes factor of 1 indicates that the data 
are equally consistent with the null and alternative hypotheses (i.e. are uninformative), whereas 
Bayes factors greater than 1 indicate that the data favour the alternative over the null hypothesis, 
and Bayes factors lower than 1 indicate that the data favour the null over the alternative hypothesis 
(Dienes, 2014). The convention of interpreting Bayes factors for null results is that a Bayes factor 
between 1 and 1/3 represents anecdotal evidence for a true null effect, between 1/3 and 1/10 
suggests some degree of support for the null hypothesis, and a Bayes factor lower than 1/10 can be 
taken as strong evidence for a null effect, though these are not rigid cut-off values. Bayesian 
ANOVAs and independent samples t-tests were used in Chapters 3, 4 and 5, as described by others 
(Rouder, Morey, Speckman, & Province, 2012; Rouder, Speckman, Sun, Morey, & Iverson, 2009). For 
Bayesian interactions, Bayes factors were created by comparing the simplest model with the 
interaction to the best model without that interaction including only main effects that were within 
the interaction model.
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Chapter 3: Hedonic profile of Tg2576 
mice 
 
3.1. Introduction 
 Chapter 1 discussed how depression is a common occurrence in Alzheimer’s disease, and 
may in fact be an early or prodromal neuropsychiatric symptom. It is also unclear whether standard 
antidepressants offer any tangible benefit in depression in Alzheimer’s disease. Anhedonia is a core 
and pernicious component of depression, which may not be sufficiently addressed by conventional 
antidepressants. It is also present in Alzheimer’s disease, and may be more common as the disease 
progresses. Mouse models of Alzheimer’s disease provide an opportunity for investigating the 
presence of a depressive behaviour such as anhedonia, its biochemical basis, and the possibility of its 
treatment. 
 A major issue in studying anhedonia in Alzheimer’s disease is determining which aspect or 
aspects of the pathological process (broadly: Aβ pathology, tau pathology, and overt 
neurodegeneration) may give rise to this depression symptom. A broad investigation of these 
possibilities is not the purpose of this thesis. However, given that depression generally, and 
anhedonia specifically, are present in both early Alzheimer’s disease and mild cognitive impairment 
(Gabryelewicz et al., 2004; Lopez et al., 2003; Starkstein et al., 2005), the latter being potentially a 
precursor to Alzheimer’s disease, a sensible place to begin the investigation is with Aβ, the earliest 
pathological event. In addition to this being a logical starting point, there are suggestions from 
biomarker studies of a relationship between Aβ levels and depression symptoms. For example, 
greater cortical Aβ load was associated with a greater apathy-anhedonia factor score in cognitively 
normal older adults with subthreshold depression symptoms (Donovan et al., 2015). In a follow-up 
study with a similar cohort, participants with current subthreshold depression had greater cortical 
Aβ load than those with no history of depression (Donovan et al., 2018). However, a longitudinal 
analysis in the latter study found that greater cortical Aβ load was associated with a steeper increase 
in depression scale score over time, and with increasing anxious-depressive but not apathy-
anhedonia symptoms (Donovan et al., 2018). Similar studies have also reported an association over 
time between greater Aβ burden and both lower mood (Babulal et al., 2016), and clinically 
significant depressive symptoms (Harrington et al., 2017). While these studies point to a potential 
relationship between Aβ and depression, if not specifically anhedonia, they measured fibrillar Aβ, 
whereas it is soluble Aβ species which are thought to have the most pathological relevance. Soluble 
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CSF Aβ42 has also been investigated in relation to depression in various populations, with both some 
type of relationship between the two (Gudmundsson et al., 2007; Pomara et al., 2012), and no 
relationship (Kramberger et al., 2012; Ramakers et al., 2013), being reported. However, CSF Aβ42 is 
essentially an inverse measure of plaque or fibrillar Aβ load (Blennow, Mattsson, Schöll, Hansson, & 
Zetterberg, 2015), and as such these studies are not necessarily providing a measure of biologically 
active soluble Aβ in the brain. Despite not being greatly informative as to the exact relationship 
between soluble Aβ and symptoms of depression such as anhedonia, considered as a whole these 
two sets of studies suggest there may be an association worth investigating. 
 If there is indeed a relationship between Aβ and anhedonia, a logical explanation could be 
that Aβ acts within the brain’s reward system in a manner detrimental to its function, resulting in a 
diminished hedonic response to pleasurable events. A general reward system comprising a number 
of cortical and limbic structures undergirds the response to a broad range of pleasurable experiences 
(Berridge & Kringelbach, 2013). The direct experience of hedonic reward appears to involve at least 
the orbitofrontal cortex (Kringelbach, O’Doherty, Rolls, & Andrews, 2003), nucleus accumbens 
(Roitman, Wheeler, Tiesinga, Roitman, & Carelli, 2010), and ventral pallidum (Tindell, Smith, Peciña, 
Berridge, & Aldridge, 2006). Finer-grained analyses have revealed that there exist in these reward 
sites and elsewhere a number of localised sub-regions responsible for generating ‘normal’ pleasure 
sensations, amplifying hedonic reactions, or dampening down pleasure (so-called hedonic ‘hot spots’ 
and ‘cold spots’) (Berridge & Kringelbach, 2015). These sub-regions are present in the nucleus 
accumbens, ventral pallidum, orbitofrontal cortex, parabrachial nucleus, and possibly insula 
(Berridge & Kringelbach, 2015; Castro & Berridge, 2017; Peciña, Smith, & Berridge, 2006). These 
reward sites, either at the level of their broad functionality, or in discrete but important sub-regions, 
could underlie the experience of anhedonia. 
 Imaging studies of depressed and non-depressed patients have revealed that reward 
circuitry dysfunction coincides with anhedonia. For example, anhedonia correlates with reduced 
nucleus accumbens reward response in non-depressed humans in relation to monetary reward, and 
also correlates with reduced nucleus accumbens volume (Wacker, Dillon, & Pizzagalli, 2009). 
Depressed patients show a lack of response to positive stimuli in the ventral striatum, the region 
containing the nucleus accumbens (Epstein et al., 2006), and an earlier fMRI-based study found that 
depressed female adults possessing a high degree of anhedonia showed, among other changes, 
increased activation of the insula (Mitterschiffthaler et al., 2003). In depressed individuals presented 
with ‘happy’ stimuli, anhedonia severity showed, among other correlations, a negative correlation 
with ventral striatum activity (Keedwell, Andrew, Williams, Brammer, & Phillips, 2005). Collectively, 
studies such as these suggest that anhedonia may be a consequence of dysfunctional components of 
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the brain’s reward system. As noted in Chapter 1, reward sites such as the nucleus accumbens 
(Suenaga et al., 1990), orbitofrontal cortex (Van Hoesen et al., 2000), and parabrachial nucleus 
(German et al., 1987; Parvizi et al., 1998), are pathologically altered in Alzheimer’s disease. These 
alterations include the appearance of Aβ plaques, suggesting the possibility of soluble Aβ perturbing 
the reward system and producing anhedonia. 
 One way of investigating the potential association between soluble Aβ and anhedonia, and 
whether such an anhedonia can be treated, is by using a mouse model of Alzheimer’s disease. 
Mouse models such as Tg2576 mice, which accumulate soluble Aβ in the brain, but do not display 
the other pathological hallmarks of NFTs and overt neurodegeneration, are an ideal type of model to 
use for this. Tg2576 mice accumulate both soluble and insoluble Aβ40 and Aβ42 as they age, a 
process which begins at around 8 months of age for soluble Aβ (Kawarabayashi et al., 2001). Mouse 
models of Alzheimer’s disease which principally accumulate Aβ, such as Tg2576 mice, exhibit 
regional Aβ plaque deposition similar to human Alzheimer’s disease cases (Hsiao et al., 1996), and as 
such it could reasonably be assumed that Aβ species will be present in nodes of the Tg2576 mouse 
reward system much as they are in humans. If there is an association between soluble Aβ and 
anhedonia, and Aβ is present and biologically active in reward sites of Tg2576 mice, then this 
regional activity could account for the emergence of anhedonia. This finer-grained regional 
specificity is not a topic of investigation in this thesis, but will form a working assumption moving 
forwards. 
 This chapter also aims to investigate the utility of an anti-depressant agent in improving 
hedonic behaviour. As mentioned in Chapter 1, standard antidepressant agents, such as SSRIs and 
SNRIs, have no clear therapeutic benefit in Alzheimer’s disease (Orgeta et al., 2017). This, coupled 
with the fact that the serotonergic and noradrenergic neurotransmitter systems are pathologically 
altered in Alzheimer’s disease (Garcia-Alloza et al., 2005; Iversen et al., 1983; Palmer et al., 1987; 
Reinikainen et al., 1988), suggests that trialling an antidepressant agent acting on other 
neurotransmitter systems may be worthwhile. In addition, an antidepressant with a demonstrable 
anti-anhedonic effect would be desirable, given that anhedonia is the specific component of 
depression under investigation in this thesis. Lastly, an antidepressant agent that could potentially 
decrease Aβ levels would be an attractive prospect, as it would provide an opportunity for further 
examining the relationship between Aβ and anhedonia. One compound which appears to fulfil these 
criteria is the novel antidepressant agent, ketamine. 
 Ketamine is an NMDA receptor antagonist, which in recent years has come under 
investigation as a novel antidepressant agent at sub-anaesthetic doses, with a rapid onset of action 
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and utility in treatment-resistant cases (Berman et al., 2000; Murrough, Iosifescu, et al., 2013; 
Murrough, Perez, et al., 2013). Unlike conventional antidepressants, ketamine interacts with or 
influences receptors within a wide range of neurotransmitter systems, including NMDA and AMPA 
receptors (Browne & Lucki, 2013; Kavalali & Monteggia, 2015), 5HT receptors (Gigliucci et al., 2013; 
Yamanaka et al., 2014), and opioid receptors (Gupta, Devi, & Gomes, 2011; Nemeth et al., 2010). 
Ketamine also appears, at least in bipolar disorder patients, to have a specific anti-anhedonic effect 
(Lally et al., 2014), marking it as a drug that may be able to address this core, common, and difficult 
to treat depression symptom. There is also some evidence that ketamine, at least at anaesthetic 
doses, can lower Aβ levels in Tg2576 mice (Quiroga et al., 2014). Due to its broad pharmacological 
profile, and its potential as both an anti-anhedonic and Aβ-lowering agent, ketamine would appear 
to be a good candidate drug in attempting to treat anhedonia in Tg2576 mice. 
 While depressive behaviour has been investigated previously in Alzheimer’s disease mouse 
models, the behavioural tests used may not be particularly sensitive to anhedonia (see discussion in 
Section 3.4). It is therefore currently unclear whether this core symptom of depression is present in 
Alzheimer’s disease model mice, and whether it is responsive to treatment. In addition, if anhedonia 
does arise in Tg2576 mice as a result of Aβ, then given the accumulation of Aβ in these mice over 
time, anhedonia should be of an age-dependent nature. That is, it should emerge and potentially 
worsen with greater Aβ accumulation over time. The first major aim of this chapter, therefore, is to 
use lick cluster analysis (an approach thought to be sensitive to anhedonia) in a longitudinal fashion, 
to investigate whether anhedonia is present in the Tg2576 mouse model of Alzheimer’s disease. The 
second major aim is to investigate whether any hedonic deficit that does occur is treatable with a 
non-standard antidepressant agent. Experiment 1 of this chapter will gauge the presence and extent 
of anhedonia in Tg2576 mice over time, and Experiment 2 will examine whether anhedonia in these 
mice responds to low-dose ketamine therapy. 
 
3.2. Experiment 1 
3.2.1 Subjects & apparatus 
 Experiment 1 is a longitudinal investigation of the licking behaviour of two mouse cohorts, 
whose data were combined for analysis. These two cohorts consisted of male Tg2576 mice and age-
matched wild-type male littermates, housed as previously described (Chapter 2) and tested at 4-5, 8, 
12 and 16 months of age. Mice were initially group-housed, but due to aggressive behaviour many 
were eventually separated, beginning around 3 months of age, and single-housed. To ensure 
separation did not disproportionately affect one genotype, roughly equivalent percentages of each 
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genotype were single-housed prior to the start of behavioural testing. The combined numbers of 
each genotype, and percentage single-housed, at each time point were as follows (and declined 
largely due to attrition from animal death): 4-5 months – 42 Tg2576 (76.2%) and 41 wild-type 
(75.6%); 8 months – 42 Tg2576 (85.7%) and 39 wild-type (84.6%); 12 months – 40 Tg2576 (90%) and 
38 wild-type (89.5%); 16 months – 34 Tg2576 (97%) and 37 wild-type (97.3%). Mice were placed on a 
mild food deprivation regime, as described in Chapter 2. At 4-5, 8 and 12 months of age, food 
deprivation was present throughout pre-training and testing. At 16 months of age the effect of food 
deprivation versus free-feeding on lick cluster size was investigated; at this age mice alternated 
between food-deprived and free-feeding days throughout pre-training and testing, with both 
genotypes counterbalanced by day and concentration order. At 4-5, 8 and 12 months of age, both 
genotypes were counterbalanced with respect to sucrose concentration order. Baseline weights and 
deprivation-induced weight change are presented in Section 3.2.4. Testing apparatus was as 
described in Chapter 2. 
 The rationale for investigating the effect of food deprivation versus a free-feeding state on 
lick cluster size at 16 months was as follows: The previous lick cluster experiments within this thesis 
had taken place exclusively under the condition of food deprivation, therefore there was a question 
as to whether any observed lick cluster size deficit was state-dependent, that is, would only manifest 
when mice were food deprived and not when mice were free-feeding. To explicitly examine this at 
16 months of age, a manipulation was introduced such that mice were tested under both food 
deprived and free-feeding conditions on alternate days, and in a counterbalanced manner. There 
was no specific prediction as to whether a lick cluster size deficit would be dependent on food 
deprivation or would be a generalised deficit present in both conditions. 
 
3.2.2 Procedure 
 Pre-training was conducted as described in Chapter 2, using an 8% sucrose solution made 
daily with deionised water. Drinking spouts were initially extended inside the drinking chambers to 
facilitate their detection, generally for 1-2 days, then shortened so mice could only lick the tip of the 
spout. The pre-training period needed to produce a consistent level of licking behaviour shortened 
with repeated testing, and was of the following ranges at each time point: 7-10 days at 4-5 months; 
5-6 days at 8 months; 4-5 days at 12 months; 6 days at 16 months. Testing occurred in two phases 
using 4% and 16% sucrose solutions, as described in Section 2.2.2. At 4-5, 8 and 12 months of age, 
phase 1 and 2 each lasted 5 days. At 16 months of age, phase 1 and 2 each lasted 6 days (each phase 
consisting of 3 days food-deprived and 3 days free-feeding, alternated). 
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3.2.3 Data analysis 
 Data were initially collected as described in Chapter 2. Inter-lick intervals were calculated 
within lick clusters, and were recorded onset to onset. Licking data were cleaned to remove low or 
unreliable drinking measurements, as described in Section 2.2.2. Data cleaning resulted in excluded 
licking data of 8 mice at 4-5 months and 1 mouse at 8 months (plus 1 mouse culled during the 
experiments at 4-5, 8 and 16 months). Only the subset of mice which were present at every time 
point until (and including) 16 months of age informed the aging analysis. For baseline weight and 
weight change data over time, 34 Tg2576 and 36 wild-type mice were analysed. After drinking data 
were cleaned, the consumption and licking behaviour over time of 31 Tg2576 and 31 wild-type mice 
was analysed. The number of animals in the aging analysis differs from the numbers analysed at 
each individual time point, the latter of which are noted in the relevant figures and tables. The 
analyses of each individual time point are presented after the aging data. 
 For the aging analysis, aggregated licking data were analysed using mixed ANOVA, with a 
between-subjects factor of genotype, and a within-subjects factors of age and concentration. As 
mice at the first 3 time points were tested under food-deprived conditions, the 16-month data were 
taken only from the food-deprived condition, which still provided a reasonable sampling period of 
drinking behaviour. At each individual time point aggregated licking data were analysed using mixed 
ANOVA, with a between-subjects factor of genotype, and a within-subjects factor of concentration. 
Follow-up tests between groups or conditions were conducted using t-tests, as described in Section 
2.7. 
 
3.2.4 Results 
3.2.4.1 Aging study 
 Table 3.1 presents the mean baseline weights and deprivation-induced weight change of all 
Tg2576 and wild-type mice in the aging analysis. Inspection of the baseline weight data indicates 
that mice gain weight over their lifespan irrespective of genotype, but that Tg2576 mice have a 
lower body weight in general, and this genotype difference becomes more pronounced over time. 
The precise sucrose concentration being consumed in the test sessions seems to have little material 
effect on baseline body weight for either genotype. ANOVA revealed a significant effect of age 
(F(1.734,117.913) = 93.877, p<.001, MSE = 1014.854, η2p=0.580), genotype (F(1,68) = 19.09, p<.001, 
MSE = 1868.55, η2p=0.219), and a significant age × genotype interaction (F(1.734,117.913) = 5.655, p 
= .007, MSE = 61.134, η2p= 0.077). There was no significant main effect of concentration (F(1,68) = 
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0.911, p = .343, MSE = 0.157, η2p= 0.013), nor any significant interaction featuring concentration 
(highest F for age × concentration × genotype (3,204) = 0.378, p = .769, MSE = 0.075, η2p= 0.006). 
 Inspection of the weight loss data indicates that absolute weight loss as a result of food 
deprivation generally increased with age for both genotypes, but that Tg2576 mice were affected 
more at each time point than were wild-type mice. No consistent appreciable effect of sucrose 
concentration on weight loss appears to be present. ANOVA revealed a significant effect of age 
(F(2.716,184.701) = 10.622, p<.001, MSE = 1.859, η2p= 0.135) and genotype (F(1,68) = 29.60, p<.001, 
MSE = 11.033, η2p= 0.303), but no significant age × genotype interaction (F(2.716,184.701) = 0.537, p 
= .640, MSE = 0.094 , η2p= 0.008). There was no significant main effect of concentration (F(1,68) = 
0.639, p = .427, MSE = 0.048, η2p= 0.009), nor any significant interaction featuring concentration 
(highest F for age ×  concentration × genotype (3,204) = 1.798, p = .149, MSE = 0.164, η2p= 0.026). 
 
Age Weight 
variable 
TG 4% TG 16% WT 4% WT 16% 
4 – 5 months Baseline 
weight (g) 
29.58 
(±0.506) 
29.54  
(±0.490) 
32.07 
(±0.458) 
 
32.11 
(±0.448) 
Weight 
change (g) 
0.806 
(±0.065) 
0.847  
(±0.072) 
0.544 
(±0.062) 
 
0.611 
(±0.055) 
8 months Baseline 
weight (g) 
32.02  
(±0.552) 
 
32.00  
(±0.562) 
 
35.28 
(±0.588) 
 
35.18 
(±0.580) 
 
Weight 
change (g) 
1.071 
(±0.062) 
 
1.006 
(±0.056) 
 
0.756 
(±0.049) 
 
0.683 
(±0.051) 
 
12 months Baseline 
weight (g) 
32.94 
(±0.643) 
 
32.96 
(±0.626) 
 
36.99 
(±0.792) 
 
36.93 
(±0.806) 
 
Weight 
change (g) 
1.012 
(±0.075) 
 
1.059 
(±0.082) 
 
0.772 
(±0.071) 
 
0.644 
(±0.058) 
 
16 months Baseline 
weight (g) 
32.97 
(±0.599) 
 
32.87 
(±0.581) 
37.79  
(±0.914) 
37.77 
(±0.888) 
Weight 
change (g) 
1.127 
(±0.070) 
 
1.029 
(±0.080) 
0.819 
(±0.057) 
0.880 
(±0.067) 
Table 3.1. Mean data (±SEM) for baseline weights and food deprivation-induced weight change (g) of Tg2576 
(TG) and wild-type (WT) mice at each sucrose concentration and time point. N=34 TGs and 36 WTs. The 16 
month weight data are from the food deprived phase of the experiment. All weights were taken prior to food 
deprivation. 
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 Figure 3.1 shows the consumption and lick cluster data for aging Tg2576 and wild-type mice 
at each sucrose concentration. Inspection of panel A of Figure 3.1 indicates that consumption of 
sucrose initially increases with age for both genotypes, plateauing somewhere around 8 to 12 
months of age. Within this general aging profile, Tg2576 mice consistently consume greater amounts 
of sucrose than wild-type mice, and this may be more pronounced over time for 16% sucrose. In 
general, though not consistent at all time points, both genotypes appear to consume slightly more 
4% than 16% sucrose. ANOVA results were broadly consistent with these observations, revealing 
significant effects of age (F(2.549,152.937) = 11.891, p<.001, MSE = 4.678, η2p= 0.165), and genotype 
(F(1,60) = 16.07, p<.001, MSE = 15.408, η2p= 0.211), with no significant age × genotype interaction 
(F(2.549,152.937) = 1.686, p = .180, MSE = 0.663, η2p= 0.027). There was a significant effect of 
concentration (F(1,60) = 5.47, p = .023, MSE = 0.747, η2p= 0.084), and a non-significant age × 
concentration × genotype interaction (F(3,180) = 2.464, p = .064, MSE = 0.194, η2p= 0.039).  
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 Figure 3.1. Mean (±SEM) consumption (g) (A) and lick cluster size data (B), in response to 4% and 16% 
 sucrose solutions, of Tg2576 and wild-type mice in 10 minute test sessions, over time. N = 31 Tg2576 
 and 31 wild-type mice. The 16 month data are from the food-deprived phase of the experiment. 
 
Inspection of panel B of Figure 3.1 suggests that both genotypes generally display the 
expected lick cluster size increase at a higher sucrose concentration. However, after the first time 
point Tg2576 mice display a noticeably lower lick cluster size than wild-type mice. This begins at 8 
months of age, and is numerically apparent at both 4% and 16% sucrose (especially at later 
timepoints), though is most prominent at 16% sucrose. This genotypic difference occurs within the 
context of an aging profile displayed by both genotypes; lick cluster size tends to initially increase 
with age, then gradually declines, and this is most pronounced at 16% sucrose, especially between 
12 and 16 months of age. ANOVA results were broadly consistent with these observations, revealing 
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a significant main effect of concentration (F(1,60) = 69.382, p<.001, MSE = 9340.59, η2p= 0.536), a 
significant main effect of genotype (F(1,60) = 4.411, p = .040, MSE = 2550.3, η2p= 0.068), and a 
significant concentration × genotype interaction (F(1,60) = 6.214, p = .015, MSE = 836.59, η2p= 
0.094). The aging profile impression was confirmed by a significant main effect of age (F(3,180) = 
8.34, p<.001, MSE = 1353.80, η2p= 0.122) and, although the genotype lick cluster size difference was 
numerically larger from 8-16 months than at 4-5 months of age, especially at 16% sucrose, neither 
the age × genotype interaction (F(3,180) = 2.144, p = .096, MSE = 348, η2p= 0.034) nor the age × 
concentration × genotype interaction (F(2.678,160.662) = 1.17, p = .321, MSE = 100.48, η2p= 0.019) 
reached conventional significance levels. There was also a non-significant age × concentration 
interaction (F(2.678,160.662) = 2.57, p = .063, MSE = 220.70, η2p= 0.041). 
 Table 3.2 presents the amount consumed per lick (µg) and inter-lick interval data for aging 
Tg2576 and wild-type mice at each sucrose concentration. Inspection of the amount consumed per 
lick indicates that, generally, amount consumed per lick increases with age for Tg2576 mice, while a 
consistently changing age profile is less obvious for wild-type mice. Wild-type mice show a 
numerically higher amount consumed per lick than Tg2576 mice until 16 months of age, at which 
point it is numerically lower than that of Tg2576 mice. There appears to be a fairly consistent effect 
of concentration, in that amount consumed per lick is generally lower at 16% sucrose compared with 
4% sucrose. ANOVA results were broadly consistent with these impressions, revealing a significant 
effect of age (F(2.024,121.440) = 3.584, p = .030, MSE = 3.148, η2p= 0.056), no significant effect of 
genotype (F(1,60) = 1.276, p = .263, MSE = 1.27, η2p= 0.021), and a significant age × genotype 
interaction (F(2.024,121.440) = 3.363, p = .037, MSE = 2.953, η2p= 0.053), consistent with the aging 
change being largely driven by Tg2576 mice. In keeping with the generally observed concentration 
change in both genotypes, there was a significant effect of concentration (F(1,60) = 7.334, p = .009, 
MSE = 1.942, η2p= 0.109), with no significant concentration × genotype interaction (F(1,60) = 1.481, p 
= .228, MSE = 0.392, η2p= 0.024). 
 Inspection of the inter-lick interval data indicates a general increase in the inter-lick interval 
with age, present in both Tg2576 and wild-type mice, albeit with different trajectories (smaller 
incremental increases in wild-type mice until 16 months of age). No clear and consistent difference 
between Tg2576 and wild-type mice is apparent. Inter-lick interval of Tg2576 mice looks to decrease 
slightly as concentration increases; no clear relationship with concentration is apparent in wild-type 
mice. ANOVA results were consistent with these impressions, revealing a significant effect of age 
(F(2.571,154.249) = 29.756, p<.001, MSE = 2115.83, η2p= 0.332), no significant effect of genotype 
(F(1,60) = 0.367, p = .547, MSE = 198.4, η2p= 0.006), and a significant age × genotype interaction 
(F(2.571,154.249) = 4.59, p = .006, MSE = 326.35, η2p= 0.071). A non-significant effect of 
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concentration (F(1,60) = 1.782, p = .187, MSE = 45.07, η2p= 0.029) was consistent with the lack of a 
clear overall concentration relationship, and a significant concentration × genotype interaction 
(F(1,60) = 8.591, p = .005, MSE = 217.28, η2p= 0.125) was in keeping with the decrease seen in 
Tg2576 mice as concentration increased. 
 
Age Control 
variable 
TG 4% TG 16% WT 4% WT 16% 
4 – 5 months Amount 
consumed per 
lick (µg) 
1.142  
(±0.068) 
1.128  
(±0.09) 
1.631 
(±0.288) 
1.328 
(±0.082) 
Inter-lick 
interval (ms) 
 118.4 
(±1.875) 
116.8  
(±1.45) 
119.8 
(±1.79) 
121 
(±1.899) 
8 months Amount 
consumed per 
lick (µg) 
1.09 
(±0.061) 
 
1.115 
(±0.063) 
 
1.383 
(±0.066) 
 
1.286 
(±0.037) 
 
Inter-lick 
interval (ms) 
124.3 
(±1.752) 
 
122.2 
(±1.716) 
 
121.2 
(±2.359) 
 
120.2 
(±1.722) 
 
12 months Amount 
consumed per 
lick (µg) 
1.408 
(±0.103) 
 
1.296 
(±0.076) 
 
1.473 
(±0.066) 
 
1.365 
(±0.073) 
 
Inter-lick 
interval (ms) 
127.1 
(±1.629) 
 
123.7 
(±1.292) 
 
120.4 
(±2.023) 
 
121.9 
(±1.65) 
 
16 months Amount 
consumed per 
lick (µg) 
1.734 
(±0.224) 
1.558 
(±0.192) 
1.516  
(±0.08) 
1.300 
(±0.113) 
Inter-lick 
interval (ms) 
129 
(±1.53) 
128.4 
(±1.512) 
127  
(±2.144) 
128.2 
(±1.933) 
Table 3.2. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of Tg2576 (TG) and 
wild-type (WT) mice at each sucrose concentration and time point. N=31 Tg2576 and 31 wild-type mice. The 
16 month data are from the food-deprived phase of the experiment. 
 The results of these control variables suggest that the lower lick cluster sizes present in 
Tg2576 mice are not an artefact of motor differences in licking behaviour. For example, the aging 
analysis revealed an overall lick cluster size decrement in Tg2576 mice, while there was no overall 
genotype difference in amount consumed per lick or inter-lick interval. Further, the lick cluster size 
deficit was numerically most apparent at 16% sucrose from 8 months of age onward, at which points 
the control variables do not appear appreciably different. Inter-lick interval, in particular, shows 
greater numerical differences at 4% sucrose than 16% sucrose from 8 months onwards, while the 
Tg2576 lick cluster size deficit shows the opposite pattern. Taken together, these observations 
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suggest that the lick cluster size decrease shown by Tg2576 mice in the aging analysis can be 
interpreted as a hedonic deficit. 
 Although the aging lick cluster size data shown in Figure 3.1 suggested a Tg2576 hedonic 
deficit that emerged with age after 4-5 months, the analysis revealed only a main effect of genotype, 
with no significant age × genotype or age × concentration × genotype interactions. The lack of a 
significant age × genotype or age × concentration × genotype interaction could be due to 3 of the 4 
tests occurring after this genotype difference was numerically apparent, limiting the power of the 
interaction test. An exploratory re-analysis was thus conducted, comparing lick cluster sizes 
averaged across 8-16 months against lick cluster sizes at 4-5 months. Results of this ANOVA revealed 
a significant effect of concentration (F(1,60) = 52.298, p<.001, MSE = 4053.20, η2p= 0.466), no 
significant effects of age (F(1,60) = 2.417, p = .125, MSE = 270.90, η2p= 0.039) or genotype (F(1,60) = 
2.370, p = .129, MSE = 591.1, η2p= 0.038), but a significant age × genotype interaction (F(1,60) = 
4.636, p = .035, MSE = 519.48, η2p= 0.072). None of the other interactions were significant (highest F 
for concentration × genotype (1,60) = 2.787, p = .100, MSE = 216.02, η2p= 0.044). The significant age 
× genotype interaction is consistent with the Tg2576 lick cluster size deficit appearing after 4-5 
months, supporting the impression that the hedonic capacity of Tg2576 mice does materially change 
with age. Each individual time point will be analysed in isolation next, to determine both the time at 
which anhedonia first presents in Tg2576 mice, and its concentration dependency. 
 
3.2.4.2 4-5 month licking results 
Inspection of panel A of Figure 3.2 indicates that at 4-5 months of age, Tg2576 mice 
consume more sucrose than wild-type mice overall, with generally (across genotypes) greater 
consumption of 4% than 16% sucrose. ANOVA results were consistent with these observations, 
revealing significant effects of genotype (F(1,72) = 9.675, p = .003, MSE = 4.811, η2p= 0.118), and 
concentration (F(1,72) = 4.605, p = .035, MSE = 0.358, η2p= 0.06), with no significant concentration × 
genotype interaction (F(1,72) = 0.001, p = .975, MSE = 7.889e-5, η2p<0.001).  
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 Figure 3.2. Mean (±SEM) consumption (g) (A) and lick cluster size data (B), in response to 4% and 16% 
 sucrose solutions, of Tg2576 (TG) and wild-type (WT) mice in 10 minute test sessions, at 4-5 months 
 of age. N = 38 Tg2576 and 36 wild-type mice. 
 
 Inspection of panel B of Figure 3.2 indicates that both Tg2576 and wild-type mice display the 
typical lick cluster size increase with increasing sucrose concentration. Lick cluster size values for 
both genotypes at each concentration appear similar, albeit those of wild-type mice are numerically 
lower than in Tg2576 mice. ANOVA results were consistent with these observations, revealing a 
significant effect of concentration (F(1,72) = 21.429, p<.001, MSE = 1682.709, η2p= 0.229), no 
significant effect of genotype (F(1,72) = 0.177, p = .675, MSE = 28.72, η2p= 0.002), and no significant 
concentration × genotype interaction (F(1,72) = 0.005, p = .942, MSE = 0.418, η2p<0.001). The 
absence of a Tg2576 lick cluster size deficit at this initial time point is clearly of material importance. 
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Importantly, a Bayesian mixed ANOVA provided evidence suggesting a genuine absence of genotype 
effect regarding lick cluster size (BF10 = 0.273). Lick cluster sizes within each genotype were 
compared at 4% vs 16% to investigate hedonic sensitivity to concentration change: both Tg2576 and 
wild-type mice showed a significant difference between concentrations (Student’s t(37) = 2.742, p = 
.009, d = 0.445) and (t(35) = 4.394, p<.001, d = 0.732) respectively.  
 Inspection of Table 3.3 indicates that amount consumed per lick data is in keeping with the 
general description in the aging results in Section 3.2.4.1. That is, amount consumed per lick is 
higher in wild-type mice, and numerically decreases with concentration across both genotypes. 
ANOVA results were consistent with this impression, revealing a significant effect of genotype 
(F(1,72) = 4.304, p = .042, MSE = 3.117, η2p= 0.056), no significant effect of concentration (F(1,72) = 
1.543, p = .218, MSE = 1.017, η2p= 0.021), and no significant concentration × genotype interaction 
(F(1,72) = 0.63, p = .430, MSE = 0.415, η2p= 0.009).  
 
Control variable TG 4% TG 16% WT 4% WT 16% 
Amount 
consumed per 
lick (µg) 
 1.172 
(±0.06) 
 1.112 
(±0.075) 
1.568 
(±0.25) 
1.296 
(±0.075) 
Inter-lick interval 
(ms) 
120 
(±1.693) 
 
118 
(±1.339) 
 
120.1 
(±1.59) 
121.6 
(±1.695) 
Table 3.3. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of Tg2576 (TG) and 
wild-type (WT) mice at each sucrose concentration, at 4-5 months of age. N=38 Tg2576 and 36 wild-type mice. 
 
 Little material difference in inter-lick interval between genotypes is visually apparent in 
Table 3.3, though concentration increase appears to produce diverging effects in Tg2576 and wild-
type mice. ANOVA results were consistent with this impression, revealing no significant effects of 
genotype (F(1,72) = 0.701, p = .405, MSE = 118.8, η2p= 0.010) or concentration (F(1,72) = 0.119, p = 
.731, MSE = 1.914, η2p= 0.002), but a significant concentration × genotype interaction (F(1,72) = 
6.862, p = .011, MSE = 109.989, η2p= 0.087). Motoric differences between the two genotypes do not 
appear to be complicating lick cluster size interpretation. Firstly, while inter-lick interval responds 
differently to concentration increase in Tg2576 and wild-type mice, the numeric differences at each 
concentration are negligible. Secondly, while wild-type mice do consume a greater amount of 
sucrose per lick than Tg2576 mice, the numeric difference is greatest at 4% sucrose, where it is 
largely driven by the data from one mouse. Thus motor effects are unlikely to meaningfully impact 
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the licking of one genotype over another, and the lick cluster size results can be interpreted as a 
measure of hedonic capacity. 
 
3.2.4.3 8 month licking results 
Inspection of panel A of Figure 3.3 indicates that at 8 months of age, the same genotype and 
concentration consumption pattern occurs as at 4-5 months of age. ANOVA results were consistent 
with this observation, revealing a significant effect of genotype (F(1,77) = 6.257, p = .014, MSE = 
3.568, η2p= 0.075), a non-significant effect of concentration (F(1,77) = 3.649, p = .060, MSE = 0.424, 
η2p= 0.045), and a non-significant concentration × genotype interaction (F(1,77) = 0.182, p = .671, 
MSE = 0.021, η2p= 0.002). Inspection of panel B of Figure 3.3 indicates that while both Tg2576 and 
wild-type mice show the usual lick cluster size increase with concentration, at 8 months of age 
Tg2576 mice have a numerically lower lick cluster size at both concentrations, particularly so at 16% 
sucrose. This impression was confirmed by ANOVA results, which revealed significant effects of both 
concentration (F(1,77) = 65.97, p<.001, MSE = 4084.85, η2p= 0.461), and genotype (F(1,77) = 4.117, p 
= .046, MSE = 1102.2, η2p= 0.051). The blunted lick cluster response to an increase in sucrose 
concentration shown by Tg2576 mice was confirmed by a significant concentration × genotype 
interaction (F(1,77) = 10.31, p = .002, MSE = 638.41, η2p= 0.118). Follow-up unpaired t-tests 
comparing Tg2576 and wild-type lick cluster size at 4% and 16% sucrose revealed no significant 
genotype difference at 4% sucrose (Student’s t(77) = 0.59, p = .557, d = 0.133), but a significant 
genotype difference at 16% sucrose (Student’s t(77) = 2.673, p = .009, d = 0.603). Despite this 
Tg2576 lick cluster size reduction, paired samples t-tests comparing lick cluster size at 4% and 16% 
sucrose for each genotype revealed a significant difference for both Tg2576 (Student’s t(41) = 3.979, 
p<.001, d = 0.614) and wild-type (Student’s t(36) = 7.057, p<.001, d = 1.160) mice. 
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Figure 3.3.  Mean (±SEM) consumption (g) (A) and lick cluster size data (B), in response to 4% and 16% sucrose 
solutions, of Tg2576 (TG) and wild-type (WT) mice in 10 minute test sessions, at 8 months of age. N = 42 Tg2576 
and 37 wild-type mice. 
 
 Inspection of Table 3.4 indicates that, at 8 months of age, the amount of sucrose consumed 
per lick data is similar to that at the 4-5 month time point. ANOVA results were consistent with this 
impression, revealing a significant effect of genotype (F(1,77) = 7.365, p = .008, MSE = 1.32, η2p= 
0.087), no significant effect of concentration (F(1,77) = 1.763, p = .188, MSE = 0.085, η2p= 0.022) and 
no significant concentration × genotype interaction (F(1,77) = 2.264, p = .137, MSE = 0.11, η2p= 
0.029). Inspection of the inter-lick interval data in Table 3.4 indicates a similar pattern of results as 
seen at 4-5 months, though without concentration appearing to interact with genotype. ANOVA 
results were consistent with this impression, revealing non-significant effects of both genotype 
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(F(1,77) = 3.689, p = .058, MSE = 667.9, η2p= 0.046) and concentration (F(1,77) = 3.27, p = .074, MSE 
= 72.57, η2p= 0.041), and a non-significant concentration × genotype interaction (F(1,77) = 2.082, p = 
.153, MSE = 46.21, η2p= 0.026). The lick cluster size difference observed does not appear to be an 
artefact of these control variables, as the lick cluster size deficit was statistically confirmed at 16% 
sucrose, while amount consumed per lick and inter-lick interval numerically differ most at 4% 
sucrose and least at 16% sucrose. That these control measures show the opposite pattern to the lick 
cluster size results suggests that the Tg2576 lick cluster size reduction at 8 months can be 
interpreted as a hedonic deficit. 
 
Control variable TG 4% TG 16% WT 4% WT 16% 
Amount 
consumed per 
lick (µg) 
 1.123 
(±0.062) 
 1.130 
(±0.05) 
1.359 
(±0.056) 
1.260 
(±0.04) 
Inter-lick interval 
(ms) 
125.3 
(±1.487) 
 
122.9 
(±1.334) 
 
120.1 
(±2.051) 
119.9 
(±1.54) 
Table 3.4. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of Tg2576 (TG) and 
wild-type (WT) mice at each sucrose concentration, at 8 months of age. N=42 Tg2576 and 37 wild-type mice. 
 
3.2.4.4 12 month licking results 
Inspection of panel A of Figure 3.4 indicates that, at 12 months of age, consumption follows 
a pattern similar to that reported at previous time points, although wild-type mice now display a 
response to concentration increase in opposition to that of Tg2576 mice. ANOVA results were 
consistent with these observations, revealing a significant effect of genotype (F(1,76) = 22.61, 
p<.001, MSE = 13.898, η2p= 0.229), no significant effect of concentration (F(1,76) = 0.552, p = .460, 
MSE = 0.045, η2p= 0.007), but a significant concentration × genotype interaction (F(1,76) = 5.525, p = 
.021, MSE = 0.447, η2p= 0.068). Inspection of panel B of Figure 3.4 indicates a similar pattern of lick 
cluster size results as described at 8 months of age, albeit the genotype lick cluster size difference at 
16% sucrose is numerically smaller than at 8 months. ANOVA results were partially consistent with 
this impression, revealing a significant effect of concentration (F(1,76) = 43.949, p<.001, MSE = 
5788.6, η2p= 0.366), a non-significant effect of genotype (F(1,76) = 2.87, p = .094, MSE = 1083.1, η2p= 
0.036), and a non-significant concentration × genotype interaction (F(1,76) = 2.115, p = .150, MSE = 
278.5, η2p= 0.027). A Bayesian mixed ANOVA provided uninformative evidence regarding the null 
genotype effect as regards lick cluster size (BF10 = 0.791). Despite a numerical Tg2576 lick cluster size 
reduction, paired samples t-tests comparing lick cluster size at 4% and 16% sucrose for each 
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genotype revealed a significant difference for both Tg2576 (Student’s t(39) = 3.285, p=.002, d = 
0.519) and wild-type (Student’s t(37) = 6.692, p<.001, d = 1.086) mice. 
 
 
 
 
Figure 3.4. Mean (±SEM) consumption (g) (A) and lick cluster size data (B), in response to 4% and 16% sucrose 
solutions, of Tg2576 (TG) and wild-type (WT) mice in 10 minute test sessions, at 12 months of age. N = 40 Tg2576 
and 38 wild-type mice. 
 
 Inspection of Table 3.5 indicates a similar pattern of amount consumed per lick results as 
described at 4-5 months, only with a more apparent effect of concentration increase. ANOVA results 
were consistent with this impression, revealing no significant effect of genotype (F(1,76) = 0.935, p = 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
TG WT
Su
cr
o
se
 c
o
n
su
m
ed
 (
g)
Consumption: 12 months
4% 16%
0
5
10
15
20
25
30
35
40
TG WT
M
ea
n
 li
ck
s 
p
er
 c
lu
st
er
Lick cluster size: 12 months
4% 16%
A 
B 
64 
 
.337, MSE = 0.29, η2p= 0.012), a significant effect of concentration (F(1,76) = 8.504, p = .005, MSE = 
0.546, η2p= 0.101), and no significant concentration × genotype interaction (F(1,76) = 0.004, p = .949, 
MSE = 2.625e-4, η2p<0.001). The inter-lick interval data in Table 3.5 also show a similar pattern to that 
observed at 4-5 months, although at 12 months longer inter-lick intervals are seen in Tg2576 mice. 
ANOVA results were consistent with these observations, revealing a significant effect of genotype 
(F(1,76) = 5.116, p = .027, MSE = 814.6, η2p= 0.063), no significant effect of concentration (F(1,76) = 
2.667, p = .107, MSE = 36.52, η2p= 0.034), and a significant concentration × genotype interaction 
(F(1,76) = 14.164, p<.001, MSE = 193.92, η2p= 0.157). Though a clear Tg2576 lick cluster size decrease 
was not statistically confirmed at 12 months of age, the numerically greater genotype lick cluster 
size difference seen at 16% sucrose would not appear to be the result of control measure 
differences. No significant differences were found in amount consumed per lick, and any notable 
numeric differences in inter-lick interval are apparent at 4%, not 16%, sucrose. 
 
Control variable TG 4% TG 16% WT 4% WT 16% 
Amount 
consumed per 
lick (µg) 
 1.392 
(±0.086) 
 1.271 
(±0.067) 
1.475 
(±0.057) 
1.36 
(±0.06) 
Inter-lick interval 
(ms) 
126.8 
(±.1.389) 
 
123.6 
(±1.13) 
 
120 
(±1.825) 
121.3 
(±1.565) 
Table 3.5. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of Tg2576 (TG) and 
wild-type (WT) mice at each sucrose concentration, at 12 months of age. N=40 Tg2576 and 38 wild-type mice. 
 
3.2.4.5 16 month licking results 
Inspection of panel A of Figure 3.5 indicates that consumption was lower with ad-lib feeding 
than under food restriction, and that the relationship between consumption and concentration was 
reversed between feeding conditions, while the overall higher consumption by Tg2576 mice was 
maintained. ANOVA results were consistent with this impression, revealing significant effects of 
genotype (F(1,67) = 13.58, p<.001, MSE = 11.78, η2p= 0.169) and deprivation (F(1,67) = 125.691, 
p<.001 , MSE = 6.887, η2p= 0.652), no significant effect of concentration (F(1,67) = 0.233, p = .631, 
MSE = 0.035, η2p= 0.003), with a significant deprivation × concentration interaction (F(1,67) = 9.48, p 
= .003, MSE = 0.301, η2p= 0.124). No other interaction terms were significant (highest F for 
deprivation × concentration × genotype (1,67) = 3.186, p = .079, MSE = 0.101, η2p= 0.045). 
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Figure 3.5. Mean (±SEM) consumption (g) (A) and lick cluster size data (B), in response to 4% and 16% sucrose 
solutions, of Tg2576 (TG) and wild-type (WT) mice in 10 minute test sessions, at 16 months of age, under food 
deprived and ad lib conditions. N = 33 Tg2576 and 36 wild-type mice. 
 
 Inspection of panel B of Figure 3.5 indicates a pattern of lick cluster size results similar to 
those of 8 and 12 months, with a more pronounced overall lick cluster size reduction in Tg2576 mice, 
though still largest at 16% sucrose. In addition, lick cluster sizes are overall numerically higher in the 
free-feeding condition, regardless of genotype. ANOVA results were broadly consistent with this 
impression, revealing significant effects of both concentration (F(1,67) = 22.474, p<.001, MSE = 
3374.681, η2p= 0.251) and genotype (F(1,67) = 5.543, p = .021, MSE = 3112.4, η2p= 0.076), with no 
significant concentration × genotype interaction (F(1,67) = 3.507, p = .065, MSE = 526.568, η2p= 
0.05). There was no significant effect of deprivation (F(1,67) = 3.305, p = .074, MSE = 162.330, η2p= 
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0.047), and no other significant interaction (highest F for deprivation × concentration (1,67) = .465, p 
= .498, MSE = 33.342, η2p= 0.007). Follow-up unpaired t-tests comparing Tg2576 and wild-type lick 
cluster size at 4% and 16% sucrose, averaged across deprivation condition, revealed no significant 
genotype difference at 4% sucrose (Student’s t(68) = 1.802, p = .076, d = 0.431), but a significant 
genotype difference at 16% sucrose (Student’s t(68) = 2.324, p = .023, d = 0.556).  Paired samples t-
tests comparing lick cluster size at 4% and 16% sucrose, averaged across deprivation condition, 
within each genotype revealed a significant difference for both Tg2576 (Student’s t(33) = 4.106, 
p<.001, d = 0.704) and wild-type (Student’s t(35) = 3.571, p = .001, d = 0.595) mice. 
 Inspection of Table 3.6 indicates that the amount consumed per lick, unlike at earlier time 
points, was generally numerically higher in Tg2576 mice, while the decrease with concentration seen 
at previous time points remained in place. There was no clear effect of deprivation on amount 
consumed per lick, nor did deprivation clearly interact with genotype or concentration. ANOVA 
results were generally consistent with this impression, revealing a significant effect of concentration 
(F(1,67) = 5.166, p = .026, MSE = 1.103, η2p= 0.072), no significant effect of genotype (F(1,67) = 0.224, 
p = .637, MSE = 0.648, η2p= 0.003), and no significant effect of deprivation (F(1,67) = 1.506, p = .224, 
MSE = 0.411, η2p= 0.022). No interaction terms were significant (highest F for deprivation × 
concentration (1,67) = 2.196, p = .143, MSE =0.751 , η2p= 0.032).  
 
Control variable TG 4% TG 16% WT 4% WT 16% 
 
Amount 
consumed 
per lick 
(µg) 
 
Deprived 
 1.724 
(±0.211) 
 1.564 
(±0.180) 
1.677 
(±0.160) 
1.375 
(±0.113) 
Non-
deprived 
1.518 
(±0.156) 
1.573 
(±0.235) 
1.519 
(±0.121) 
1.420 
(±0.111) 
 
Inter-lick 
interval 
(ms) 
 
Deprived 
129.3 
(±.1.287) 
 
127.9 
(±1.474) 
 
127.1 
(±1.904) 
127.9 
(±1.687) 
Non-
deprived 
127.7 
(±1.298) 
125.5 
(±1.321) 
125.2 
(±2.009) 
126.3 
(±1.831) 
Table 3.6. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of food-deprived 
and non-deprived Tg2576 (TG) and wild-type (WT) mice at 4% and 16% sucrose, at 16 months of age. N=33 
Tg2576 and 36 wild-type mice. 
  
 The inter-lick interval data presented in Table 3.6 show that, consistent with some previous 
time points, concentration increase has opposing effects in Tg2576 and wild-type mice, while across 
concentration there is little material difference between genotypes. In addition, food deprivation 
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appears to increase inter-lick interval in both genotypes and at both concentrations. ANOVA results 
were consistent with this impression, revealing no significant effects of genotype (F(1,67) = 0.188, p 
= .666, MSE = 60.79, η2p= 0.003) or concentration (F(1,67) = 0.410, p = .524, MSE = 12.603, η2p= 
0.006), and a significant concentration × genotype interaction (F(1,67) = 4.480, p = .038, MSE = 
137.850, η2p= 0.063). There was a significant effect of deprivation (F(1,67) = 20.653, p<.001 , MSE = 
236.136, η2p= 0.236), and no other significant interaction (highest F for deprivation × concentration × 
genotype (1,67) = 0.554, p = .459, MSE = 4.919, η2p= 0.008). As at prior time points, these control 
measures do not appear to account for the Tg2576 lick cluster size decrease, as there were no 
statistically detectable genotype differences, and inter-lick interval numeric differences were 
smallest at 16% sucrose, where the genotype lick cluster size difference is numerically largest. These 
facts suggest that the lick cluster size decrease can be interpreted as a hedonic deficit. 
 
3.2.5 Summary 
 Experiment 1 investigated the lick cluster size responses of Tg2576 mice to two sucrose 
concentrations longitudinally, from 4-5 months to 16 months of age. The critical finding, suggested 
visually by the complete aging study and supported by further analysis, was that Tg2576 mice 
develop a lick cluster size deficit over time. The follow-up aging analysis was consistent with this 
deficit emerging at some point after 4-5 months of age. Investigation of each time point in isolation 
demonstrated that the lick cluster size reactions of Tg2576 mice were comparable to those of wild-
type mice at 4-5 months, where a Bayesian analysis suggested this was a genuine absence of 
genotype difference. However, at 8 months of age a lick cluster size deficit had manifested, 
specifically at 16% sucrose. At 12 months of age, despite the lick cluster size patterns being 
numerically similar to those of the 8-month time point, there was no significant difference between 
Tg2576 and wild-type mice; here a Bayesian analysis suggested the evidence was uninformative 
rather than indicating a true null genotype effect. At the final aging time point of 16 months of age, 
Tg2576 mice displayed lower lick cluster sizes, particularly in response to 16% sucrose. An added 
manipulation at 16 months of age, comparing food-deprived with free-feeding mice, revealed no 
statistically significant effect of food deprivation on lick cluster size, though lick cluster sizes of both 
genotypes were numerically higher when free-feeding. Taken together, these results suggest that 
Tg2576 mice develop a hedonic deficit with age, most obviously at 16% sucrose, which manifests at 
some point between 4-5 and 8 months of age. 
 A notable feature of the drinking behaviour of Tg2576 mice seen in Experiment 1 is that 
their hedonic reactions dissociate from their consumption levels. That is, Tg2576 mice consistently 
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consume more sucrose than wild-type mice regardless of sucrose concentration, and this elevated 
consumption still occurs when a lick cluster size deficit is present. Having demonstrated a hedonic 
deficit in Tg2576 mice that appears to be age-dependent, a second experiment was conducted to 
determine whether this deficit could be alleviated by the novel antidepressant agent ketamine. 
Section 3.3 details this experiment and its results. 
  
3.3. Experiment 2 
3.3.1 Subjects & apparatus 
 Experiment 2 is a single study of the licking behaviour of Tg2576 and wild-type mice 
featuring a between-subjects drug condition. The mice used were the same mice that had gone 
through the aging study presented in Experiment 1. 31 Tg2576 and 31 wild-type mice were used in 
the experiment, at 19 months of age; 16 mice of each genotype were assigned to the ketamine 
treatment group, and 15 mice of each genotype were assigned to the vehicle group. At this time 
point, the percentage of mice in each genotype being single housed was 96.7%. Both genotypes 
were counterbalanced with respect to concentration order and treatment group. Testing apparatus 
used was as described in Chapter 2. 
 
3.3.2 Procedure 
 Pre-training was conducted as described in Chapter 2. The pre-training period needed to 
produce a consistent level of licking behaviour was 4 days. Testing occurred as described in Chapter 
2, with each test phase lasting 4 days. To ensure the ketamine and vehicle groups were equivalent 
prior to ketamine administration, the treatment groups within each genotype were matched on 
their baseline weight, consumption and lick cluster size. Ketamine hydrochloride (Sigma) and vehicle 
(0.9% sodium chloride) stock solutions were made up during the pre-training period using deionised 
water and stored at 2-5°C. Ketamine was administered via intraperitoneal injection at a dose of 
30mg/kg, and both ketamine and vehicle were injected at a volume of 10mL/kg. Each mouse 
received one ketamine or vehicle injection per test phase of the experiment: the first on the day 
after pre-training, 24 hours before the start of test phase 1, and the second on the day between 
phases 1 and 2, 24 hours before the start of test phase 2. 
 
69 
 
3.3.3 Data analysis 
 Data were collected and cleaned as described in Chapter 2. No mice had their drinking data 
excluded from the analysis. Data were analysed using mixed ANOVA, with between-subjects factors 
of genotype and drug, and a within-subjects factor of concentration. Pairwise comparisons between 
genotypes within a concentration were conducted using unpaired Student’s t-tests. 
 
3.3.4 Results 
 Table 3.7 presents the mean baseline weight and deprivation-induced weight change of 
ketamine- and vehicle-treated Tg2576 and wild-type mice. Inspection of the baseline weight data 
indicates that Tg2576 display the typical lower weight seen at previous ages, with no clear 
differences seen due to ketamine treatment or concentration change. ANOVA results were 
consistent with this impression, revealing a significant effect of genotype (F(1,58) = 21.387, p<.001 , 
MSE = 803.334, η2p= 0.269), and no significant effects of concentration (F(1,58) = 2.057, p = .157, 
MSE = 1.291, η2p= 0.034) or drug (F(1,58) = 0.157, p = .693, MSE = 5.899, η2p= 0.003). No interaction 
terms were significant (highest F for concentration × genotype × drug (1,58) = 1.103, p = .298, MSE = 
0.692, η2p= 0.019).  
 
 
 
Baseline 
weight (g) 
 
Treatment TG 4% TG 16% WT 4% WT 16% 
 
Ketamine 
32.25  
(±0.702) 
 32.39 
(±0.650) 
37.22 
(±1.362) 
37.33 
(±1.488) 
 
Vehicle 
32.62 
(±1.018) 
32.62 
(±1.081) 
37.57 
(±1.178) 
38.13 
(±1.118) 
 
Weight 
change 
(g) 
 
Ketamine 
1.188 
(±0.100) 
 
0.953 
(±0.086) 
 
0.859 
(±0.079) 
1.000 
(±0.116) 
 
Vehicle 
1.017 
(±0.082) 
0.950 
(±0.095) 
0.783 
(±0.084) 
0.800 
(±0.124) 
Table 3.7. Mean data (±SEM) for baseline weight and deprivation-induced weight change (g) of ketamine- and 
vehicle-treated Tg2576 (TG) and wild-type (WT) mice at each sucrose concentration. N=31 TGs and 31 WTs, 16 
receiving ketamine and 15 receiving vehicle in each genotype. 
  
 Inspection of the weight change data indicates that Tg2576 mice generally display the 
previously observed greater weight loss, with concentration change having opposing effects in both 
genotypes regardless of treatment. Ketamine-treated mice of both genotypes display a numerically 
greater weight loss. ANOVA results were generally consistent with this impression, revealing a 
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significant effect of genotype (F(1,58) = 4.100, p = .047, MSE = 0.855, η2p= 0.066), no significant 
effect of concentration (F(1,58) = 0.468, p = .497, MSE = 0.040, η2p= 0.008), and a significant 
concentration × genotype interaction (F(1,58) = 4.754, p = .033, MSE = 0.407, η2p= 0.076). There was 
no significant effect of drug (F(1,58) = 1.880, p = .176, MSE = 0.392, η2p= 0.031), and no other 
interaction was significant (highest F for concentration × genotype × drug (1,58) = 1.925, p = .171, 
MSE = 0.165, η2p= 0.032). 
Inspection of panel A of Figure 3.6 indicates that Tg2576 mice continue to display greater 
consumption than wild-type mice regardless of concentration or drug treatment, albeit at this age 
there is generally numerically greater consumption at 16%, rather than 4%, sucrose. No consistent 
effect of ketamine treatment on consumption is apparent, though ketamine-treated Tg2576 mice 
display numerically higher consumption than their vehicle-treated counterparts at both sucrose 
concentrations. ANOVA results were consistent with this impression, revealing a significant effect of 
genotype (F(1,58) = 28.046, p<.001 , MSE = 11.456, η2p= 0.326), and no significant effects of 
concentration (F(1,58) = 0.016, p = .900, MSE = 0.002, η2p<0.001) or drug (F(1,58) = 2.458, p = .122, 
MSE = 1.004, η2p= 0.041). No interaction term was significant (highest F for concentration × 
genotype (1,58) = 1.649, p = .204, MSE = 0.159, η2p= 0.028). 
Inspection of panel B of Figure 3.6 indicates that the general lick cluster size pattern 
observed at 16 months of age is still present, regardless of drug treatment. There is no appearance 
of a pronounced effect of ketamine treatment, though in ketamine-treated Tg2576 mice lick cluster 
size numerically decreased, while in ketamine-treated wild-type mice it numerically increased. 
ANOVA results were consistent with this impression, revealing significant effects of concentration 
(F(1,58) = 42.313, p<.001 , MSE = 1515.008, η2p= 0.422), genotype (F(1,58) = 8.828, p = .004, MSE = 
1842.55, η2p= 0.132), and a significant concentration × genotype interaction (F(1,58) = 15.512, 
p<.001 , MSE = 555.393, η2p= 0.211). There was no significant effect of drug (F(1,58) = 0.205, p = 
.652, MSE = 42.88, η2p= 0.004), and no other interaction term was significant (highest F for genotype 
× drug (1,58) = 0.647, p = .424, MSE = 135.05, η2p= 0.011). Bayesian mixed ANOVA provided 
uninformative evidence regarding the null effect of ketamine on lick cluster size (BF10 = 0.567), and 
the null genotype × drug interaction (BF10 = 0.580). Follow-up unpaired t-tests comparing Tg2576 
and wild-type lick cluster size at 4% and 16% sucrose, across treatment groups, revealed a significant 
difference at 16% (Student’s t(60) = 3.780, p<.001, d = 0.960) but not 4% (Student’s t(60) = 1.528, p = 
.132, d = 0.388) sucrose. Despite this Tg2576 lick cluster size reduction, paired samples t-tests 
comparing lick cluster size at 4% and 16% sucrose within each genotype, across treatment groups, 
revealed a significant difference for both Tg2576 (Student’s t(30) = 2.263, p = .031, d = 0.406) and 
wild-type (Student’s t(30) = 6.445, p<.001, d = 1.158) mice. 
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Figure 3.6. Mean (±SEM) sucrose consumption (g) (A) and lick cluster size (B) data of ketamine- and vehicle-
treated Tg2576 (TG) and wild-type (WT) mice, in response to 4% and 16% sucrose solutions and in 10 minute 
test sessions, at 19 months of age. N = 31 Tg2576 and 31 wild-type mice, 16 receiving ketamine and 15 
receiving vehicle in each genotype. 
 
 Inspection of Table 3.8 indicates that the amount consumed per lick data show the same 
general pattern as described in Experiment 1, Sections 3.2.4.4 and 3.2.4.5, regardless of treatment 
group. Ketamine treatment appeared to have numerically opposing effects in the two genotypes. 
ANOVA results were consistent with this impression, revealing a significant effect of concentration 
(F(1,58) = 6.438, p = .014, MSE = 0.467, η2p= 0.100), and no significant effects of genotype (F(1,58) = 
0.114, p = .736, MSE = 0.054, η2p= 0.002) or drug (F(1,58) = 0.756, p = .388, MSE = 0.355, η2p= 0.013). 
None of the interaction terms were significant (largest F for genotype × drug (1,58) = 2.343, p = .131, 
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MSE = 1.102, η2p= 0.039). Inspection of the inter-lick interval data in Table 3.8 indicates a similar 
pattern of results as seen in Experiment 1, Section 3.2.4.5, regardless of treatment group. ANOVA 
results were consistent with this impression, revealing no significant effects of genotype (F(1,58) = 
2.769, p = .101, MSE = 408.51, η2p= 0.046) or drug (F(1,58) = 0.108, p = .743, MSE = 15.95, η2p= 
0.002). There was a significant effect of concentration (F(1,58) = 11.144, p = .001, MSE = 133.521, 
η2p= 0.161), and significant concentration × genotype (F(1,58) = 25.036, p<.001, MSE = 299.961, η2p= 
0.302) and concentration × genotype × drug (F(1,58) = 7.023, p = .010, MSE = 84.142, η2p= 0.108) 
interactions. No other interaction terms were significant (highest F for genotype × drug (1,58) = 
0.306, p = .582, MSE = 45.15, η2p= 0.005). As in Experiment 1, the lack of overall genotype difference 
in these measures, and larger numeric differences in inter-lick interval occurring at 4% sucrose, 
where lick cluster size differences are numerically smaller, would suggest that the genotype lick 
cluster size difference is not artefactual, and can be interpreted as a hedonic impairment. 
 
 
 
Amount 
consumed 
per lick 
(µg) 
 
Treatment TG 4% TG 16% WT 4% WT 16% 
 
Ketamine 
1.471  
(±0.144) 
 1.418 
(±0.141) 
1.283 
(±0.081) 
1.146 
(±0.059) 
 
Vehicle 
1.387 
(±0.178) 
1.340 
(±0.100) 
1.637 
(±0.167) 
1.384 
(±0.147) 
 
Inter-lick 
interval 
(ms) 
 
Ketamine 
133.7 
(±2.032) 
 
126.6 
(±1.292) 
 
126.6 
(±1.897) 
129.0 
(±1.964) 
 
Vehicle 
132.3 
(±2.223) 
129.0 
(±2.301) 
126.0 
(±3.133) 
125.7 
(±2.972) 
Table 3.8. Mean data (±SEM) for amount consumed per lick (µg) and inter-lick interval (ms) of ketamine- and 
vehicle-treated Tg2576 (TG) and wild-type (WT) mice at 4% and 16% sucrose. N=31 TG and 31 WT mice, 16 
receiving ketamine and 15 receiving vehicle in each genotype. 
 
3.3.5 Summary 
 Experiment 2 investigated whether the lick cluster size deficit exhibited by Tg2576 mice, 
established in Experiment 1, could be alleviated by treatment with the novel antidepressant agent 
ketamine. The results showed that, despite receiving one conventional dose of ketamine per test 
phase, drug-treated Tg2576 mice showed no improvement in their lick cluster size response. In fact, 
lick cluster size of ketamine-treated Tg2576 mice was numerically lower than that of their vehicle-
treated counterparts. In contrast to this, ketamine-treated wild-type mice displayed numerically 
higher lick cluster sizes than their vehicle-treated counterparts. As at the final time point (16 
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months) tested in Experiment 1, the lick cluster size deficit shown here at 19 months of age, 
regardless of treatment group, was numerically present at both 4% and 16% sucrose, though 
statistically demonstrable only at 16% sucrose. This lick cluster size deficit appears to represent an 
anhedonia which is present only at more palatable solutions, and which is not responsive to 
ketamine treatment under the dosage regime implemented. As in Experiment 1, Tg2576 mice still 
retained a hedonic sensitivity to an increase in concentration, suggesting their hedonic reaction to 
sucrose was attenuated rather than entirely blunted. 
 Similar to the results seen in Experiment 1, lowered hedonic responsiveness in Tg2576 mice 
occurred alongside a high level of sucrose consumption, in both treatment groups. Though 
ketamine-treated mice displayed numerically greater amounts of sucrose consumption, most 
notably with Tg2576 mice, there was no statistically demonstrable effect of ketamine on sucrose 
consumption. 
 
3.4. Discussion 
 Experiment 1 demonstrated that Tg2576 mice develop a hedonic deficit which is not present 
at 4-5 months of age. The complete aging study visually suggested that this was an age-related 
deficit, and this suggestion was supported by an additional aging analysis. Examination of the 
hedonic behaviour at each individual time point revealed that the hedonic deficit manifests at some 
point between 4-5 and 8 months of age, and is statistically demonstrable only at 16% sucrose. This 
appears to demonstrate a selective reduction in the hedonic response to more rewarding solutions, 
rather than a generalised anhedonia (although the possibility of a floor effect at 4% sucrose masking 
a generalised hedonic deficit cannot be discounted). Moreover, at all ages Tg2576 mice retained the 
capacity to distinguish between 4% and 16% sucrose, suggesting diminished but not totally 
insensitive hedonic responsiveness over this age range. While it is possible that the Tg2576 mouse 
hedonic deficit is to some extent attributable to their increased single housing with age, this seems 
unlikely for two reasons. Firstly, the majority of Tg2576 mice were already single housed before 
testing occurred at 4-5 months of age, at which time point Tg2576 mice displayed lick cluster sizes 
numerically greater than wild-type mice. Secondly, roughly equivalent percentages of single- and 
group-housed Tg2576 and wild-type mice were tested at every time point; there was no time point 
at which Tg2576 mice experienced single-housing to a greater extent than wild-type mice. This is not 
only the first study in which lick cluster analysis has been used to profile the hedonic capacity of a 
mouse model of Alzheimer’s disease, but also the first study in which hedonic responses to sucrose 
in mice have been examined longitudinally. 
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The results of this chapter, which reveal a depressive phenotype in Tg2576 mice, are 
consistent with the wider literature, in which depressive behaviour has been observed in various 
Alzheimer’s disease mouse models using conventional behavioural tests. Studies conducted at single 
time points have revealed that both APP/PS1 and tgDimer mice show some degree of ‘depressive’ 
behaviour using the forced swim test, at 6-9 and 7 months of age, respectively (Abdel-Hafiz et al., 
2018; Filali et al., 2009), and that 18 month-old 3xTgAD mice display a depressive phenotype in 
forced swim, tail suspension and sucrose preference tests (Romano et al., 2015). While the 
procedural details of the forced swim test were not identical in these three studies, the results 
demonstrate that genetically altered rodents harbouring Alzheimer’s disease mutations display 
greater immobility or lesser swimming time in the forced swim test. These are behavioural changes 
typically interpreted as evidence of depressive behaviour. In addition, the reduced sucrose 
preference shown by 3xTgAD mice is commonly interpreted as evidence of anhedonia (Willner et al., 
1987). However, as these studies only examined one time point, a developmental profile of 
depressive behaviour in those particular mouse models has not been obtained. As a result, the age 
at which depressive behaviour emerges in APP/PS1, tgDimer and 3xTgAD mice has not be 
established. Unlike these single time point studies, the results presented in this chapter have 
revealed a depressive behaviour, consistent with anhedonia, which manifests and continues with 
age. 
Other studies of depressive behaviour in Alzheimer’s disease model mice have utilised 
multiple time points, albeit using what appears to be a cross-sectional rather than longitudinal study 
design. For example, J20 mice were considered to display a subtle depressive phenotype, as they 
spent less time immobile than wild-type mice in the tail suspension test at 5-7 months, but more 
time immobile at 13-15 months, when the first 3 minutes of the test sessions were analysed (Iascone 
et al., 2013). Tg2576 mice display impaired chocolate-induced conditioned place preference, and a 
reduction in chocolate consumption during conditioning, at 6 months of age, while these behaviours 
appear normal at 2 months of age (Nobili et al., 2017). These latter changes were interpreted by the 
authors as showing a deficit in reward-associated cognition and depressive-like symptomatology. 
While behavioural changes that are absent in younger but present in older mice, such as in these 
two studies, are certainly consistent with an age-related depressive phenotype, these studies did not 
explicitly examine the effect of age. One study reporting a null result when investigating depressive 
behaviour in an Alzheimer’s disease mouse model has also been published (Vloeberghs, Van Dam, 
Franck, Staufenbiel, & De Deyn, 2007). In this study, APP23 mice were examined for depressive 
behaviour at 3, 6 and 12 months of age, again apparently cross-sectionally, using the forced swim, 
tail suspension and sucrose preference tests. Interestingly, transgenic APP23 mice spent significantly 
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less time immobile than wild-type mice in the forced swim test at all ages, significantly less time 
immobile in the tail suspension test at 6 months, and displayed no significant diminishment in 
sucrose preference at any age. It would seem counter-intuitive to interpret the forced swim or tail 
suspension test results as evidence that APP23 mice are less depressed than their wild-type 
counterparts, and indeed the authors suggest that agitation could explain the genotype differences 
seen in these two tests. This questions how useful the forced swim and tail suspension tests may be 
for investigating depression. The results of the sucrose preference test are interesting; although no 
deficit in APP23 mice was apparent, there was an overall effect of age, in that sucrose preference 
declined in both genotypes as age increased. This pattern is somewhat similar to the lick cluster size 
aging profile presented in Experiment 1, in which lick cluster size initially increased then declined, in 
both genotypes and at both sucrose concentrations. This convergence upon a similar decline with 
age could be taken as evidence that the sucrose preference test results are providing at least in part 
a measure of hedonic response. While the results of Experiment 1 are largely consistent with the 
wider literature, the lick microstructure technique used has some distinct differences from the more 
traditional behavioural tests for depression used in other studies. These differences and their 
implications will be discussed shortly. Before that discussion, the question of how attributable the 
results of this chapter, and of other studies, are to the pathological hallmarks of Alzheimer’s disease 
will be addressed. 
A possibility that has been explored by this chapter is that Aβ, in particular soluble Aβ, could 
account for a depression symptom such as anhedonia. Were this causal relationship to exist, then 
whatever its precise nature, an age-related hedonic deficit should be expected to arise in Tg2576 
mice. That this exact phenomenon was observed suggests that Aβ may contribute to hedonic 
dysfunction. An important point is that, in principle, APP overexpression in its own right can produce 
phenotypic differences in transgenic mice (Hsiao et al., 1995; Saito, Matsuba, Yamazaki, Hashimoto, 
& Saido, 2016). However, the simple presence of APP overexpression seems unlikely to be a cause of 
the hedonic deficit observed here in Tg2576 mice; in the Tg2576 mouse brain, human APP is 
detectable from at least 2 months of age (Kawarabayashi et al., 2001), and does not show an 
increased expression in older mice (Hsiao et al., 1996; Kawarabayashi et al., 2001). That elevated 
APP levels are present from an early age and stable over time, while the hedonic deficit was not 
present at 4-5 months of age and appeared as Tg2576 mice aged, would suggest that APP 
overexpression per se is unlikely to be the cause of the deficit. Soluble Aβ species, however, are 
known to accumulate over time in the Tg2576 mouse brain (Kawarabayashi et al., 2001), and would 
appear to be a more likely candidate to explain the observed hedonic deficit. Existing studies of 
depressive behaviour in Alzheimer’s disease model mice have either only studied one time point in 
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isolation, or have not explicitly examined the effect of age on depressive behaviour. As a result, prior 
investigations cannot exclude the possibility of APP overexpression in its own right causing a 
depressive phenotype. The current results in Tg2576 mice presented herein are thus the first 
suggestion that a depressive phenotype in an Alzheimer’s disease mouse model can reasonably be 
attributed to Aβ accumulation. This is in keeping with a study in rats which found that soluble Aβ42 
administration led to a depressive phenotype, as evidenced by greater immobility time and reduced 
swimming time in the forced swim test (Colaianna et al., 2010). Administering Aβ, however, does not 
recapitulate the physiological process of gradual Aβ accumulation which occurs in Tg2576 mice 
(Kawarabayashi et al., 2001), and which biomarker modelling suggests occurs in human Alzheimer’s 
disease (Jack et al., 2013). Consequently, the hedonic deficit presented in this chapter specifically 
provides evidence that the gradual Aβ accumulation inherent to Alzheimer’s disease can produce a 
symptom of depression. This is not to say that pathological aspects of Alzheimer’s disease other than 
Aβ, such as tau pathology and neurodegeneration, have no relation to depression symptoms. For 
example, the depressive phenotype seen in 3xTgAD mice could plausibly be attributed to some 
effect of either Aβ or tau pathology (or both) (Romano et al., 2015). Behavioural tests in transgenic 
mice exclusively harbouring human tau mutations have revealed depressive phenotypes (Egashira et 
al., 2005; Koss et al., 2016; Van der Jeugd et al., 2013), suggesting pathological tau species can 
induce depression symptoms in their own right, though these are based on mutations underlying a 
non-Alzheimer’s disease dementia (Hutton et al., 1998; Sperfeld et al., 1999). A cross-sectional 
analysis of psychiatric symptoms in cases of probable Alzheimer’s disease found that while major 
depression frequency decreased as disease severity increased, anhedonia frequency increased 
(Lopez et al., 2003). This suggests that pathological events downstream of Aβ, such as tau species or 
neurodegeneration, could also underlie certain depression symptoms. Taken together, the results 
presented herein and published elsewhere suggest that Aβ accumulation alone could be sufficient to 
account for a depression symptom such as anhedonia, but this is not to imply that other pathological 
features of Alzheimer’s disease have no relevance. 
An outstanding point of discussion is how lick cluster analysis compares with other standard 
behavioural tests of depression. The forced swim test and tail suspension tests, perhaps the most 
commonly used of such assays, were initially conceived of as tools for screening potential anti-
depressant compounds in rodents (Porsolt et al., 1977; Steru, Chermat, Thierry, & Simon, 1985). 
Time spent immobile in these tests is generally interpreted as evidence of a depressive phenotype, 
because certain anti-depressants reduced immobility time in both of these paradigms (Porsolt et al., 
1977; Steru et al., 1985). It does not follow, however, that validity as a screening tool for a drug 
necessitates validity as a test for revealing the condition treated by that drug (Stanford, 2017). This 
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logical point aside, it is also the case that drugs not thought to exert an anti-depressant effect have 
also reduced immobility time in the forced swim test (Schechter & Chance, 1979), and that anxiolytic 
and anti-psychotic agents have increased immobility in the tail suspension test (Cryan, Mombereau, 
& Vassout, 2005). These latter findings suggest that these tests could produce false negative and 
false positive results, as differences in calmness and docility, for example, could either mask or be 
mistaken for a depressive phenotype. Refinements to the forced swim test have been proposed, 
however, to improve its reliability (Castagné, Porsolt, & Moser, 2009; Sunal, Gümüşel, & Kayaalp, 
1994). Other interpretations of immobility in these tests include implementing a stress-coping 
strategy in the forced swim test (Commons, Cholanians, Babb, & Ehlinger, 2017), and motor 
dysfunction in the tail suspension test (Mori, Ohashi, Nakai, Moriizumi, & Mitsumoto, 2005). In sum, 
the inference that reduced mobility or struggling represents ‘depressive-like behaviour’ may not 
always be appropriate, especially as confounding motor differences are not always examined in such 
studies. In addition, the feelings of despair, and ‘searching’ rather than ‘waiting’, which forced swim 
and tail suspension tests purportedly measure (Porsolt et al., 1977; Steru et al., 1985), are not core 
clinical symptoms of depression. In comparison to these two commonly used behavioural tests, lick 
cluster analysis includes the ability to record and examine potentially confounding variables, such as 
inter-lick interval and amount consumed per lick (Lydall et al., 2010; McNamara et al., 2016). If these 
variables fail to account for lick cluster size differences between groups, then such a difference can 
be interpreted as one of hedonics. One major advantage of using lick cluster analysis, then, is that 
other variables which could account for a depressive phenotype can be investigated and, when 
appropriate, discounted. This approach allows for the possibility of false negative and false positive 
results to be considered. Another considerable advantage of using lick cluster analysis is that it can 
plausibly claim to directly index hedonic response (Dwyer, 2012), and thus can reveal anhedonia, an 
important and core clinical symptom of depression. 
Behavioural tests based on measuring the consumption of palatable substances, including 
sucrose preference testing or overall intake testing, are assumed to reveal hedonic or depressive 
changes (Katz, 1982; Muscat & Willner, 1992; Papp, Willner, & Muscat, 1991; Willner et al., 1987). 
While this may be a more appropriate approach than forced swim or tail suspension testing, as it 
aims to measure a core component of depression, consumption can be influenced by factors other 
than hedonic response. In fact, consumption and hedonics can sometimes dissociate from one 
another. For example, consumption of a palatable substance can be reduced while hedonic reactions 
to that substance remain intact (Pelchat et al., 1983). Indeed, a major dissociation between 
consumption and hedonic response was shown in this chapter, in which Tg2576 mice consume much 
more sucrose solution than wild-type mice, while displaying a diminished hedonic response. Thus 
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testing sucrose preference or overall consumption may reveal hedonic changes in certain 
circumstances, but does not necessarily always do so. In contrast, lick cluster analysis provides a 
measure of hedonic response which is not derived from consumption, and also allows consumption 
to be measured alongside lick cluster size. Lick cluster analysis, then, allows for a fuller examination 
of rodent appetitive behaviour, providing measures of both total intake and hedonic response within 
that intake. Consumption and preference tests also do not typically investigate confounding 
variables such as motoric influences on licking; lick cluster analysis therefore both provides a clearer 
measure of hedonic behaviour, and reveals whether lick cluster size differences are simply artefacts 
of motor differences. As a consequence of the advantages offered by lick cluster analysis, the 
hedonic deficit in Tg2576 mice in this chapter provides clearer evidence of a depressive phenotype 
in an Alzheimer’s disease mouse model than both studies using forced swim or tail suspension 
testing (Abdel-Hafiz et al., 2018; Filali et al., 2009; Iascone et al., 2013; Romano et al., 2015), and 
studies using consumption or preferences tests (Nobili et al., 2017; Romano et al., 2015). 
One observation yet to be discussed is the peculiar occurrence in Tg2576 mice of a lower 
body weight coupled with greater sucrose consumption, something which may initially appear 
counter-intuitive. Low body weight and increased food consumption have both been previously 
documented in transgenic mouse models of Alzheimer’s disease (Pugh, Richardson, Bate, Upton, & 
Sunter, 2007; Vloeberghs et al., 2008), which may be evidence of metabolic alterations present in 
APP overexpressing mice. Indeed, Tg2576 mice show a range of metabolic disturbances, including 
increased energy expenditure, increased metabolic rate, reduced plasma leptin, and abnormal 
hypothalamic responses to both low plasma leptin and fasting (Ishii et al., 2014). Given that leptin is 
involved in the regulation of food intake, energy expenditure and body weight (Friedman & Halaas, 
1998; Schwartz, Woods, Porte, Seeley, & Baskin, 2000), it seems likely that some type of metabolic 
alteration underlies the low body weight and increased consumption shown by Tg2576 mice in this 
chapter. That fasting produces different hypothalamic responses in Tg2576 and wild-type mice is 
interesting, as food deprivation was used in Experiments 1 and 2 of this chapter. However, this 
effect of fasting on the hypothalamus was observed after 48 hours of food deprivation (Ishii et al., 
2014), whereas experiments in this chapter used 6-8 hours of deprivation, and similar consumption 
and lick cluster size results were seen at 16 months whether food was deprived or present. 
Therefore it is unlikely that the results of Experiments 1 and 2 are a product of the differential 
effects of fasting on Tg2576 and wild-type mice. The potential presence of metabolic disturbances in 
Alzheimer’s disease model mice underscores the importance of using lick cluster analysis rather than 
standard consumption or preference testing. Differences in hunger, satiety signalling or energy 
requirements could produce meaningful differences in intake, such that sucrose consumption is 
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being largely driven by non-hedonic factors, as appears to be the case in Experiments 1 and 2. Only 
when metabolic and other differences can be excluded, can consumption-based tests potentially 
provide a good index of hedonic behaviour. 
In sum, previous studies examining depressive behaviour in Alzheimer’s disease model mice 
have either used methods which, at best, measure a non-core symptom of depression, or have 
attempted to measure hedonic change with an imprecise technique. In addition, prior studies have 
failed to explicitly investigate the effect of age, and thus it has been unclear what the original 
molecular cause of a depressive phenotype could be. The results in this chapter therefore provide 
clearer evidence of a depressive state in Tg2576 mice, specifically a state consistent with an 
anhedonic phenotype, which appears age-dependent and attributable to Aβ. The biological changes 
which may underlie this state will be examined in Chapter 5. The failure of ketamine to induce a 
change in the hedonic response of Tg2576 mice will also be explored in Chapter 5, as this topic is 
better addressed when the biochemical effects of ketamine have been investigated. 
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Chapter 4: Cognitive profile of Tg2576 
mice 
 
4.1. Introduction 
 One component of memory which is degraded in Alzheimer’s disease is recognition memory 
– that is, the remembrance of things previously encountered (Mandler, 1980). Patients with 
Alzheimer’s disease display impaired recognition memory across a range of stimuli, including 
colours, patterns, faces, pictures and spatially repositioned objects (Abrisqueta-Gomez, Bueno, 
Oliveira, & Bertolucci, 2002; Eslinger & Damasio, 1986; Moss, Albert, Butters, & Payne, 1986). 
Changes in recognition memory may be an early event in Alzheimer’s disease, as they also appear in 
mild cognitive impairment (Barbeau et al., 2004; Hudon, Belleville, & Gauthier, 2009), and may have 
some value in predicting conversion to Alzheimer’s disease (Didic et al., 2013). Considered an 
example of declarative memory (Manns, Hopkins, Reed, Kitchener, & Squire, 2003), recognition 
memory is a mnemonic ability well-suited for studying in non-human animals, which investigate 
objects and spaces as part of their behavioural repertoire. The investigation of recognition memory 
in primates and rodents has yielded much insight into its underlying processes (Dere, Huston, & De 
Souza Silva, 2007; Warburton & Brown, 2010). 
 Recognition memory in non-human animals can be fractionated into a number of subtypes, 
including memory for object novelty (Ennaceur & Delacour, 1988), relative object recency (Mitchell 
& Laiacona, 1998), object location novelty (Ennaceur et al., 1997), and object-in-place conjunctions 
(Dix & Aggleton, 1999). While a detailed description of the neural substrates of these different forms 
of recognition memory will not be presented here, a brief overview is as follows: object information 
is processed by the perirhinal cortex (Brown & Aggleton, 2001; Wan, Aggleton, & Brown, 1999), 
while the hippocampus is critical to forms of object recognition memory that involve a spatial or 
temporal dimension (Barker & Warburton, 2011). In addition, the medial prefrontal cortex is an 
important site which may integrate object information from the perirhinal cortex with spatial or 
temporal information from the hippocampus (Barker, Bird, Alexander, & Warburton, 2007; Barker & 
Warburton, 2015), and is critical to remembrance of object-in-place associations and relative object 
recency. 
 The object-in-place task, introduced in Chapter 2, is one of particular relevance to Tg2576 
mice. Tg2576 mice display an impairment in successfully integrating object identity with spatial 
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location, at ages ranging from 10-12 months to 21 months of age (Good & Hale, 2007; Good, Hale, et 
al., 2007; Hale & Good, 2005). This cognitive deficit does not seem to result from a general inability 
to process objects or sustain attention, as aged Tg2576 mice can successfully distinguish between 
novel and familiar objects, and familiar and novel locations (Good & Hale, 2007). Nor does this 
object-in-place deficit likely result from task complexity per se, as the intact novel object and 
location preferences previously mentioned were in response to 4 object arrays, the same array size 
on which Tg2576 mice display an object-in-place impairment (Good & Hale, 2007). Rather, Tg2576 
mice appear to have a selective deficit for a task requiring the integration of object identity with 
specific spatial locations; where wild-type mice preferentially explore objects which exchange 
positions, Tg2576 mice do not. While this has been investigated in multiple single studies, a 
longitudinal profile of Tg2576 object-in-place memory has yet to be captured. Indeed a longitudinal 
examination of object-in-place memory has only been attempted in one Alzheimer’s disease mouse 
model to date (Evans et al., 2019). A longitudinal object-in-place memory profile in Tg2576 mice 
would allow the notion that Aβ is responsible for this cognitive deficit to be indirectly tested, in that 
a deficit would be expected to occur as Aβ accumulated in Tg2576 mice with age (Kawarabayashi et 
al., 2001). An aging study of this nature would also complement Chapter 3, in which a hedonic deficit 
was revealed as Tg2576 mice aged. If a longitudinal profile of the Tg2576 object-in-place memory 
deficit could be similarly captured, its emergence and progression relative to the hedonic deficit 
could prove informative, as regards the vulnerabilities of their respective underlying circuitries to Aβ 
pathology. To this end, the neural circuitry involved in successful object-in-place memory will now 
be outlined in more detail. 
 A number of studies have revealed that object-in-place associative recognition memory is 
underpinned by at least three structures in primates and rodents, namely the hippocampus, 
perirhinal cortex and medial prefrontal cortex (Warburton & Brown, 2010). These three structures 
form an integrated circuit, and manipulations which disrupt the functioning of this circuit lead to 
deficits in object-in-place memory (Barker & Warburton, 2015). A number of transmitters contribute 
to successful performance in this task, including glutamatergic (Barker & Warburton, 2015; Evans et 
al., 2019) and cholinergic (Barker & Warburton, 2009; Sabec, Wonnacott, Warburton, & Bashir, 
2018) systems, as well as potentially Rho GTPase regulatory proteins (De Viti, Martino, Musilli, 
Fiorentini, & Diana, 2010). As described earlier, it seems likely that for successful object-in-place 
memory, the perirhinal cortex encodes object information, with the hippocampus encoding spatial 
information about objects, and the medial prefrontal cortex possibly integrating information from 
the former structures (Barker & Warburton, 2015). 
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 The hypothesis of this chapter is that Tg2576 mice will develop impaired object-in-place 
memory with age, and that the accumulation of Aβ within the hippocampus may be sufficient to 
hinder their performance on this task. Experiment 3 will longitudinally examine object-in-place 
memory in Tg2576 and wild-type mice. As these same cohorts of mice were treated with sub-
anaesthetic ketamine and vehicle in Chapter 3, Experiment 4 will examine the effects of ketamine on 
associative recognition memory in Tg2576 and wild-type mice. While ketamine was selected for its 
potential anti-depressant effect, given that another NMDA receptor antagonist aids cognition in 
Alzheimer’s disease patients (Danysz & Parsons, 2012), the effect of ketamine on cognition merits 
investigation. In addition, to the extent that a Tg2576 object-in-place memory deficit is Aβ-
dependent, the fact that ketamine may lower brain Aβ levels suggests that it could, in principle, 
improve cognition in Tg2576 mice (Quiroga et al., 2014). Experiment 5 will examine short-term 
spatial memory in ketamine- and vehicle-treated Tg2576 and wild-type mice, using a one-trial T-
maze task which was introduced due to low object contact times observed in Tg2576 mice. 
 
4.2. Experiment 3 
4.2.1 Subjects, apparatus & procedure 
 Experiment 3 investigates the cognitive ability of the same cohorts of Tg2576 and wild-type 
mice used in Chapter 3. Mice were tested at 5-6, 8-9, 12-13 and 16-17 months of age, immediately 
after the individual lick cluster studies that comprised Experiment 1. The combined numbers of each 
genotype at each time point were as follows: 5-6 months – 42 Tg2576 and 40 wild-type; 8-9 months 
– 42 Tg2576 and 38 wild-type; 12-13 months – 40 Tg2576 and 38 wild-type; 16-17 months – 34 
Tg2576 and 36 wild-type. Housing conditions were as previously described. As the earliest age at 
which Tg2576 mice had previously displayed a cognitive deficit in the object-in-place test was at 10-
12 months (Good, Hale, et al., 2007), it was anticipated that 3 time points would be sufficient to 
reveal the presence of this deficit. However, an additional testing age was included after the 12-13 
month time point. Consequently, the aging study utilised 4 sets of 4 object arrays; the first 3 time 
points were counterbalanced with respect to object array selection, whereas the final time point 
used one set of 4 object arrays. Other counterbalancing details, testing apparatus and experimental 
procedure were as described in Chapter 2. As the squads in which mice were run did not always 
contain equal numbers of Tg2576 and wild-type mice, on occasion two wild-type mice would be 
yoked to the same Tg2576 mouse, or there would be a Tg2576 mouse with no yoked wild-type 
mouse. While the latter could theoretically result in lower overall Tg2576 object sampling, the 
individual time point analyses would suggest this made no material difference. Nonetheless, to 
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remove this as a potential influence in Experiment 4, no unyoked Tg2576 mice were used. This 
involved, on occasion, one wild-type mouse being yoked to two Tg2576 mice and being given the 
average of their object sampling time. 
  
4.2.2 Data analysis 
 Data were initially collected as described in Chapter 2. Object-in-place data were cleaned to 
remove low or unreliable object contact measurements, as described in Section 2.3.2. Data cleaning 
resulted in excluded data of 4 mice at 8-9 months, 3 mice at 12-13 months, and 3 mice at 16-17 
months. Only the subset of mice which were present at every time point until (and including) 16-17 
months of age after data cleaning (n = 26 Tg2576, 35 wild-type mice), informed the aging analysis. 
Failure of recording equipment caused one additional Tg2576 mouse at 8-9 months to be excluded 
from the habituation data. The analyses of each individual time point were also conducted and are 
presented after the aging data. 
 For the aging analysis, habituation and object-in-place test phase data were analysed using 
mixed ANOVA, with a between-subjects factor of genotype, and within-subjects factors of age and 
day, and age and object, respectively. Sample phase data were analysed as total contact time by 
mixed ANOVA, with a between-subjects factor of genotype, and a within-subjects factor of age. 
Discrimination ratios were analysed using mixed ANOVA, with a between-subjects factor of 
genotype, and a within-subjects factor of age. At each individual time point, habituation and object-
in-place test phase data were analysed using mixed ANOVA, with a between-subjects factor of 
genotype, and within-subjects factors of day and object, respectively. Sample phase total contact 
time data of each genotype were compared by unpaired Student’s t-tests. Tg2576 and wild-type 
discrimination ratios were compared using unpaired t-tests, and the discrimination ratio of each 
genotype was compared against chance performance (0.5) using one-sample t-tests. Pairwise 
comparisons between object groupings within each genotype were conducted by paired t-tests. 
Data are presented as follows: all forms of object contact (habituation, sample phase, and test phase 
(both raw contact times and discrimination ratios)) are presented graphically in the aging analysis; in 
the individual time point analysis the presentation is the same, except the sample phase data are 
described in the text. 
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4.2.3 Results 
4.2.3.1 Aging study 
 Figure 4.1 presents the mean object contact times during habituation of all Tg2576 and wild-
type mice in the aging analysis. Inspection of this figure indicates that contact times were high across 
genotypes at 5-6 months, with a marked reduction at day 2; both overall object contact and the 
effect of day were generally relatively low thereafter. Notably, Tg2576 mice consistently explored 
objects less than wild-type mice, across age and day. ANOVA revealed significant effects of age 
(F(1.566,90.849) = 111.954, p<.001, MSE = 19888.19, η2p=0.659), genotype (F(1,58) = 23.09, p<.001, 
MSE = 6920.3, η2p=0.285) and day (F(1,58) = 60.407, p<.001, MSE = 3462.61, η2p=0.510). There was 
also a significant age × day interaction (F(1.724,99.966) = 30.215, p<.001, MSE = 1990.34, η2p= 
0.343). No other interaction reached statistical significance (highest F for age × genotype 
(1.566,90.849) = 2.197, p = .128, MSE = 390.23, η2p= 0.036). 
 
 
Figure 4.1. Mean contact times (s) of Tg2576 (TG) and wild-type (WT) mice when habituating to objects with 
age, over two consecutive days and in 10 minute sessions. n= 25 Tg2576 and 35 wild-type mice. 
  
 Figure 4.2 presents the mean sample and test phase object contact times, and 
discrimination ratios, of all Tg2576 and wild-type mice in the aging analysis. Inspection of panel A of 
Figure 4.2 indicates that, in the sample phase, object contact of all mice markedly decreased after 
the 5-6 month time point. In addition, Tg2576 mice displayed numerically larger object sampling 
times than wild-type mice, across age, although this difference appeared negligible after the 5-6 
month time point. ANOVA results were consistent with this impression, revealing a significant effect 
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of age (F(1.975,116.505) = 42.314, p<.001, MSE = 5057.0, η2p= 0.418), no significant effect of 
genotype (F(1,59) = 0.898, p = .347, MSE = 415.1, η2p= 0.015), and a non-significant age × genotype 
interaction (F(1.975,116.505) = 0.979, p = .378, MSE = 117.1, η2p= 0.016). The genotype sampling 
discrepancy may seem counter-intuitive given that wild-type mice were yoked to match sampling 
times; this is explained by the fact that cohort attrition and data cleaning impacted Tg2576 mice 
more than wild-types. For example, by 16-17 months of age several Tg2576 mice had died and could 
not contribute to the aging analysis, while their yoked wild-type counterparts were included, with 
the effect of raising the mean Tg2576 contact time. Analyses at individual time points presented in 
Sections 4.2.4.2-5, however, demonstrate that yoking was effective at matching genotype object 
contact times in the sample phase. 
 Inspection of panel B of Figure 4.2 indicates that in the test phases, mice generally explored 
objects less with age, across genotype and object type. In addition, mice generally spent numerically 
more time exploring mismatched objects than familiar ones, across genotype and age. As with the 
habituation data, Tg2576 mice showed lower levels of object exploration than wild-type mice, across 
age and object type. While the numeric contact time difference between familiar and mismatched 
objects declined with age for both genotypes, by 16-17 months Tg2576 but not wild-type mice 
displayed numerically near-identical exploration of both object types. ANOVA revealed significant 
effects of age (F(2.637,155.611) = 13.090, p<.001, MSE = 796.724, η2p= 0.182), object (F(1,59) = 
71.202, p<.001, MSE = 1344.212, η2p= 0.547) and genotype (F(1,59) = 82.89, p<.001, MSE = 26448.6, 
η2p= 0.584), but no significant age × genotype interaction (F(2.637,155.611) = 0.211, p = .866, MSE = 
12.836, η2p= 0.004). There was a significant object × genotype interaction (F(1,59) = 28.393, p<.001, 
MSE = 536.030, η2p= 0.325), but a non-significant age × object × genotype interaction (F(3,177) = 
0.375, p = .771, MSE = 4.063, η2p= 0.006). No other interaction was statistically significant (highest F 
for age × object (3,177) = 2.333, p = .076, MSE = 25.303, η2p= 0.038). 
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Figure 4.2. Mean object contact times in 10 minute sample (A) and test (B) phases, and discrimination ratios 
(C), for aging Tg2576 (TG) and wild-type (WT) mice (at 5-6, 8-9, 12-13 and 16-17 months of age). (A) presents 
total sample phase object contact, while (B) presents separate contact times for familiar and mismatched 
objects. n = 26 Tg2576 and 35 wild-type mice. 
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 Inspection of panel C of Figure 4.2 indicates that Tg2576 mice display a numerically lower 
preference ratio for exploring mismatched objects at all ages, though this is numerically most 
pronounced at 16-17 months of age. In addition, while both wild-type and Tg2576 mice showed an 
overall numeric discrimination ratio decline with age, this decline appears numerically larger in 
Tg2576 mice. ANOVA results were partially consistent with this impression, and revealed a 
significant effect of genotype (F(1,59) = 4.488, p = .038, MSE = 0.062, η2p= 0.071), but no significant 
effect of age (F(2.669,157.470) = 1.680, p = .179, MSE = 0.022, η2p= 0.028), and a non-significant age 
× genotype interaction (F(2.669,157.470) = 0.296, p = .805, MSE = 0.004, η2p= 0.005). 1 As occurred 
with the sample phase data, cohort attrition and data cleaning led to data exclusion of several 
Tg2576 mice from the aging analysis. This numerically lowered the mean Tg2576 discrimination 
ratios at the first three time points, and numerically raised it at the fourth. The discrimination ratios 
presented in the individually analysed time points more accurately represent object discrimination 
at each age. 
 While the aging analysis did not provide direct evidence of an age-dependent Tg2576 deficit 
in associative object-in-place memory, there did appear to be a noticeable numeric decline in both 
the degree to which mismatched objects were explored more than familiar ones, and in the 
discrimination ratio, in Tg2576 mice at 16-17 months of age. In Chapter 3, the hedonic 
responsiveness of Tg2576 and wild-type mice was examined at each individual time point following 
the aging analysis, in part to determine at which age a hedonic deficit first manifests. To examine 
whether a cognitive deficit emerges at any individual time point, and to evaluate the time of 
emergence in relation to the previously established hedonic deficit, cognitive performance at each 
time point will be analysed next. 
 
4.2.3.2 5-6 month object-in-place test results 
Inspection of Figure 4.3 indicates that at 5-6 months of age, both Tg2576 and wild-type mice 
decreased their object exploration on day 2 of habituation, while Tg2576 mice display less object 
exploration than wild-type mice across habituation days. ANOVA results were consistent with these 
                                                          
1 A second data cleaning strategy was also employed, similar to that described in 4.2.2, but with the additional 
step that any mouse removed from the test phase data also had its yoked/master counterpart removed. This 
second strategy produced the same pattern of test results seen in the individual time point analysis, with a 
Tg2576 deficit absent at the first 3 time points but present at the final time point. However, the significant 
genotype effect observed in the aging discrimination ratio analysis was not seen (F for main effect of genotype 
(1,49) = 2.792, p = .101, MSE = 0.045, η2p= 0.054) (n = 26 Tg2576 and 25 wild-type mice). Therefore, other than 
this non-significant effect of genotype in the aging discrimination ratio analysis, the precise cleaning strategy 
made little material difference to the overall interpretation of results. The analysis presented herein for 
Experiment 3 is that which used the first cleaning strategy. 
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observations, revealing significant effects of day (F(1,80) = 88.000, p<.001, MSE = 9206.20, η2p= 
0.524) and genotype (F(1,80) = 22.76, p<.001, MSE = 8157.0, η2p= 0.221), with no significant day × 
genotype interaction (F(1,80) = 0.388, p = .535, MSE = 40.63, η2p= 0.005). 
 
 
Figure 4.3. Mean object contact times (s) from 10 minute habituation sessions over two consecutive days, for 5-
6 month old Tg2576 (TG) and wild-type (WT) mice. n = 42 Tg2576 and 40 wild-type mice. 
 
 At 5-6 months of age, the yoking procedure produced near-identical object sampling in both 
genotypes; Tg2576 mice explored objects for 24.91(±2.807) seconds, and wild-type mice for 
24.68(±2.632) seconds (t(80) = 0.058, p = .954, d = 0.013). Inspection of panel A of Figure 4.4 
indicates that, at 5-6 months of age, both Tg2576 and wild-type mice show greater exploration of 
mismatched than familiar objects. In addition, Tg2576 mice show numerically lower contact times at 
both object types compared with wild-type mice, especially on mismatched objects. ANOVA results 
were consistent with this impression, revealing significant effects of object (F(1,80) = 69.37, p<.001, 
MSE = 703.72, η2p= 0.464) and genotype (F(1,80) = 93.73, p<.001, MSE = 11088.5, η2p= 0.540), and a 
significant object × genotype interaction (F(1,80) = 13.61, p<.001, MSE = 138.03, η2p= 0.145). Despite 
this general reduction in Tg2576 contact time, paired samples t-tests comparing familiar versus 
mismatched contact time within each genotype revealed a significant difference for both Tg2576 
(Student’s t(41) = 4.867, p<.001, d = 0.751) and wild-type (Student’s t(39) = 6.719, p<.001, d = 1.062) 
mice. Similarly, inspection of panel B of Figure 4.4 indicates that, when exploration is expressed as a 
discrimination ratio, Tg2576 mice display a preference for mismatched objects which is numerically 
greater than wild-type preference, while all mice display a preference above chance performance. 
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An unpaired t-test revealed no significant difference between Tg2576 and wild-type discrimination 
ratios (Welch’s t(50.66) = 0.972, p = .336, d = 0.211). A Bayesian independent samples t-test 
provided an indication that the null effect of genotype on discrimination ratio was a genuine 
absence of effect (BF10 = 0.341). One sample t-tests comparing discrimination ratios against chance 
performance (0.5) revealed significant differences for both Tg2576 (Student’s t(41) = 3.464, p = .001, 
d = 0.535) and wild-type (Student’s t(39) = 7.034, p<.001, d = 1.112) mice. 
 
 
 
 
Figure 4.4. Mean object contact times (s) for familiar and mismatched objects (A) and discrimination ratios (B) 
for 5-6 month old Tg2576 (TG) and wild-type (WT) mice, in 10 minute test sessions. n = 42 Tg2576 and 40 wild-
type mice. 
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4.2.3.3 8-9 month object-in-place test results 
Inspection of Figure 4.5 indicates that at 8-9 months of age, a similar habituation pattern 
occurred as at 5-6 months, albeit the reduction in object contact time at habituation day 2 was more 
pronounced in Tg2576 mice. ANOVA results were consistent with this impression, revealing 
significant effects of day (F(1,73) = 48.201, p<.001, MSE = 408.806, η2p= 0.398) and genotype (F(1,73) 
= 30.95, p<.001, MSE = 1430.58, η2p= 0.298), and a significant day × genotype interaction (F(1,73) = 
8.450, p = .005, MSE = 71.668, η2p= 0.104). 
 
 
Figure 4.5. Mean object contact times (s) from 10 minute habituation sessions over two consecutive days, for 8-
9 month old Tg2576 (TG) and wild-type (WT) mice. n = 37 Tg2576 and 38 wild-type mice. 
 
 At 8-9 months of age, yoking again produced roughly numerically equivalent genotypic 
object sampling. Tg2576 mice accumulated 12.606(±1.458) seconds and wild-type mice 
13.73(±1.439) seconds of object contact time (t(74) = 0.549, p = .585, d = 0.126). Inspection of panel 
A of Figure 4.6 reveals the same pattern of object contact time results at 8-9 months of age as seen 
at 5-6 months of age. This impression was confirmed by ANOVA results, which revealed significant 
effects of object (F(1,74) = 53.46, p<.001, MSE = 481.988, η2p= 0.419) and genotype (F(1,74) = 95.66, 
p<.001, MSE = 9565.8, η2p= 0.564), and a significant object × genotype interaction (F(1,74) = 21.14, 
p<.001, MSE = 190.557, η2p= 0.222). As seen at 5-6 months of age, paired samples t-tests comparing 
familiar versus mismatched contact time within each genotype revealed a significant difference for 
both Tg2576 (Student’s t(37) = 2.169, p = .037, d = 0.352) and wild-type (Student’s t(37) = 7.634, 
p<.001, d = 1.238) mice.  
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Figure 4.6. Mean object contact times (s) for familiar and mismatched objects (A) and discrimination ratios (B) 
for 8-9 month old Tg2576 (TG) and wild-type (WT) mice, in 10 minute test sessions. n = 38 Tg2576 and 38 wild-
type mice. 
 
 Inspection of panel B of Figure 4.6 indicates that Tg2576 mice display a numerically lower 
discrimination ratio than wild-type mice, while all mice display a preference for mismatched objects 
which is numerically greater than chance performance. An unpaired t-test revealed no significant 
difference between Tg2576 and wild-type discrimination ratios (Welch’s t(45.33) = 0.938, p = .353, d 
= 0.215). A Bayesian independent samples t-test gave an indication that the null genotype effect on 
discrimination ratio was a genuine absence of effect (BF10 = 0.347). One sample t-tests comparing 
discrimination ratios against chance performance (0.5) revealed no significant difference for Tg2576 
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mice (Student’s t(37) = 1.662, p = .105, d = 0.270), and a significant difference for wild-type mice 
(Student’s t(37) = 7.856, p<.001, d = 1.274). A Bayesian one sample t-test provided uninformative 
evidence regarding the Tg2576 discrimination ratio not differing from 0.5 (BF10 = 0.612). 
 
4.2.3.4 12-13 month object-in-place test results 
Inspection of Figure 4.7 indicates that, at 12 months of age, habituation followed a pattern 
similar to that reported at previous time points. ANOVA results were consistent with this 
observation, revealing significant effects of day (F(1,73) = 18.211, p<.001, MSE = 142.549, η2p= 0.200) 
and genotype (F(1,73) = 60.14, p<.001, MSE = 1925.10, η2p= 0.452), with no significant day × 
genotype interaction (F(1,73) = 0.554, p = .459, MSE = 4.338, η2p= 0.008). 
 
 
Figure 4.7. Mean object contact times (s) from 10 minute habituation sessions over two consecutive days, for 
12-13 month old Tg2576 (TG) and wild-type (WT) mice. n = 37 Tg2576 and 38 wild-type mice. 
 
As at previous ages, yoking at 12-13 months produced numerically near-equivalent total 
object contact for the two genotypes during the sample phase. Tg2576 mice accrued 10.964(±2.111) 
seconds, and wild-type mice 11.246(±1.352) seconds, of total object contact (Student’s t(73) = 0.113, 
p = .910, d = 0.026). Inspection of panel A of Figure 4.8 indicates that, at 12-13 months of age, both 
Tg2576 and wild-type mice display a similar pattern of object contact time results as seen at 
previous time points. ANOVA results were consistent with this impression, revealing significant 
effects of object (F(1,73) = 49.76, p<.001, MSE = 645.75, η2p= 0.405) and genotype (F(1,73) = 85.78, 
p<.001, MSE = 9131.0, η2p= 0.540), and a significant object × genotype interaction (F(1,73) = 18.94, 
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p<.001, MSE = 245.78, η2p= 0.206). Consistent with prior ages, paired samples t-tests comparing 
familiar versus mismatched contact time within each genotype revealed significant differences for 
both Tg2576 (Student’s t(36) = 3.958, p<.001, d = 0.651) and wild-type (Student’s t(37) = 6.139, 
p<.001, d = 0.996) mice.  
 
 
 
Figure 4.8. Mean object contact times (s) for familiar and mismatched objects (A) and discrimination ratios (B) 
for 12-13 month old Tg2576 (TG) and wild-type (WT) mice, in 10 minute test sessions. n = 37 Tg2576 and 38 
wild-type mice. 
 
Inspection of panel B of Figure 4.8 indicates that Tg2576 mice display a discrimination ratio 
numerically greater than wild type mice, while all mice continue to display a preference for 
mismatched objects which is numerically greater than chance performance. An unpaired t-test 
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revealed no significant difference between Tg2576 and wild-type discrimination ratios (Welch’s: 
t(58.46) = 0.361, p = .720, d = 0.084). A Bayesian independent samples t-test provided evidence 
which suggested this null genotype effect on discrimination ratio was a genuine null effect (BF10 = 
0.253). One sample t-tests comparing discrimination ratios against chance performance (0.5) 
revealed significant differences for both Tg2576 (Student’s t(36) = 3.689, p<.001, d = 0.607), and 
wild-type mice (Student’s t(37) = 5.555, p<.001, d = 0.901). 
 
4.2.3.5 16-17 month object-in-place test results 
Inspection of Figure 4.9 indicates that, at 16-17 months of age, as seen at prior time points, 
Tg2576 mice reduced their object exploration on habituation day 2, and showed lower contact times 
than wild-type mice across habituation days. However, unlike previous time points, 16-17 month old 
wild-type mice did not reduce their exploration on habituation day 2. In fact, wild-type mice 
displayed numerically greater contact time on habituation day 2. ANOVA results were largely 
consistent with this impression, revealing no significant effect of day (F(1,63) = 2.105, p = .152, MSE 
= 65.24, η2p= 0.032), a significant effect of genotype (F(1,63) = 32.88, p<.001, MSE = 3346.6, η2p= 
0.343), and a non-significant day × genotype interaction (F(1,63) = 3.459, p = .068, MSE = 107.21, 
η2p= 0.052). 
 
 
Figure 4.9. Mean object contact times (s) from 10 minute habituation sessions over two consecutive days, for 
16-17 month old Tg2576 (TG) and wild-type (WT) mice. n = 30 Tg2576 and 35 wild-type mice. 
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 Once again, yoking at 16-17 months produced numerically near-equivalent total object 
contact for the two genotypes during the sample phase. Tg2576 mice accumulated 12.822(±2.158) 
seconds, and wild-type mice 13.256(±1.829) seconds, of total object contact (Student’s t(63) = 0.155, 
p = .878, d = 0.038). Inspection of panel A of Figure 4.10 indicates that, as at previous ages, both 
Tg2576 and wild-type mice display numerically greater exploration of mismatched objects, with 
Tg2576 mice displaying lower contact times than wild-type mice across object type. ANOVA results 
were somewhat consistent with this impression, revealing significant effects of object (F(1,63) = 
8.555, p = .005, MSE = 124.30, η2p= 0.120) and genotype (F(1,63) = 74.15, p<.001, MSE = 6840.95, 
η2p= 0.541), and a significant object × genotype interaction (F(1,63) = 6.214, p = .015, MSE = 90.28, 
η2p= 0.090). Unlike previous ages, however, paired samples t-tests comparing familiar versus 
mismatched contact time within each genotype revealed a significant difference only for wild-type 
mice (Student’s t(34) = 3.123, p = .004, d = 0.528), and a non-significant difference for Tg2576 mice 
(Student’s t(29) = 0.575, p = .569, d = 0.105). Inspection of panel B of Figure 4.10 indicates that 
Tg2576 mice display a discrimination ratio lower than that of wild-type mice, while only wild-type 
mice continue to display a preference for mismatched objects which is greater than chance. A one-
tailed unpaired t-test revealed a significant difference between Tg2576 and wild-type discrimination 
ratios (Welch’s: t(46.37) = 1.819, p = .038, d = 0.469). A one-tailed t-test was used in this analysis 
because it was anticipated that, based on existing literature, Tg2576 mice would be impaired in 
object-in-place memory by 16 months of age (Good & Hale, 2007; Hale & Good, 2005). One sample 
t-tests comparing discrimination ratios against chance performance (0.5) revealed a significant 
difference for wild-type (Student’s t(34) = 2.651, p = .012, d = 0.448), but not Tg2576 (Student’s t(29) 
= 0.594, p = .557, d = 0.108) mice. A Bayesian one sample t-test provided evidence suggesting the 
Tg2576 discrimination ratio genuinely did not differ from 0.5 (BF10 = 0.229). 
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Figure 4.10. Mean object contact times (s) for familiar and mismatched objects (A) and discrimination ratios (B) 
for 16-17 month old Tg2576 (TG) and wild-type (WT) mice, in 10 minute test sessions. n = 30 Tg2576 and 35 
wild-type mice. 
 
4.2.4 Summary 
 Experiment 3 examined the associative object-in-place memory of Tg2576 mice 
longitudinally, from 5-6 to 16-17 months of age. Both the aging and individual time point analyses 
presented a largely similar pattern of results. Firstly, the habituation results revealed that object 
exploration generally decreased with age and on the second habituation day for both genotypes, 
and that Tg2576 mice consistently explored both object types to a lesser extent than wild-type mice. 
This general genotype-independent reduction in object exploration over time, and consistently 
lower object exploration in Tg2576 mice, was also observed in the test phase data. Secondly, and 
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critically, while Tg2576 and wild-type mice display noticeably numerically greater exploration of 
mismatched objects up to 12-13 months, this exploratory numeric preference remains clearly 
noticeable at 16-17 months only in wild-type, but not in Tg2576, mice. However, this genotypic 
difference coincides with generally low object exploration by Tg2576 mice. When object contact 
times are converted into discrimination ratios, to account for differences in overall object contact, a 
similar pattern of results occurs. That is, Tg2576 and wild-type mice display discrimination ratios 
which are not dissimilar from one another, and numerically above chance performance (0.5), from 5-
6 months until (and including) 12-13 months of age. At 16-17 months of age, however, the Tg2576 
discrimination ratio is markedly lower than that of wild-type mice, and both numerically below and 
meaningfully indistinguishable from chance performance (0.5). Importantly, this eventual genotype 
difference in preference for mismatched objects occurred after Tg2576 and wild-type mice were 
given approximately equal amounts of object sampling, prior to two objects exchanging locations. 
The apparent Tg2576 reduction in mismatched object preference, therefore, cannot be attributed to 
a lower level of object exploration in the sample phase. 
 
4.3 Experiment 4 
4.3.1 Subjects, apparatus & procedure 
 Experiment 4 is a single study of the associative object-in-place memory of 19-20 month old 
Tg2576 and wild-type mice, featuring a between subjects drug condition. Animals used were the 
mice which had gone through all time points in Experiment 3, and the experiment occurred directly 
after the ketamine licking study presented in Experiment 2, Chapter 3 (see Figure 4.11). Mice were 
kept in the treatment groups assigned in Experiment 3; the numbers of mice entered into the study, 
within both each genotype and treatment group, were as reported in Experiment 3. Testing 
apparatus and procedure were as previously described, with the addition of one further dose of 
ketamine (30 mg/kg) or vehicle being administered 24h prior to each squad of mice beginning the 
habituation phase. This resulted in all mice having received 3 doses of either ketamine or vehicle 
when beginning Experiment 4. A new set of 4 object arrays was chosen for Experiment 4; object set 
and diagonal shift were counterbalanced across genotype, treatment group, and day. 
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Figure 4.11. Time course of behavioural tests for aging mouse cohorts. Tg2576 and wild-type mice                    
went through both sets of tests, then the T-maze test (Experiment 5, Section 4.4), before being                
sacrificed for brain biochemistry. 
 
4.3.2 Data analysis 
 Data were collected and cleaned as for Experiment 3, resulting in 5 vehicle-treated Tg2576 
mice having their data removed.2 Habituation and test data were analysed using mixed ANOVA, with 
between-subjects factors of genotype and drug, and within-subjects factors of day (for habituation) 
and object (for test phase). Sample phase data were analysed by ANOVA, with between-subjects 
factors of genotype and drug. Overall Tg2576 and wild-type discrimination ratios (across treatment 
group) were compared using unpaired t-tests, and the overall discrimination ratio of each genotype 
was compared against chance performance (0.5) using one-sample t-tests. Pairwise comparisons 
between overall object groupings within a genotype were conducted by paired t-tests. Data are 
presented in the same manner as for Experiment 3. That is, all object contact times or discrimination 
ratios are presented graphically, except for sample phase contact times which are described in the 
text. 
                                                          
2 The same cleaning strategy used in Experiment 3, described in footnote 1, was also carried out for 
Experiment 4 test data. As with Experiment 3, this produced the same pattern of results as the cleaning 
strategy described in the main text. For example, in the discrimination ratio analysis there was a significant 
effect of genotype (F(1,51) = 5.789, p = .020, MSE = 0.104, η2p= 0.102), a non-significant effect of drug (F(1,51) 
= 0.031, p = .860, MSE = 5.598e-4, η2p= 0.001), and a non-significant genotype × drug interaction (F(1,51) = 
0.167, p = .685, MSE = 0.003, η2p= 0.003) (n = 26 Tg2576 mice (16 ketamine- and 10 vehicle-treated), 29 wild-
type mice (16 ketamine- and 13 vehicle-treated)). Therefore the results presented for Experiment 4 are those 
which resulted from the original cleaning strategy. 
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4.3.3 Results 
 Inspection of Figure 4.12 indicates that, in general, ketamine- and vehicle-treated mice 
displayed the same pattern of habituation results seen at the final time point of Experiment 3. That 
is, Tg2576 mice exhibited lower object contact times than wild-type mice, regardless of treatment 
group or habituation day. There was also no obvious effect of ketamine in either genotype. ANOVA 
results were largely consistent with this observation, revealing no significant effect of day (F(1,53) = 
0.014, p = .906, MSE = 0.057, η2p<.001), a significant effect of genotype (F(1,53) = 24.414, p<.001, 
MSE = 402.093, η2p= 0.315), and no significant day × genotype interaction (F(1,53) = 0.920, p = .342, 
MSE = 3.719, η2p= 0.017). There was no significant effect of ketamine treatment (F(1,53) = 0.098, p = 
.756, MSE = 1.610, η2p= 0.002), and no other interaction term reached statistical significance (highest 
F for day × genotype (1,53) = 0.920, p = .342, MSE = 3.719, η2p= 0.017). 
 
 
Figure 4.12. Mean object contact times (s) from 10 minute habituation sessions, over two consecutive days, for 
19-20 month old, ketamine- and vehicle-treated, Tg2576 (TG) and wild-type (WT) mice. n = 26 Tg2576 (16 
ketamine- and 10 vehicle-treated) and 31 wild-type (16 ketamine- and 15 vehicle-treated) mice. 
 
 At 19-20 months of age, yoking produced numerically near-equivalent object contact times 
between genotypes during the sample phase within both ketamine and vehicle treatment groups. In 
addition, ketamine-treated mice of both genotypes displayed numerically lower sample phase object 
contact times than their vehicle-treated counterparts. Within ketamine-treated mice, Tg2576 mice 
accrued 10.53(±2.233) seconds and wild-type mice 10.77(±1.643) seconds of total object contact 
time in the sample phase, while in vehicle-treated animals Tg2576 mice accumulated 14.31(±2.645) 
seconds and wild-type mice 15.32(±2.072) seconds of total object contact time. ANOVA results 
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revealed no significant effect of genotype (F(1,53) = 0.084, p = .773, MSE = 5.373, η2p= 0.002), a non-
significant effect of ketamine (F(1,53) = 3.734, p = .059, MSE = 237.827, η2p= 0.066), and a non-
significant genotype × drug interaction (F(1,53) = 0.032, p = .858, MSE = 2.053, η2p= 0.001).  
 
 
 
Figure 4.13. Mean object contact times for familiar and mismatched objects (A) and discrimination ratios (B) 
for 19-20 month old, ketamine- and vehicle-treated, Tg2576 (TG) and wild-type (WT) mice, in 10 minute test 
sessions. n = 26 Tg2576 (16 ketamine- and 10 vehicle-treated) and 31 wild-type (16 ketamine- and 15 vehicle-
treated) mice. 
 
 Inspection of panel A of Figure 4.13 indicates that, as in Experiment 3, in the test phase all 
groups of mice display numerically greater contact times with mismatched than familiar objects, 
especially so in wild-type mice, while Tg2576 display much lower contact times than wild-type mice, 
regardless of object type. In addition, ketamine-treated mice exhibited small differences in contact 
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times compared with vehicle-treated mice; a numeric decrease in Tg2576 and a numeric increase in 
wild-type mice. ANOVA results were broadly consistent with this impression, revealing significant 
effects of object (F(1,53) = 9.075, p = .004, MSE = 402.03, η2p= 0.146) and genotype (F(1,53) = 
40.934, p<.001, MSE = 4657.901, η2p= 0.436), and a significant object × genotype interaction (F(1,53) 
= 5.403, p = .024, MSE = 239.35, η2p= 0.093). There was no significant effect of ketamine treatment 
(F(1,53) = 0.084, p = .773, MSE = 9.529, η2p= 0.002), and no other interaction reached statistical 
significance (highest F for genotype × drug (1,53) = 0.779, p = .381, MSE = 88.677, η2p= 0.014). A 
Bayesian mixed ANOVA here provided uninformative evidence regarding the null effect of ketamine 
on object contact times (BF10 = 0.735), and the null genotype × drug interaction (BF10 = 1.776). Paired 
samples t-tests comparing familiar versus mismatched contact time within each genotype (across 
treatment groups) revealed a significant difference only for wild-type mice (Student’s t(30) = 3.122, 
p = .004, d = 0.561), and a non-significant difference for Tg2576 mice (Student’s t(25) = 1.182, p = 
.248, d = 0.232). 
 Inspection of panel B on Figure 4.13 indicates that mice of all genotypes and treatment 
groups displayed discrimination ratios numerically greater than chance performance, though only 
narrowly in the case of Tg2576 mice. In addition, Tg2576 mice displayed notably smaller 
discrimination ratios than wild-type mice, regardless of treatment group. ANOVA results were 
consistent with this impression, revealing a significant effect of genotype (1,53) = 7.294, p = .009, 
MSE = 0.144, η2p= 0.121), no significant effect of ketamine treatment (1,53) = 0.041, p = .841, MSE = 
8.056e-4, η2p= 0.001), and no significant genotype × drug interaction (1,53) = 4.849e-4, p = .983, MSE 
= 9.593e-6, η2p<.001). A Bayesian ANOVA provided evidence suggesting that the null effect of 
ketamine on discrimination ratios represented a true null drug effect (BF10 = 0.294), and supporting 
the absence of a genotype × drug interaction (BF10 = 0.095). An unpaired t-test comparing 
discrimination ratios of Tg2576 and wild-type mice, across treatment groups, revealed a significant 
genotype difference (Student’s t(55) = 2.816, p = .007, d = 0.749). One sample t-tests comparing 
these same overall genotype discrimination ratios against chance performance (0.5) revealed a 
significant difference for wild-type (Student’s t(30) = 4.588, p<.001, d = 0.824), but not Tg2576 
(Student’s t(25) = 0.533, p = .599, d = 0.105), mice. A Bayesian one sample t-test provided evidence 
suggesting that the overall Tg2576 discrimination ratio genuinely did not differ from chance 
performance (BF10 = 0.236). 
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4.3.4 Summary 
 Experiment 4 examined the associative object-in-place memory of ketamine- and vehicle-
treated Tg2576 and wild-type mice at 19-20 months of age. Habituation results revealed that the 
general trend observed in Experiment 3, of object exploration decreasing after the first time point, 
had continued, with overall habituation-phase contact times in Experiment 4 at or below that seen 
at the end of Experiment 3. The pattern of test phase results was largely similar to that seen at the 
final time point in Experiment 3, in that wild-type mice displayed a greater exploration of 
mismatched objects while Tg2576 mice did not.  When object contact times were expressed as 
discrimination ratios, wild-type mice clearly performed above chance (0.5), while Tg2576 mice did 
not, and were in fact not distinguishable from chance in their performance. In addition, overall 
Tg2576 mice displayed a significantly lower discrimination ratio than that of wild-type mice. There 
was no significant effect of ketamine on test phase data, whether expressed as object contact times 
or discrimination ratios. 
 
4.4 Experiment 5 
4.4.1 Subjects, apparatus & procedure 
 Experiment 5 is a single study of the short-term spatial memory of 19-20 month old Tg2576 
and wild-type mice, featuring a between-subjects drug condition. Animals used were the same mice 
from Experiment 4, with each squad of mice entering Experiment 5 24h after the final object-in-
place test day for that squad. Mice were kept in the treatment groups assigned in Experiments 2 and 
4; 31 Tg2576 and 31 wild-type mice (16 ketamine- and 15 vehicle-treated in each genotype) were 
entered into the experiment. The apparatus was a T-maze with clear Perspex walls and a wooden 
base, with a start arm 52cm long, left and right goal arms 26cm long, and an opaque Perspex 
guillotine door for closing off one arm. Test sessions were recorded via a small camera connected to 
a monitor and DVD recorder mounted on the ceiling directly above the T-maze. The testing 
procedure was a modified version of a Y-maze task (Sanderson et al., 2007), and occurred in a new, 
quiet, room with extra-maze cues distinct from those used in the object-in-place tests. The T-maze 
was elevated 40cm from the ground, and the testing procedure was as follows: all mice received a 5 
minute exposure phase, during which access to one of the left and right arms (the novel arm) was 
blocked by the Perspex guillotine, while the remaining two arms could be freely explored. Mice were 
returned to their home cage for 1 minute, during which the T-maze was cleaned with 70% isopropyl 
alcohol, then received a 2-minute test phase during which the two familiar arms and the novel arm 
could be freely explored. Mice were placed at the base of the start arm prior to exposure and test 
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phases, which began once mice had left the start arm. The amount of time that mice spent in each of 
the three arms was manually recorded; a mouse was considered to have entered and exited an arm 
once all four of its paws had crossed the threshold of that arm. To prevent the longer start arm 
distorting the results (as a mouse would likely take more time to reach the end of the start arm 
compared with the other arms), only time spent in the length of start arm equal to that of the other 
arms was recorded. Selection of novel arm (left or right) was counterbalanced across genotype and 
treatment group. 
 
4.4.2 Data analysis 
 Time spent in arms was analysed using mixed ANOVA, with between-subjects factors of 
genotype and drug, and a within-subjects factor of arm. Time taken to leave the start arm, and 
discrimination ratios derived from time spent in arms were analysed by ANOVA, with between-
subjects factors of genotype and drug. Overall Tg2576 and wild-type discrimination ratios (across 
treatment group) were compared using unpaired Student’s t-tests, and the overall discrimination 
ratio of each genotype was compared against chance performance (0.33) using one-sample t-tests. 
Discrimination ratios were calculated by the following formula: (time spent in novel T-maze 
arm)/(time spent in all three T-maze arms). Two mice (one ketamine-treated Tg2576 mouse and one 
vehicle-treated wild-type mouse) had their data lost due to recording error; the final number of mice 
analysed was 30 Tg2576 (15 ketamine- and 15 vehicle-treated) and 30 wild-type (16 ketamine- and 
14 vehicle-treated) mice. 
 
4.4.3 Results 
 Tg2576 mice, across treatment groups, took longer to leave the start arm during the test 
phase than wild-type mice. Within Tg2576 mice, ketamine-treated mice took 54.26(±22.536) 
seconds and vehicle-treated mice took 82.42(±36.375) seconds to leave the start arm. For wild-type 
mice, ketamine-treated mice took 10.37(±4.215) seconds and vehicle-treated mice took 
14.30(±11.449) seconds to leave the start arm. ANOVA revealed a significant effect of genotype 
(F(1,56) = 6.371, p = .014, MSE = 46948, η2p= 0.102) but no significant effect of drug (F(1,56) = 0.523, 
p = .473, MSE = 3854, η2p= 0.009) and no significant genotype × drug interaction (F(1,56) = 0.298, p = 
.587, MSE = 2197, η2p= 0.005). Inspection of panel A of Figure 4.14 indicates that mice of all 
genotypes and treatment groups spent the greatest amount of time in the novel T-maze arm, less 
time in the other (familiar) T-arm, and less time still in the start arm, with no obvious effect of drug 
treatment. Other than the difference between time spent in the start arm and the other two arms 
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being more marked in Tg2576 than wild-type mice, there was no obvious genotype difference. 
ANOVA results were broadly consistent with this impression, revealing a significant effect of arm 
(F(1.556,87.140) = 22.458, p<.001, MSE = 11473.98, η2p= 0.286), and no significant effects of either 
drug (F(1,56) = 1.646, p = .205, MSE = 205.53, η2p= 0.029) or genotype (F(1,56) = 0.543, p = .464, MSE 
= 67.85, η2p= 0.010). The arm × genotype interaction was non-significant (F(1.556,87.140) = 2.777, p 
= .081, MSE = 1418.99, η2p= 0.047), and no other interaction reached statistical significance (highest 
F for arm × drug (1.556,87.140) = 0.359, p = .646, MSE = 183.50, η2p= 0.006). 
 
 
 
 
Figure 4.14. Mean time spent in T-maze arms (A) and derived discrimination ratios showing preference for the 
novel arm (B) for 19-20 month old, ketamine- and vehicle-treated, Tg2576 (TG) and wild-type (WT) mice. n = 30 
Tg2576 (15 ketamine- and 15 vehicle-treated) and 30 wild-type (16 ketamine- and 14 vehicle-treated) mice. 
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 Inspection of panel B of Figure 4.14 indicates that mice of all genotypes and treatment 
groups display discrimination ratios above chance performance (0.33), with no obvious differences 
between genotypes or treatment groups. ANOVA results were consistent with this impression, 
revealing no significant effects of genotype (F(1,56) = 0.833, p = .365, MSE = 0.033, η2p= 0.015) or 
drug (F(1,56) = 0.064, p = .802, MSE = 0.003, η2p= 0.001), and no significant genotype × drug 
interaction (F(1,56) = 0.153, p = .697, MSE = 0.006, η2p= 0.003). An unpaired t-test comparing 
discrimination ratios of Tg2576 and wild-type mice, across treatment groups, revealed no significant 
genotype difference (t(58) = 0.906, p = .369, d = 0.234). One sample t-tests comparing these same 
overall genotype discrimination ratios against chance performance (0.33) revealed significant 
differences for both Tg2576 (t(29) = 3.554, p = .001, d = 0.649) and wild-type (t(29) = 3.371, p = .002, 
d = 0.615) mice. A Bayesian independent samples t-test examining the genotype difference in 
discrimination ratios lent support to the notion that there was no overall difference between 
genotypes (BF10 = 0.370). 
 However, as this analysis included the non-counterbalanced start arm, a further analysis was 
conducted which was restricted to the two counterbalanced choice arms, presented in Figure 4.15. 
Inspection of Figure 4.15 indicates that, as in Figure 4.14, all genotype treatment groups display 
discrimination ratios numerically above chance performance (0.5), with no obvious differences 
between genotypes or treatment groups. ANOVA results were consistent with this impression, 
revealing no significant effects of genotype (F(1,56) = 0.001, p = .971, MSE = 6.274e-5, η2p<0.001) or 
drug (F(1,56) = 0.196, p = .660, MSE = 0.009, η2p = 0.003), and no significant genotype × drug 
interaction (F(1,56) = 0.157, p = .694, MSE = 0.007, η2p = 0.003). An unpaired t-test comparing 
discrimination ratios of Tg2576 and wild-type mice, across treatment groups, revealed no significant 
genotype difference (t(58) = 0.036, p = .972, d = 0.009). One sample t-tests comparing these same 
overall genotype discrimination ratios against chance performance (0.5) revealed a non-significant 
difference for Tg2576 mice (t(29) = 1.466, p = .153, d = 0.268) and a significant difference for wild-
type mice (t(29) = 2.084, p = .046, d = 0.381). While the Tg2576 mouse discrimination ratio was not 
significantly different from 0.5, a Bayesian independent samples t-test examining the genotype 
difference in discrimination ratios suggested there was no meaningful difference between the 
performance of the two genotypes (BF10 = 0.263). 
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Figure 4.15. Mean  discrimination ratios showing preference for the novel arm  for 19-20 month old, ketamine- 
and vehicle-treated, Tg2576 (TG) and wild-type (WT) mice. n = 30 Tg2576 (15 ketamine- and 15 vehicle-treated) 
and 30 wild-type (16 ketamine- and 14 vehicle-treated) mice. 
 
4.4.4 Summary 
 Experiment 5 examined the short-term spatial memory of ketamine- and vehicle-treated 
Tg2576 and wild-type mice at 19-20 months of age, immediately subsequent to Experiment 4. 
Results revealed that both Tg2576 and wild-type mice spent the greatest amount of time in the 
novel T-maze arm, and lesser amounts of time in the start and familiar T-arm, with no apparent 
genotype or drug effects. Although there was a suggestion from the overall ANOVA of a difference in 
how the two genotypes explored the T-maze arms, this looks to have been driven by differences in 
exploration of the two previously explored arms, rather than a difference in the tendency to spend 
more time in the novel arm. When time spent in the novel arm was expressed as a ratio of time 
spent in all arms, overall Tg2576 and wild-type mice ratios did not significantly differ from one 
another, and were greater than chance (0.33) performance. 
 
4.5. Discussion 
 Experiment 3 demonstrated that Tg2576 mice exhibit impaired object-in-place associative 
memory function at 16-17 months of age. While the age-dependency of this memory deficit was not 
statistically evident, the cognitive ability of Tg2576 mice was nonetheless comparable to that of 
wild-type mice in the object-in-place task at 5-6, 8-9 and 12-13 months of age, prior to its decline. 
Despite the aging analysis not explicitly demonstrating an age-related cognitive deficit in Tg2576 
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mice, the eventual appearance of a deficit at 16-17 months of age is consistent with a memory 
impairment which requires a period of aging to manifest. Critically, this Tg2576 memory deficit 
occurred after both genotypes had received approximately equal amounts of object sampling prior 
to objects exchanging locations, meaning that the impaired Tg2576 performance could not be 
attributed to lesser object contact time in the sample phase. Experiment 4 revealed that this deficit 
in object-in-place associative memory was still present in Tg2576 mice at 19-20 months of age, and 
was not alleviated by sub-anaesthetic ketamine treatment. Ketamine treatment also failed to alter 
the performance of wild-type mice in the object-in-place task, whose discrimination ratios remained 
greater than both those of Tg2576 mice and chance performance, regardless of treatment group. 
Experiment 5 revealed that, despite an eventually impaired ability to form specific object-location 
associations, at 19-20 months aged Tg2576 mice remain sensitive to spatial novelty per se. 
 This study marks the first time performance in the object-in-place task has been 
longitudinally investigated in Tg2576 mice. Previous studies at single time points have revealed 
Tg2576 mice to be deficient in this task at 14 months of age (Hale & Good, 2005), 10-12 months of 
age (Good, Hale, et al., 2007), and at 16 and 21 months of age (Good & Hale, 2007). While the 
longitudinal Tg2576 cognitive tests shown in Experiment 3 differ somewhat from these individual 
experiments, in that a deficit was not apparent at 12-13 months of age, they still revealed a deficit at 
16-17 months of age. In addition, Experiment 4 confirmed this cognitive deficit was still present at 
19-20 months of age. Therefore Experiments 3 and 4 taken together are broadly in keeping with 
previous reports of a failure of object-in-place associative memory in aged Tg2576 mice. Critically, 
this memory deficit is unlikely to simply reflect a generalised impairment in object processing or 
recognition memory more broadly, as aged Tg2576 mice still showed intact object novelty detection 
(Good & Hale, 2007). While an age-related cognitive impairment in Tg2576 mice was not statistically 
proven, taken together Experiments 3 and 4 are nonetheless suggestive of an age-related cognitive 
decline in Tg2576 mice.  This cognitive deficit would not appear to be the result of a floor effect due 
to a low level of object contact; Tg2576 mice displayed similar levels of object contact at both 12-13 
and 16-17 months, at which time points a deficit was apparent only at the latter age. In addition, 
Tg2576 object contact was numerically greater at 19-20 months of age than at 12-13 months of age, 
with a deficit present at 19-20 months of age, while at 12-13 months of age Tg2576 mice were able 
to discriminate between familiar and mismatched objects. 
 It was anticipated that Experiment 3 would reveal the age of emergence of the Tg2576 
object-in-place memory deficit. Taking the results of that experiment at face value, it appears that 
this deficit emerges later than other studies have suggested. The earliest a deficit has been 
previously detected is 10-12 months of age (Good, Hale, et al., 2007), whereas in the present 
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experiment memory was not impaired until 16-17 months of age. As the number of mice at each 
individual time point in Experiment 3 was greater than these previous studies, which typically used 
10-11 mice of each genotype, it could be argued that Experiment 3 provides a better estimate of the 
time point at which a deficit first manifests. However, the repeated testing used in Experiment 3 
may have influenced the general exploratory behaviour of the mice, in particular in Tg2576 mice. For 
example, Figure 4.1 and panels A and B of Figure 4.2 demonstrate that, after the first time point, 
habituation of both genotypes to objects was markedly reduced, and Tg2576 mice explored objects 
less in both the sample and test phases, respectively. Both the decreased object exploration of 
Tg2576 mice after 5-6 months, and the yoking process itself, may have increased ‘noise’ in the 
results. Therefore, interpretation of the results of Experiment 3 as regards the precise time of a 
deficit first appearing should be undertaken with caution. It seems sensible to interpret the results 
of Experiment 3 as evidence of a cognitive deficit that is absent at 5-6 months of age, and which 
emerges by 16-17 months of age at the latest. 
 One implication of Experiment 3 could be that the aging process alters the general or object-
related exploratory behaviour of Tg2576 mice, causing them to generally explore objects less with 
age. This account seems implausible, however, as in one previous report 21 month-old Tg2576 mice 
showed greater amounts of test phase object contact than a similar cohort at 16 months of age 
(Good & Hale, 2007). It seems more likely that, when given multiple exposures to objects over a 
series of object-related tests, mice (in particular Tg2576 mice) will generally explore objects to a 
lesser extent after the first test; this appears to be borne out in panel B of Figure 4.2, and the 
associated main effect of age. Given that repeated testing itself may cause low object contact times 
in Tg2576 mice after the first testing, longitudinally assessing cognition in Tg2576 mice with a test 
which relies on object exploration should perhaps be approached cautiously in future studies. 
However, it is worth noting that in Experiment 3, despite there being generally and similarly low 
Tg2576 object contact at both 12-13 and 16-17 months of age, at the former age Tg2576 mice could 
distinguish familiar from mismatched objects, while at the latter age they could not. This suggests 
that, while object contact was reduced in Tg2576 mice, it was still at or above the minimum level 
sufficient to reveal a deficit. 
 One final, and interesting, point about the nature of repeated object-in-place testing is that 
it may in itself influence when a deficit is detected. It has been reported that giving Tg2576 mice 6 
days of training in the Morris water maze is sufficient to improve their associative memory as 
measured by contextual fear conditioning, both 24h and 28 days after initial fear conditioning 
training, alongside reducing Aβ levels, enhancing hippocampal LTP, causing dendritic remodelling 
and other changes (Jiang et al., 2015). While the object-in-place test may not be training per se, it is 
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possible that the added stimulation and test process itself could induce similar types of changes in 
Tg2576 mice. Such changes could potentially explain why the Tg2576 cognitive deficit in Experiment 
3 manifested later than may have been anticipated based on previous reports. An additional and 
complementary possibility is that the food deprivation regime used in Chapter 3, Experiments 1 and 
2, may have interacted with Tg2576 cognitive ability. For example, when an APP knock-in mouse 
model of Alzheimer’s disease was subjected to an intermittent fasting regime, it improved spatial 
working memory in the Y-maze, spatial learning and memory in a water maze task, and enhanced 
hippocampal LTP (Liu et al., 2019). There was also a suggestion that this intervention may reduce Aβ 
accumulation in the hippocampus. While this intermittent fasting involved longer periods of food 
deprivation than were used in Experiments 1 and 2, nonetheless food deprivation may have also had 
a beneficial effect on Tg2576 cognition. 
 In addition to broadly confirming earlier reports of an associative recognition memory deficit 
in Tg2576 mice, the present results are in keeping with reports from other Alzheimer’s disease 
mouse models. For example, PDAPP mice show an age-dependent deficit in the object-in-place task 
at 14-16 months of age, at both short and long delays, while object novelty detection remains intact 
(Evans et al., 2019). Similarly, APPswe/PS1dE9 mice are impaired in the object-in-place task at 5 
months of age, while object novelty and relative recency detection are unimpaired (Bonardi, Pardon, 
& Armstrong, 2016). Taken together, these studies and the results from Tg2576 mice demonstrate 
that a number of APP overexpressing mouse models exhibit a selective deficit in associative 
recognition memory. 
 This selective deficit may be the result of Aβ disrupting the neural circuitry underlying the 
object-in-place task, for example by causing synaptic loss and impairment in the hippocampus (Li et 
al., 2009, 2011; Mucke & Selkoe, 2012). APPswe/PS1dE9 mice display deposition of Aβ in the 
hippocampus from an early age (Garcia-Alloza et al., 2006; Jankowsky et al., 2004), and hippocampal 
soluble Aβ levels in these mice correlate with spatial and associative memory deficits (Zhang et al., 
2011). When APP processing was altered in PDAPP mice by the monoclonal antibody 2B3, soluble Aβ 
levels were reduced in the hippocampus (along with other biochemical changes), and the PDAPP 
object-in-place memory deficit was both reversed by acute treatment and prevented by chronic 
treatment (Evans et al., 2019). These findings in APPswe/PS1dE9 and PDAPP mice are consistent 
with Aβ ultimately underlying their object-in-place memory deficit. The possibility of this being the 
case in Tg2576 mice will be examined next.  
 Given that the hippocampus is a critical structure for object-in-place memory (Barker & 
Warburton, 2011, 2015; Good, Barnes, Staal, McGregor, & Honey, 2007), the presence of Aβ in the 
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hippocampus of Tg2576 mice may well account for their deficit in associative recognition memory 
(Hsiao et al., 1996). Synapse density is decreased in Tg2576 dentate gyrus, a subfield of the 
hippocampus, in the presence and vicinity of Aβ plaques, suggesting synapse loss may be caused by 
Aβ (Dong et al., 2007). Dendritic spine density loss in Tg2576 dentate gyrus coincides with LTP 
impairment at 4 months of age, and is closely followed by a deficit in an associative memory task 
(Jacobsen et al., 2006). Synaptic loss and disruption in the hippocampus due to Aβ (Li et al., 2009, 
2011; Mucke & Selkoe, 2012), over time, could account for the object-in-place memory deficit in 
Tg2576 mice, by weakening the hippocampal component of the underlying and interdependent 
circuitry. Further, a specific Aβ assembly has been identified in Tg2576 mice which could be 
particularly important in impairing cognition (Lesné et al., 2006). This dodecameric Aβ assembly, 
termed Aβ*56, is present in Tg2576 mouse brain, its level correlates with a spatial memory 
impairment and, when isolated and administered to rats, it impairs performance on a spatial 
memory task (Lesné et al., 2006). This Aβ assembly and others may be particularly impactful in 
impairing cognition in Tg2576 mice, and could underlie their object-in-place memory deficit. This 
prospect, and other Aβ-related biochemical changes which could underlie this deficit, will be 
explored in more depth in Chapter 5. Similarly, the lack of an effect of ketamine on both cognitive 
tests will be discussed in Chapter 5, once the biochemical effects (or lack of effects) of ketamine in 
the brain have been presented. 
 Aged Tg2576 mice displaying an intact preference for spatial novelty in the T-maze task is in 
keeping with object recognition studies in which object-in-place memory is impaired but preference 
for objects in novel locations is intact (Good & Hale, 2007). However, such a result seems to be 
contrary to other studies of spatial working memory, using T-maze forced choice alternation or Y-
maze continuous alternation, in which Tg2576 mice appear impaired (Cacucci, Yi, Wills, Chapman, & 
O’Keefe, 2008; Chapman et al., 1999; Deacon et al., 2008; Hale & Good, 2005; Hsiao et al., 1996; 
Wilcock et al., 2004), though these deficits have not been consistently replicated (Stewart, Cacucci, 
& Lever, 2011). However, this apparent discrepancy may be due to the relative complexities of the 
different tasks. The one-trial spatial novelty task used in Experiment 5 was a simple and absolute 
novel versus familiar task, whereas spontaneous alternation and forced choice alternation both rely 
upon relative novelty judgements, and forced choice alternation also requires rule-learning. The 
demands of these latter tasks may require a more sophisticated recollective ability which the 
hippocampus is unable to support in Tg2576 mice, while cruder environmental representations 
which allow absolute novel versus familiar judgements can still be created. 
 In sum, the results of this chapter are consistent with Aβ accumulation disrupting the ability 
of Tg2576 mice to form or recall stable and specific object-location associations, something which 
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will be explored further when some related receptors are examined in Chapter 5. It does not appear, 
however, that the build-up of Aβ over time results in a global impairment in Tg2576 mouse memory, 
suggesting that some degree of hippocampal functionality, or ability to distinguish between absolute 
spatial novelty and familiarity, remains intact. 
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Chapter 5: Biochemical changes in 
Tg2576 mice 
 
5.1. Introduction 
 Chapter 1 briefly outlined some of the broad neurotransmitter systems of interest to this 
thesis, namely the glutamatergic, serotonergic and opioidergic systems; the former primarily in 
relation to cognition, and the latter two in relation to depression. These systems were chosen 
because they may underlie or contribute to the hedonic and cognitive deficits displayed in Chapters 
3 and 4, as well as potentially reveal information about the usefulness of ketamine in alleviating 
these deficits. 
 Glutamate, an excitatory amino acid, is the major excitatory neurotransmitter in the 
mammalian brain (Niciu, Kelmendi, & Sanacora, 2012), and is known to play a critical role in learning 
and memory (McEntee & Crook, 1993). In particular, ionotropic glutamate receptors, notably NMDA 
and AMPA receptors, facilitate memory encoding and retrieval (Bast, da Silva, & Morris, 2005; Lopez, 
Gamache, Schneider, & Nader, 2015), and underlie long term potentiation (LTP), a cellular model for 
learning and memory (Bliss, Collingridge, Morris, & Reymann, 2018; Nicoll, 2017). The NMDA 
receptor (NMDAR) in particular has long been recognised as integral to learning and memory 
(Leuner, Falduto, & Shors, 2003; Morris, 1989; Morris, Anderson, Lynch, & Baudry, 1986; Steele & 
Morris, 1999), and this is thought to be due to certain properties which characterise the receptor, 
described below. In addition to their importance to mnemonic processes, NMDARs also mediate 
excitotoxicity when overstimulated by glutamate (Hardingham & Bading, 2003). 
 NMDARs are expressed widely throughout the mammalian brain (Moriyoshi et al., 1991; 
Young & Fagg, 1990), and are populous in structures essential for learning and memory such as the 
hippocampus (Greenamyre, Olson, Penney, & Young, 1985; Monaghan, Holets, Toy, & Cotman, 
1983). While postsynaptic NMDARs are inactive under baseline conditions due to magnesium (Mg2+) 
blockade, postsynaptic membrane depolarisation alleviates this blockade, allowing presynaptically 
released glutamate to bind to the NMDAR (Traynelis et al., 2010). Glutamate binding opens the ion 
channel, allowing cations (notably calcium) to enter the postsynaptic bouton (Lee et al., 2014). 
Calcium influx then leads to a series of cellular events, including activation of calcium/calmodulin-
dependent protein kinase II (CaMKII) and a resultant increase in AMPARs at the synapse (Herring & 
Nicoll, 2016). This NMDAR-dependent process allows for a form of synaptic plasticity, which may 
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enable learning and memory, to occur. The voltage-dependent nature of the Mg2+ blockade allows 
the NMDAR to act as a coincidence detector, only allowing Ca2+ entry when postsynaptic 
depolarisation coincides with presynaptic glutamate release and NMDAR binding (Traynelis et al., 
2010). This quality of the NMDAR marks it as a good candidate for the mechanistic explanation of 
LTP (Bliss & Collingridge, 1993). 
 NMDARs are structurally heterogeneous; their composition can entail a number of subunits, 
of which seven have been identified, categorised into three subfamilies (NR1, NR2A-D, and NR3A/B) 
(Paoletti, Bellone, & Zhou, 2013). This subunit variety allows for distinct heterotetrameric 
combinations, in which NR1 subunits largely associate with NR2 subunits, with different NMDAR 
subtypes allowing the fulfilment of different functions (Paoletti et al., 2013). For example, in the 
induction and expression of LTP, di-heteromeric NR1/NR2A receptors may have a higher channel 
open probability for allowing Ca2+ influx, while the presence of the NR2B subunit on tri-heteromeric 
NR1/NR2A/NR2B receptors may be responsible for CaMKII recruitment and LTP expression (Paoletti 
et al., 2013). These subunits undergo post-translational modifications, such as phosphorylation by 
various kinases, which alter NMDAR trafficking and distribution (Wang et al., 2014).  
  Given that NMDARs play a critical role in cognitive processes, the interaction of Aβ with the 
glutamate system broadly, and NMDARs specifically, is highly consequential. Aβ appears to increase 
glutamate availability, both by enhancing its release from astrocytes (Talantova et al., 2013), and by 
impairing neuronal glutamate uptake (Li et al., 2009), though decreases in glutamate have also been 
reported (Danysz & Parsons, 2012). In addition to altering glutamate availability, Aβ oligomers 
induce toxic effects in cell culture and entorhinal-hippocampal organotypic slice experiments, via 
NMDAR activation (Alberdi et al., 2010; Texidó, Martín-Satué, Alberdi, Solsona, & Matute, 2011). 
Here the NMDAR subunit specificity is important, as the NR2B subunit appears to mediate 
excitotoxicity (Liu et al., 2007), and longer hippocampal slice exposure to Aβ oligomers results in a 
reduction of NR2B presence at the synapse (Li et al., 2011). These findings are in keeping with the 
notion that the chronic presence and accumulation of Aβ, as occurs in Alzheimer’s disease, could 
result in an NMDAR-induced slow excitotoxicity (Danysz & Parsons, 2012; Ong, Tanaka, Dawe, Ittner, 
& Farooqui, 2013). Such a process could reasonably be expected to result in compensatory NMDAR 
changes. This tonic, rather than phasic, NMDAR over-activation due to Aβ could underlie early 
memory impairment, and explains why the NMDAR antagonist memantine is a useful therapeutic 
agent, as it may block tonic Aβ-induced NMDAR activation while still allowing non-pathological 
synaptic activation to occur (Danysz & Parsons, 2012). Given that NR1 subunit endocytosis has been 
observed in cultured Tg2576 cortical neurons, and that Aβ exposure can provoke NR2B endocytosis 
and dephosphorylation (Snyder et al., 2005), chronic Aβ accumulation in Tg2576 mice may be 
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expected to result in changes to the NR1 and NR2B subunits. These NMDAR subunits therefore merit 
further investigation in this thesis. Further, given that the NR1 and NR2B subunits are implicated in 
rodent short-term memory tasks with a spatial component (Evans et al., 2019; Niewoehner et al., 
2007), NR2B specifically in the object-in-place task (Evans et al., 2019), these subunits may plausibly 
underlie the cognitive deficit documented in Chapter 4. 
 AMPA receptors (AMPARs) are a critical component of NMDAR-dependent synaptic 
plasticity (Huganir & Nicoll, 2013; Nicoll, 2017), and as such are highly salient in processes facilitating 
learning and memory. As previously described, the trafficking and synaptic insertion of AMPARs is 
one of the features of LTP (Shepherd & Huganir, 2007). As with NMDARs, the subunit composition of 
AMPARs varies, with physiological consequences. AMPARs comprise four homologous subunits 
(GluR1-4, or GluRA-D), which form tetrameric complexes, of which the major forms in the 
hippocampus include GluR1/2 and GluR2/3 heteromers and GluR1 homomers (Huganir & Nicoll, 
2013; Malinow & Malenka, 2002). AMPAR function and synaptic plasticity are regulated by subunit 
phosphorylation, with serine, threonine and tyrosine residues being phosphorylated by a range of 
protein kinases, including CaMKII, protein kinase A (PKA) and protein kinase C (PKC) (Lu & Roche, 
2012; Shepherd & Huganir, 2007). The GluR1 subunit appears to be particularly important in 
synaptic plasticity; GluR1 presence appears to be necessary for activity-dependent delivery of 
AMPARs to synapses (Hayashi et al., 2000; Shi, Hayashi, Esteban, & Malinow, 2001), with 
phosphorylation at serine831 and serine845 by CaMKII and PKA, respectively, being important 
events (Esteban et al., 2003). Consistent with these findings, a number of studies have revealed that 
GluR1 deletion in mice results in impaired spatial working memory (Reisel et al., 2002; Schmitt, 
Deacon, Seeburg, Rawlins, & Bannerman, 2003; Schmitt et al., 2005). In addition to interacting with 
NMDARs, Aβ also influences AMPAR trafficking and functionality. For example, Aβ depresses 
synapses via removing AMPARs from the synapse by endocytosis (Hsieh et al., 2006). In addition, 
hippocampal synaptic AMPAR content is decreased with age in a double knock-in Alzheimer’s 
disease mouse model (Chang et al., 2006), consistent with Aβ having a role in disrupting AMPAR 
function. A decrease in synaptically available GluR1 is seen in Tg2576 primary neurons and mouse 
hippocampus (Almeida et al., 2005; Cavallucci et al., 2013; D’Amelio et al., 2011), and 
dephosphorylation of GluR1 at the serine845 residue is also seen in Tg2576 mouse hippocampus 
(Cavallucci et al., 2013; D’Amelio et al., 2011). Moreover, there is evidence that NMDAR function 
may also be compromised in Tg2576 mice (Snyder et al., 2005), and that both NMDAR and AMPAR 
transmission are needed for object-in-place task performance (Barker & Warburton, 2015). Thus 
there is a basis for investigating both NMDAR and AMPAR expression in Tg2576 and wild-type mice 
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in relation to the cognitive deficit described in Chapter 4. In particular, the NR1, NR2B and GluR1 
subunits merit examination, especially in the hippocampus. 
 In addition to NMDARs and AMPARs themselves, scaffolding proteins such as postsynaptic 
density protein-95 (PSD-95) may play a role in any NMDAR and AMPAR changes in Tg2576 mice. 
PSD-95 belongs to a group of proteins known as membrane-associated guanylate kinases (MAGUKS), 
and stabilises NMDAR and AMPAR presence at the synaptic membrane surface (MacGillavry, Song, 
Raghavachari, & Blanpied, 2013; Nair et al., 2013; Roche et al., 2001). Soluble Aβ can reduce PSD-95 
levels (Liu et al., 2010), and PSD-95 reductions are seen in Tg2576 cultured neurons and cortical 
tissue (Almeida et al., 2005; Oulès et al., 2012). Thus cognitive deficits in Tg2576 mice could be 
caused by synaptic NMDAR and/or AMPAR unavailability owing to a reduced anchoring or 
stabilisation by PSD-95, and this scaffolding protein should also be investigated. 
 Neurotransmitter systems that may mediate the depressive phenotype characterised in 
Chapter 3 also require investigating. To this end, Chapter 5 will also examine the serotonergic and 
opioidergic systems. Chapter 1 observed that Alzheimer’s disease includes a degradation of the 
serotonergic system (Garcia-Alloza et al., 2005; Halliday et al., 1992; Palmer et al., 1987; Yamamoto 
& Hirano, 1985). However, these results were discovered in post-mortem cases, meaning that they 
were revealed following years of pathology which included neurodegeneration as well as effects of 
Aβ and tau. Preclinical studies suggest that there may be a relationship between serotonin and Aβ, 
and as a result serotonergic changes could potentially occur in early Alzheimer’s disease and relate 
to depression. For example, acute application of both SSRIs and serotonin to the hippocampus of 
APP/PS1 mice reduced the Aβ content in the interstitial fluid, and chronic SSRI administration 
reduced cortical and hippocampal plaque load and CSF Aβ40 and Aβ42 (Cirrito et al., 2011). This 
demonstrates a relationship in one direction between serotonin and Aβ. Evidence that Aβ itself may 
disturb various aspects of serotonin signalling is seen in studies of transgenic Alzheimer’s disease 
model mice; a reduced number of serotonin transporter (5HTT or SERT) binding sites and SERT 
mRNA-positive cells are seen in the dorsal raphe of APP/PS1 mice (Metaxas et al., 2018). A follow-up 
study revealed a reduced SERT density in frontal and parietal cortex of APP/PS1 mice, diminished 
SERT activity in APP/PS1 mouse neocortex, and that synthetic soluble Aβ40 can inhibit SERT activity 
(Metaxas et al., 2019). In addition, a reduction in both SERT and the 5HT1B receptor has been 
observed in Tg2576 mouse hippocampus (Tajeddinn et al., 2015). This latter finding is especially 
intriguing as the 5HT1B receptor may be an important component of ketamine’s mechanism of action 
as an antidepressant (Yamanaka et al., 2014). 
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 While depression is almost certainly not reducible to disturbed serotonergic signalling alone, 
alterations in certain serotonin receptors and SERT do occur in depression (Gryglewski, 
Lanzenberger, Kranz, & Cumming, 2014; Stockmeier, 2003), and reducing serotonin availability in 
recovered depressed patients provokes a return of depressive symptoms (Cowen, 2008). Whether 
serotonergic signalling relates specifically to anhedonia in depression is unclear, as patients taking 
antidepressants, including SSRIs, have described feeling a lack of positive emotions and reduced 
enjoyment of hobbies and interests which is consistent with anhedonia (Goodwin et al., 2017; Price 
et al., 2009). This could represent either an unfortunate side effect or consequence of SSRIs, or a 
sign that SSRIs have little or limited impact on anhedonia in depression. Some limited evidence from 
chronically stressed mice has shown that hippocampal SERT expression is lower in anhedonic mice 
than in non-anhedonic and control mice, and that fluoxetine treatment restores both hedonic 
behaviour and SERT expression in treatment-responsive anhedonic mice (Tang, Lei, Sun, Liu, & Zhao, 
2013). This does not, however, directly prove a connection between SERT and anhedonia. Given that 
SERT could possibly relate to anhedonia and appears reduced in Tg2576 mice in a prior study 
(Tajeddinn et al., 2015), it would seem prudent to investigate its abundance in Tg2576 mice which 
have consistently displayed a hedonic deficit. In addition, as ketamine did not improve hedonic 
responsiveness in these same Tg2576 mice (Chapter 3, Experiment 2), and part of ketamine’s 
mechanism of action may involve the 5HT1B receptor (which may be reduced in Tg2576 mice), the 
5HT1B receptor should be investigated as a potential explanation of this null result. 
 A further serotonin receptor which may relate Aβ to both depression and cognition is the 
5HT4 receptor. Individuals with a family history of major depressive disorder display lower striatal 
5HT4 receptor binding, and lower 5HT4 binding was associated with greater number of depressed 
relatives in both the striatum and limbic region in these individuals (Madsen et al., 2014). In 
addition, the Flinders Sensitive Line rat model of depression shows reduced 5HT4 receptor binding in 
the hippocampus and lateral globus pallidus (Licht et al., 2009). Taken together, these studies 
suggest that the 5HT4 receptor may be involved in the risk of developing depression, as well as 
potentially being a component of the condition itself. The fact that 5HT4 receptor knockout mice 
show a reduced sucrose intake (Amigó et al., 2016), and that a 5HT4 receptor agonist improves 
sucrose intake in treatment-responsive chronically stressed rats (Lucas et al., 2007), provides an 
additional suggestion that this receptor may contribute to anhedonia specifically. It is notable in this 
context that 5HT4 receptors are highly expressed in both human and rodent brain in reward-related 
sites such as the nucleus accumbens, as well as in the hippocampus (Varnäs, Halldin, Pike, & Hall, 
2003; Waeber, Sebben, Nieoullon, Bockaert, & Dumuis, 1994). In addition, stimulating 5HT4 
receptors improves performance in hippocampal-dependent learning and memory tasks in rodents 
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(Hagena & Manahan-Vaughan, 2017), and post-mortem investigation reveals that Alzheimer’s 
disease brains display a loss of 5HT4 receptors in regions including the hippocampus (Reynolds et al., 
1995). Interestingly, among newly-diagnosed living Alzheimer’s disease patients, those with a 
detectable insoluble Aβ burden show an increase in brain 5HT4 receptor levels (Madsen et al., 2011). 
Also, chronic activation of 5HT4 receptors in young APP/PS1 mice lowers soluble and insoluble 
hippocampal Aβ40 and Aβ42, as well as hippocampal plaque count (Tesseur et al., 2013). Thus the 
5HT4 receptor elevation seen in the aforementioned Alzheimer’s disease patients could reflect a 
compensatory response to both the presence of Aβ, and also symptoms such as memory loss and 
potentially depression. Due to its links to the Aβ peptide, Alzheimer’s disease, cognition and 
potentially anhedonia, the 5HT4 receptor may represent a point of convergence for the major 
interests of this thesis, and as such strongly warrants investigation in Tg2576 mice. 
 The final neurotransmitter system that this chapter aims to explore in Tg2576 mice is the 
opioidergic system. Opioid receptors and their endogenous ligands are expressed widely throughout 
the mammalian brain; there are three opioid receptors, known as mu, kappa and delta, and a 
number of endogenous peptides that bind to these receptors, namely β-endorphin, dynorphins and 
enkephalins, respectively (Le Merrer, Becker, Befort, & Kieffer, 2009; Pasternak & Pan, 2013). 
Important sites of opioid receptor expression include components of the reward network such as 
the nucleus accumbens, ventral pallidum, orbitofrontal cortex and parabrachial nucleus, as well as 
other structures such as the hippocampus (Castro & Berridge, 2014, 2017; Le Merrer et al., 2009). 
Opioidergic signalling is involved in various physiological events, including nociception (pain), 
substance addiction, and, importantly, sensations of pleasure and reward (Berridge & Kringelbach, 
2015; Le Merrer et al., 2009). In the main, mu opioid receptor agonism is thought to induce or 
enhance a positive affective state (Kelley et al., 2002; Peciña & Smith, 2010), while kappa opioid 
receptor agonism mediates dysphoric, depressive and potentially anhedonic states (Lalanne, 
Ayranci, Kieffer, & Lutz, 2014; Taylor & Manzella, 2016). In addition, delta opioid receptor agonism is 
also thought to have an antidepressant effect in rodents (Pradhan, Befort, Nozaki, Gavériaux-Ruff, & 
Kieffer, 2011). Broadly speaking then, mu and delta receptor signalling can be thought to work in 
opposition to kappa receptor signalling. One caveat to this broad view of the opioid system is that in 
minute subregions within many of the aforementioned reward sites, all three opioid receptors can 
amplify or suppress hedonic reactions in rodents when activated (Berridge & Kringelbach, 2015; 
Castro & Berridge, 2014, 2017; Peciña et al., 2006). Perturbed opioidergic signalling could thus in 
principle underlie a hedonic deficit such as that present in Tg2576 mice in Chapter 3. Here it is 
noteworthy that reward sites such as the nucleus accumbens, orbitofrontal cortex and parabrachial 
nucleus display Aβ plaques and NFTs in post mortem studies of Alzheimer’s disease brain tissue 
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(German et al., 1987; Parvizi et al., 1998; Suenaga et al., 1990; Van Hoesen et al., 2000). In addition, 
post mortem studies also reveal changes in opioid receptor availability in Alzheimer’s disease brain. 
While a non-specific ligand revealed a decrease in the overall availability of opioid receptors in 
certain parts of the hippocampal formation (Jansen, Faull, Dragunow, & Synek, 1990), in general 
there is an increase in kappa opioid receptor binding in several brain regions, while mu and delta 
availability is generally reduced or unchanged (Barg et al., 1993; Hiller, Itzhak, & Simon, 1987; 
Mathieu-Kia, Fan, Kreek, Simon, & Hiller, 2001) (though see Ikeda, Mackay, Dewar, & McCulloch, 
1993). The fact that Alzheimer’s disease pathology accumulates in reward regions, and that even 
advanced pathology seems to generally include an increase in kappa receptor availability and 
possibly changes in mu and delta receptor expression, raises the possibility that opioid receptors in 
reward sites may be altered in Alzheimer’s disease. If such changes occurred early in Alzheimer’s 
disease, i.e. initially as a function of Aβ accumulation, then they may be seen in Tg2576 mice, and 
could underlie or contribute to the hedonic deficit observed in Chapter 3. Chapter 5 will therefore 
examine all three opioid receptors in Tg2576 and wild-type mice, in order to obtain a general 
overview of how the opioidergic system may be functioning in mice with typical and diminished 
hedonic responsiveness. 
 
5.2. Experiment 6 
5.2.1 Subjects, apparatus, procedure & data analysis 
 Experiment 6 investigates the effect of sub-anaesthetic ketamine treatment on soluble and 
insoluble Aβ levels in the hippocampus and cortex of the Tg2576 mice used in Experiments 2, 4 and 
5. As the principal Aβ species which accumulates in Tg2576 mice, and which are absent in wild-type 
mice, are human Aβ, and the ELISAs used are specific to human Aβ, only Tg2576 mouse brains were 
examined. Apparatus, procedure and data collection are as described in Sections 2.4 and 2.5. Due to 
low sample volume following the extraction procedure, only 11 ketamine- and 11 vehicle-treated 
Tg2576 hippocampal samples underwent ELISA quantification. All 16 ketamine- and 15 vehicle-
treated Tg2576 cortex samples were analysed by ELISA. Soluble and insoluble Aβ40 and Aβ42 levels 
were statistically analysed using Student’s t-tests, with drug treatment as the dependent variable. 
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5.2.2 Results 
5.2.2.1 Hippocampus Aβ levels 
 Inspection of Figure 5.1 indicates that for both soluble (panel A) and insoluble (panel B) 
hippocampal Aβ40, there was no appreciable effect of ketamine treatment in Tg2576 mice. 
Student’s t-tests revealed no significant differences in soluble and insoluble Aβ40 between 
ketamine- and vehicle-treated Tg2576 mice (t(20) = 0.018, p = .986, d = 0.008) and (t(20) = 0.368, p = 
.717, d = 0.157), respectively. Bayesian independent samples t-tests were suggestive of a genuine 
absence of effect of ketamine on either soluble or insoluble Aβ40 (BF10 = 0.385 and 0.404, 
respectively).  
 
Figure 5.1. Mean hippocampal soluble (A) and insoluble (B) human Aβ40 concentrations (pg/mg) for ketamine- 
(Tg Ket) and vehicle-treated (Tg Veh) 19-20 month old Tg2576 mice. n = 11 ketamine- and 11 vehicle-treated 
Tg2576 mice. 
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 Inspection of panel A of Figure 5.2 indicates that ketamine-treated Tg2576 mice display a 
markedly lower hippocampal soluble Aβ42 concentration than vehicle-treated Tg2576 mice, which a 
Student’s t-test revealed to be statistically significant (t(20) = 2.190, p = .041, d = 0.934). In contrast, 
inspection of panel B of Figure 5.2 indicates that ketamine treatment had no meaningful effect on 
hippocampal insoluble Aβ42 in Tg2576 mice. A Student’s t-test revealed the difference in insoluble 
Aβ42 between treatment groups to be non-significant (t(20) = 0.465, p = .647, d = 0.198). A Bayesian 
independent samples t-test was consistent with, though not conclusive evidence of, a genuinely null 
ketamine effect on insoluble Aβ42 (BF10 = 0.416). 
 
 
Figure 5.2. Mean hippocampal soluble (A) and insoluble (B) human Aβ42 concentrations (pg/mg) for ketamine- 
(Tg Ket) and vehicle-treated (Tg Veh) 19-20 month old Tg2576 mice. n = 11 ketamine- and 11 vehicle-treated 
Tg2576 mice. 
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5.2.2.2 Cortex Aβ levels 
 Inspection of Figure 5.3 indicates that ketamine treatment had no notable effect on soluble 
(panel A) and insoluble (panel B) cortical Aβ40 concentrations in Tg2576 mice. Student’s t-tests 
revealed that for neither Aβ aggregation state was there a significant difference between ketamine- 
and vehicle-treated Tg2576 mice; for soluble Aβ40 (t(29) = 0.267, p = .791, d = 0.096) and for 
insoluble Aβ40 (t(29) = 0.934, p = .358, d = 0.336). Bayesian independent samples t-tests were 
suggestive of no effect of ketamine on soluble Aβ40 (BF10 = 0.350), though less conclusive regarding 
the effect of ketamine on insoluble Aβ40 (BF10 = 0.474), in Tg2576 cortex. 
 
 
Figure 5.3. Mean cortical soluble (A) and insoluble (B) human Aβ40 concentrations (pg/mg) for ketamine- (Tg 
Ket) and vehicle-treated (Tg Veh) 19-20 month old Tg2576 mice. n = 16 ketamine- and 15 vehicle-treated 
Tg2576 mice. 
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 Inspection of panel A of Figure 5.4 indicates that ketamine-treated Tg2576 mice display 
markedly lower soluble cortical Aβ42 concentrations than vehicle-treated Tg2576 mice. Panel B of 
Figure 5.3 indicated that cortical insoluble Aβ42, however, was not meaningfully altered by ketamine 
treatment in Tg2576 mice. A Student’s t-test revealed the soluble Aβ42 difference between 
treatment groups to be significant (t(29) = 2.597, p = .015, d = 0.933), while there was no significant 
treatment group difference for insoluble Aβ42 concentrations (t(29) = 0.373, p = .712, d = 0.134). A 
Bayesian independent samples t-tests was generally consistent with the absence of a ketamine 
effect on insoluble Aβ42 (BF10 = 0.359). 
 
 
Figure 5.4. Mean cortical soluble (A) and insoluble (B) human Aβ42 concentrations (pg/mg) for ketamine- (Tg 
Ket) and vehicle-treated (Tg Veh) 19-20 month old Tg2576 mice. n = 16 ketamine- and 15 vehicle-treated 
Tg2576 mice. 
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5.2.3 Summary 
 Experiment 6 revealed that sub-anaesthetic ketamine treatment significantly reduced 
soluble, but not insoluble, Aβ42 levels in both the hippocampus and cortex of Tg2576 mice. 
However, ketamine treatment had no effect on either soluble or insoluble Aβ40 concentrations in 
Tg2576 mice, in both the hippocampus and cortex. Bayesian analyses generally supported the view 
that the non-reductions of Aβ in ketamine-treated Tg2576 mice were genuine null effects of 
ketamine. 
 
5.3 Experiment 7 
5.3.1 Subjects, apparatus, procedure & data analysis 
 Experiment 7 investigates the effects of both genotype and ketamine treatment on a 
number of glutamate receptor subunits in synaptically enriched hippocampal and cortical extracts, 
as well as a post-synaptic scaffolding protein involved in glutamatergic neurotransmission and 
synaptic plasticity. The precise numbers of mice from each genotype and treatment group analysed 
by Western blot were dependent upon sample volume and prior usage at the time of probing for a 
particular protein; these numbers are reported with each figure. Apparatus, procedure and data 
collection are as described in Sections 2.4 and 2.6. 
 
5.3.2 Results 
5.3.2.1 Hippocampal glutamatergic signalling proteins 
 Inspection of panel A of Figure 5.5 indicates that hippocampal expression of the NMDA 
receptor NR1 subunit was not meaningfully altered by either genotype or ketamine treatment. 
ANOVA results were consistent with this impression, revealing non-significant effects of genotype 
(F(1,45) = 0.107, p = .745, MSE = 0.101, η2p= 0.002) and drug (F(1,45) = 0.924, p = .342, MSE = 0.872, 
η2p= 0.020), and a non-significant genotype × drug interaction (F(1,45) = 0.802, p = .375, MSE = 
0.757, η2p= 0.018). Bayesian ANOVA results suggested the absence of a genotype effect (BF10 = 
0.292), but were less conclusive regarding a null effect of ketamine (BF10 = 0.404), and absence of a 
genotype × drug interaction (BF10 = 0.492). Panel B of Figure 5.5 displays the same pattern of no 
apparent genotype- or ketamine-induced alterations in NMDA receptor NR2B subunit expression. 
ANOVA results were again consistent with this impression, revealing non-significant effects of 
genotype (F(1,45) = 1.012, p = .320, MSE = 0.580, η2p= 0.022) and drug (F(1,45) = 1.759, p = .191, 
MSE = 1.007, η2p= 0.038), and a non-significant genotype × drug interaction (F(1,45) = 1.515, p = 
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.225, MSE = 0.868, η2p= 0.033). Bayesian ANOVA results were again suggestive of an absent 
genotype effect (BF10 = 0.394), while being less clear regarding a null ketamine effect (BF10 = 0.499), 
and absence of a genotype × drug interaction (BF10 = 0.629). Similarly, Panel C of Figure 5.5 is 
indicative of no notable genotype or treatment group differences in expression of the NR2B subunit 
phosphorylated at tyrosine 1472. ANOVA results were again consistent with this impression, 
revealing non-significant effects of genotype (F(1,45) = 0.083, p = .775, MSE = 0.017, η2p= 0.002) and 
drug (F(1,45) = 1.452, p = .235, MSE = 0.290, η2p= 0.031), and a non-significant genotype × drug 
interaction (F(1,45) = 1.399, p = .243, MSE = 0.279, η2p= 0.030). Bayesian ANOVA results were 
suggestive of the absence of a genotype effect (BF10 = 0.289), but were less informative regarding a 
null effect of drug (BF10 = 0.497), or the absence of a genotype × drug interaction (BF10 = 0.637). 
However, panel D of Figure 5.5 indicates that, across treatment groups, Tg2576 mice display a lower 
ratio of p-Y1472:total NR2B levels than their wild-type counterparts, with no appreciable impact of 
ketamine treatment. ANOVA results were consistent with this impression, revealing a significant 
effect of genotype (F(1,45) = 5.563, p = .023, MSE = 0.514, η2p= 0.110), a non-significant effect of 
drug (F(1,45) = 1.055, p = .310, MSE = 0.097, η2p= 0.023), and a non-significant genotype × drug 
interaction (F(1,45) = 0.253, p = .618, MSE = 0.023, η2p= 0.006). Bayesian ANOVA results were 
consistent with the absence of a drug effect (BF10 = 0.342), though less informative regarding the 
absence of a genotype × drug interaction (BF10 = 0.405). 
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Figure 5.5. Mean relative densities and representative Western blot images of NMDA receptor subunits NR1 
(A), NR2B (B), pY1472 NR2B (C), and the ratio of pY1472:total NR2B (D) in hippocampal synaptosomal extracts 
from 19-20 month old Tg2576 and wild-type mice. n = 11 ketamine- and 13 vehicle-treated Tg2576 mice and 
15 ketamine- and 10 vehicle-treated wild-type mice. IC = internal control. 
 
 Inspection of Figure 5.6 indicates that hippocampal PSD-95 expression was largely unaltered 
by either genotype or ketamine treatment. ANOVA results were consistent with this impression, 
revealing non-significant effects of genotype (F(1,45) = 0.328, p = .570, MSE = 0.093, η2p= 0.007) and 
drug (F(1,45) = 0.800, p = .376, MSE = 0.228, η2p= 0.017), and a non-significant genotype × drug 
interaction (F(1,45) = 1.064, p = .308, MSE = 0.303, η2p= 0.023). Consistent with this interpretation, 
Bayesian ANOVA results were suggestive of the absence of effects of genotype (BF10 = 0.318) and 
drug (BF10 = 0.374), though less clear regarding an absent genotype × drug interaction (BF10 = 0.539). 
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Figure 5.6. Mean relative densities and representative Western blot image of post-synaptic density 95 (PSD-95) 
in hippocampal synaptosomal extracts from 19-20 month old Tg2576 and wild-type mice. n = 11 ketamine- and 
13 vehicle-treated Tg2576 and 15 ketamine- and 10 vehicle-treated wild-type mice. IC = internal control. 
 
 Inspection of panel A of Figure 5.7 indicates that hippocampal expression of the AMPA 
receptor GluR1 subunit was increased by ketamine treatment in both Tg2576 and wild-type mice. 
GluR1 expression was not, however, meaningfully different between Tg2576 and wild-type mice, 
regardless of treatment group. ANOVA results were consistent with this impression, revealing a non-
significant effect of genotype (F(1,32) = 1.267, p = .269, MSE = 0.285, η2p= 0.038), a significant effect 
of drug (F(1,32) = 5.590, p = .024, MSE = 1.258, η2p= 0.149), and a non-significant genotype × drug 
interaction (F(1,32) = 0.129, p = .722, MSE = 0.029, η2p= 0.004). Bayesian ANOVA results were 
generally consistent with this interpretation, though did not conclusively reveal a null genotype 
effect (BF10 = 0.463), or the absence of a genotype × drug interaction (BF10 = 0.451).  
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Figure 5.7. Mean relative densities and representative Western blot images of AMPA receptor subunit GluR1 
(A), p-GluR1 (B), and the p-GluR1:total GluR1 ratio (C) in hippocampal synaptosomal extracts from 19-20 month 
old Tg2576 and wild-type mice. n = 9 ketamine- and 9 vehicle-treated Tg2576 mice and 10 ketamine- and 8 
vehicle-treated wild-type mice. IC = internal control. 
  
 Panels B and C of Figure 5.7 indicate that ketamine also increased p-GluR1 expression, and 
the p-GluR1:total GluR1 ratio, in both Tg2576 and wild-type mice, while no notable genotype 
difference was apparent. ANOVA results were consistent with this impression, revealing for p-GluR1 
a non-significant effect of genotype (F(1,32) = 0.133, p = .718, MSE = 1.069, η2p= 0.004), a significant 
effect of drug (F(1,32) = 4.424, p = .043, MSE = 35.688, η2p= 0.121), and a non-significant genotype × 
drug interaction (F(1,32) = 0.011, p = .919, MSE = 0.086, η2p=<.001). Bayesian ANOVA results for p-
GluR1 were also consistent with this interpretation, suggesting the absence of a genotype effect 
(BF10 = 0.329), though less clearly suggesting the absence of a genotype × drug interaction (BF10 = 
0.406). For the p-GluR1:total GluR1 ratio, ANOVA revealed a non-significant effect of genotype 
(F(1,32) = 0.251, p = .620, MSE = 0.735, η2p= 0.008), a significant effect of drug (F(1,32) = 5.349, p = 
.027, MSE = 15.684, η2p= 0.143), and a non-significant genotype × drug interaction (F(1,32) = 0.809, p 
= .375, MSE = 2.372, η2p= 0.025). Bayesian ANOVA results for p-GluR1:total GluR1 were consistent 
with this interpretation, suggesting the absence of a genotype effect (BF10 = 0.378), though less 
clearly suggesting the absence of a genotype × drug interaction (BF10 = 0.536). 
 
5.3.2.2 Cortical glutamatergic signalling proteins 
 Inspection of panel A of Figure 5.8 indicates that, despite numerical differences, there were 
no clear genotype- or ketamine-associated differences in cortical GluR1 expression. ANOVA results 
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were consistent with this impression, revealing non-significant effects of genotype (F(1,57) = 2.039, 
p = .159, MSE = 1.554, η2p= 0.035) and drug (F(1,57) = 2.359, p = .130, MSE = 1.798, η2p= 0.040), and 
a non-significant genotype × drug interaction (F(1,57) = 0.018, p = .892, MSE = 0.014, η2p<.001). 
Bayesian ANOVA results were partially consistent with this interpretation; though not conclusively 
revealing null effects of genotype (BF10 = 0.624) and drug (BF10 = 0.723), there was a clearer absence 
of a genotype × drug interaction (BF10 = 0.337). Panels B and C of Figure 5.8 display a similar, albeit 
less clear, pattern of results for p-GluR1 and the p-GluR1:total GluR1 ratio in the cortex as seen in 
the hippocampus. That is, p-GluR1 and p-GluR1:total GluR1 ratio show no notable differences 
between genotypes, with a possible effect of ketamine increasing these measures, especially in the 
case of p-GluR1:total GluR1. ANOVA results were somewhat consistent with this impression, 
revealing for p-GluR1 non-significant effects of genotype (F(1,57) = 0.040, p = .841, MSE = 0.009, η2p= 
0.001) and drug (F(1,57) = 2.486, p = .120, MSE = 0.532, η2p= 0.042), and a non-significant genotype × 
drug interaction (F(1,57) = 0.082, p = .776, MSE = 0.018, η2p = 0.001). Bayesian ANOVA results were 
suggestive of the absence of a genotype effect (BF10 = 0.264), less informative regarding an absence 
of drug effect (BF10 = 0.763), and suggested an absent genotype × drug interaction (BF10 = 0.359). For 
the p-GluR1:total GluR1 ratio, ANOVA revealed non-significant effects of genotype (F(1,57) = 0.065, 
p = .800, MSE = 0.011, η2p= 0.001) and drug (F(1,57) = 3.773, p = .057, MSE = 0.619, η2p= 0.062), and 
a non-significant genotype × drug interaction (F(1,57) = 0.433, p = .513, MSE = 0.071, η2p = 0.008). 
Bayesian ANOVA results were suggestive of the absence of a genotype effect (BF10 = 0.268), but 
were less informative regarding the presence of a drug effect (BF10 = 1.334), and the absence of a 
genotype × drug interaction (BF10 = 0.430). 
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Figure 5.8. Mean relative densities and representative Western blot images of AMPA receptor subunit GluR1 
(A), p-GluR1 (B), and the pGluR1:total GluR1 ratio (C) in cortical synaptosomal extracts from 19-20 month old 
Tg2576 and wild-type mice. n = 16 ketamine- and 15 vehicle-treated Tg2576 mice and 16 ketamine- and 14 
vehicle-treated wild-type mice. IC = internal control. 
 
  
 Inspection of Figure 5.9 indicates that cortical PSD-95 expression was not meaningfully 
different between both genotypes and treatment groups. ANOVA results were consistent with this 
impression, revealing non-significant effects of genotype (F(1,57) = 2.117, p = .151, MSE = 0.052, η2p 
= 0.036) and drug (F(1,57) = 1.874, p = .176, MSE = 0.046, η2p = 0.032), and a non-significant 
genotype × drug interaction (F(1,57) = 0.473, p = .494, MSE = 0.012, η2p = 0.008). Bayesian ANOVA 
results were consistent with this interpretation though not conclusively so, not providing clear 
evidence regarding null effects of genotype (BF10 = 0.676) and drug (BF10 = 0.575), and the absence 
of a genotype × drug interaction (BF10 = 0.417). 
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Figure 5.9. Mean relative densities and representative Western blot image of PSD-95 in cortical synaptosomal 
extracts from 19-20 month old Tg2576 and wild-type mice. n = 16 ketamine- and 15 vehicle-treated Tg2576 
mice and 16 ketamine- and 14 vehicle-treated wild-type mice. IC = internal control. 
 
 
5.3.3 Summary 
 Experiment 7 revealed that 19-20 month-old Tg2576 mice, across treatment groups, showed 
a reduction in the hippocampal p-Y1472 NR2B:total NR2B ratio compared with wild-type mice. 
However, in both the hippocampus and the cortex, the other glutamatergic receptor subunits 
examined did not differ between genotypes. For hippocampal NMDA receptor subunits NR1, NR2B 
and p-Y1472 NR2B, the Bayesian analysis generally supported the idea that these subunits were 
genuinely not different between Tg2576 and wild-type mice. In addition, ketamine treatment had no 
meaningful impact on any of the NMDAR measures, with the strongest evidence for a true null effect 
of ketamine found for the p-Y1472 NR2B:total NR2B ratio. Investigation of the AMPA receptor 
subunit GluR1 revealed no observable differences between Tg2576 and wild-type mice when GluR1, 
p-Ser845 GluR1 and the p-Ser845 GluR1:total GluR1 ratio were examined, both in the hippocampus 
and the cortex. Of these GluR1 measures, the strongest evidence for a true null effect of genotype 
was for p-Ser845 GluR1 and p-Ser845 GluR1:total GluR1 ratio, in both the hippocampus and cortex. 
Unlike the NMDAR subunits, ketamine treatment did have an effect on GluR1 subunit expression 
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and phosphorylation across both genotypes, more so in the hippocampus than cortex. Ketamine 
treatment increased the expression of GluR1, p-Ser845 GluR1, and the p-Ser845 GluR1:total GluR1 
ratio, in the hippocampus, while there was also a suggestion of an increase in the p-Ser845 
GluR1:total GluR1 ratio in the cortex. PSD-95 expression appeared to neither differ between 
genotypes, nor be altered by ketamine treatment, in both the hippocampus and the cortex, though 
the strongest evidence for null effects of genotype and ketamine treatment was in the hippocampal 
results. 
 
5.4 Experiment 8 
5.4.1 Subjects, apparatus, procedure & data analysis 
 Experiment 8 investigates the effects of both genotype and ketamine treatment on a 
number of serotonergic and opioidergic receptors in synaptically enriched hippocampal and cortical 
extracts. As with Experiment 7, the numbers of each genotype and treatment groups are reported 
with each figure, and apparatus, procedure and data collection are as previously described. 
 
5.4.2 Results 
5.4.2.1 Hippocampal serotonergic proteins 
 Inspection of panel A of Figure 5.10 indicates that 5HT1B receptor expression was largely 
similar between both genotypes and treatment groups. ANOVA results were consistent with this 
impression, revealing non-significant effects of genotype (F(1,22) = 0.476, p = .497, MSE = 0.064, η2p 
= 0.021) and drug (F(1,22) = 0.025, p = .875, MSE = 0.003, η2p = 0.001), and a non-significant 
genotype × drug interaction (F(1,22) = 0.713, p = .408, MSE = 0.096, η2p = 0.031). Bayesian ANOVA 
results were somewhat supportive of this interpretation, providing unclear evidence regarding a null 
genotype effect (BF10 = 0.451), slightly clearer evidence of a null effect of ketamine (BF10 = 0.364) 
and some evidence indicating a null genotype × drug interaction (BF10 = 0.223). Panel B of Figure 
5.10 indicates that Tg2576 and wild-type mice show very similar levels of 5HT4 receptor expression, 
with no obvious effect of ketamine treatment. ANOVA results were consistent with this impression, 
revealing non-significant effects of genotype (F(1,20) = 0.012, p = .915, MSE = 0.001, η2p = 0.001) and 
drug (F(1,20) = 0.023, p = .882, MSE = 0.002, η2p = 0.001), and a non-significant genotype × drug 
interaction (F(1,20) = 0.048, p = .829, MSE = 0.005, η2p = 0.002). Bayesian ANOVA results were 
consistent with this, suggesting some evidence in favour of null effects of genotype (BF10 = 0.378) 
and ketamine treatment (BF10 = 0.388), and less clear evidence of a null genotype × drug interaction 
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(BF10 = 0.530). However, for the hippocampal 5HT4 receptor results, the wild-type vehicle group only 
consisted of two mice, therefore these particular results should be treated with caution. Panel C of 
Figure 5.10 indicates that hippocampal SERT expression was largely similar between Tg2576 and 
wild-type mice, and between ketamine- and vehicle-treated mice. ANOVA results were consistent 
with this impression, revealing non-significant effects of genotype (F(1,34) = 0.034, p = .855, MSE = 
0.037, η2p = 0.001) and drug (F(1,34) = 0.369, p = .548, MSE = 0.406, η2p = 0.011), and a non-
significant genotype × drug interaction (F(1,34) = 0.550, p = .464, MSE = 0.606, η2p = 0.016). Bayesian 
ANOVA results generally supported this interpretation, providing some evidence of an absence of 
genotype effect (BF10 = 0.320), some evidence of an absence of ketamine effect (BF10 = 0.383), with 
less clear evidence of an absent genotype × drug interaction (BF10 = 0.508). 
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Figure 5.10. Mean relative densities and representative Western blot images of 5HT receptors 5HT1B (A), 5HT4 
(B), and SERT (C) in hippocampal synaptosomal extracts from 19-20 month old Tg2576 and wild-type mice. 
Numbers of mice in each genotype and treatment group are as follows: 5HT1B – 5 ketamine- and 8 vehicle-
treated Tg2576 and 9 ketamine- and 4 vehicle-treated wild-type mice; 5HT4 – 5 ketamine- and 8 vehicle-treated 
Tg2576 and 9 ketamine- and 2 vehicle-treated wild-type mice; SERT – 10 ketamine- and 11 vehicle-treated 
Tg2576 and 11 ketamine- and 6 vehicle-treated wild-type mice. IC = internal control. 
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5.4.2.2 Hippocampal mu opioid receptors 
 Inspection of panels A and B of Figure 5.11 indicated that while there was no clear effect of 
ketamine on mu opioid receptor expression in Tg2576 and wild-type mice, within vehicle-treated 
mice there was a suggestion of Tg2576 mice displaying greater mu receptor expression. This 
increased mu opioid receptor expression in vehicle-treated Tg2576 mice was most notable for the 
47kDa isoform (panel B). ANOVA results were consistent with this impression, revealing for the 
49kDa isoform (panel A) non-significant effects of genotype (F(1,29) = 1.678, p = .205, MSE = 2.212, 
η2p = 0.055) and drug (F(1,29) = 3.506e-4, p = .985, MSE = 4.620e-4, η2p<.001), and a non-significant 
genotype × drug interaction (F(1,29) = 1.498, p = .231, MSE = 1.974, η2p = 0.049). Bayesian ANOVA 
results were unclear regarding a null genotype effect (BF10 = 0.580), suggested the absence of a drug 
effect (BF10 = 0.341), and were less clear regarding a genotype × drug interaction (BF10 = 0.653). 
ANOVA results for the 47kDa isoform (panel B) revealed non-significant effects of genotype (F(1,29) 
= 2.856, p = .102, MSE = 3.385, η2p = 0.090) and drug (F(1,29) = 0.020, p = .889, MSE = 0.024, η2p = 
0.001), and a non-significant genotype × drug interaction (F(1,29) = 3.203, p = .084, MSE = 3.796, η2p 
= 0.099). Bayesian ANOVA results revealed uninformative evidence of a genotype effect (BF10 = 
0.814), were suggestive of a null effect of drug (BF10 = 0.362), and were not clearly informative 
regarding a genotype × drug interaction (0.433). As the conventional ANOVA suggested the 
possibility of a genotype effect which differed in each treatment group, this was investigated with 
follow-up t-tests. Student’s t-tests comparing expression of the 47kDa isoform between genotypes 
within each treatment group, revealed a non-significant difference between ketamine-treated 
Tg2576 and wild-type mice (t(16) = 0.073, p = .942, d = 0.035), and a significant difference between 
vehicle-treated Tg2576 and wild-type mice (t(13) = 2.388, p = .033, d = 1.259). A Bayesian 
independent samples t-test revealed unclear evidence regarding a null effect of genotype within 
ketamine-treated mice (BF10 = 0.414). 
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Figure 5.11. Mean relative densities and representative Western blot image of the 49kDa (A) and 47kDa (B) 
bands for mu opioid receptors in hippocampal synaptosomal extracts from 19-20 month old Tg2576 and wild-
type mice. n = 8 ketamine- and 9 vehicle-treated Tg2576 mice and 10 ketamine- and 6 vehicle-treated wild-
type mice. IC = internal control. 
 
5.4.2.3 Cortical serotonergic signalling proteins 
 Inspection of panel A of Figure 5.12 indicates that cortical 5HT1B receptor expression did not 
meaningfully differ either between genotypes or between treatment groups. ANOVA results were 
consistent with this impression, revealing non-significant effects of genotype (F(1,57) = 0.082, p = 
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.775, MSE = 0.021, η2p = 0.001) and drug (F(1,57) = 0.405, p = .527, MSE = 0.106, η2p = 0.007), and a 
non-significant genotype × drug interaction (F(1,57) = 0.007, p = .933, MSE = 0.002, η2p <.001). 
Bayesian ANOVA results were consistent with this interpretation, providing evidence in favour of null 
effects of genotype (BF10 = 0.271) and drug (BF10 = 0.312), and the absence of a genotype × drug 
interaction (BF10 = 0.353). Inspection of panel B of Figure 5.12 indicates that cortical 5HT4 receptor 
expression also did not differ between Tg2576 and wild-type mice, and did not appear affected by 
ketamine treatment. ANOVA results were consistent with this impression, revealing non-significant 
effects of genotype (F(1,57) = 0.821, p = .369, MSE = 0.045, η2p = 0.014) and drug (F(1,57) = 0.731, p 
= .396, MSE = 0.040, η2p = 0.013), and a non-significant genotype × drug interaction (F(1,57) = 0.207, 
p = .650, MSE = 0.011, η2p = 0.004). Bayesian ANOVA results were again consistent with this 
interpretation, suggestive of null effects of genotype (BF10 = 0.373) and drug (BF10 = 0.355), and an 
absent genotype × drug interaction (BF10 = 0.396). Inspection of panel C of Figure 5.12 indicates that, 
while there was no obvious effect of ketamine treatment on SERT expression for either genotype, 
overall Tg2576 mice displayed a greater cortical expression of SERT than wild-type mice. ANOVA 
results were consistent with this impression, revealing a significant effect of genotype (F(1,57) = 
8.201, p = .006, MSE = 0.751, η2p = 0.126), a non-significant effect of drug (F(1,57) = 0.097, p = .756, 
MSE = 0.009, η2p = 0.002), and a non-significant genotype × drug interaction (F(1,57) = 1.292, p = 
.261, MSE = 0.118, η2p = 0.022). Bayesian ANOVA results were consistent with this interpretation, 
providing evidence supportive of a null drug effect (BF10 = 0.269), though less clear regarding a null 
genotype × drug interaction (BF10 = 0.563). 
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Figure 5.12. Mean relative densities and representative Western blot images of 5HT1B receptors (A), 5HT4 
receptors (B), and SERT (C) in cortical synaptosomal extracts from 19-20 month old Tg2576 and wild-type mice. 
n = 16 ketamine- and 15 vehicle-treated Tg2576 mice and 16 ketamine- and 14 vehicle-treated wild-type mice. 
IC = internal control. 
 
5.4.2.4 Cortical opioid receptors 
 Inspection of panel A of Figure 5.13 indicates that, while cortical mu opioid receptor 
expression did not appear altered by ketamine treatment, there was a suggestion of an increased 
expression in Tg2576 mice overall. ANOVA results were somewhat consistent with this impression, 
revealing non-significant effects of genotype (F(1,57) = 3.320, p = .074, MSE = 0.244, η2p = 0.055) and 
drug (F(1,57) = 2.080, p = .155, MSE = 0.153, η2p = 0.035), and a non-significant genotype × drug 
interaction (F(1,57) = 0.089, p = .767, MSE = 0.007, η2p = 0.002). Bayesian ANOVA results provided 
unclear evidence regarding null effects of ketamine (BF10 = 0.638) and genotype (BF10 = 1.052), and 
suggested the absence of a genotype × drug interaction (BF10 = 0.365). Inspection of panel B of 
Figure 5.13 indicates that cortical kappa opioid receptor expression was not meaningfully altered by 
ketamine treatment across genotypes, but was increased in Tg2576 mice overall compared with 
wild-type mice. ANOVA results were consistent with this impression, revealing a significant effect of 
genotype (F(1,57) = 6.110, p = .016, MSE = 1.035, η2p = 0.097), a non-significant effect of drug 
(F(1,57) = 1.674, p = .201, MSE = 0.284, η2p = 0.029), and a non-significant genotype × drug 
interaction (F(1,57) = 0.098, p = .755, MSE = 0.017, η2p = 0.002). Bayesian ANOVA results were 
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somewhat consistent with this interpretation; while less clear regarding the absence of a drug effect 
(BF10 = 0.484), they were suggestive of a null genotype × drug interaction (BF10 = 0.364).  
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Figure 5.13. Mean relative densities and representative Western blot images of mu (A), kappa (B), and delta (C) 
opioid receptors in cortical synaptosomal extracts from 19-20 month old Tg2576 and wild-type mice. n = 16 
ketamine- and 15 vehicle-treated Tg2576 mice and 16 ketamine- and 14 vehicle-treated wild-type mice. IC = 
internal control. 
 
 Inspection of panel C of Figure 5.13 indicates that cortical delta opioid receptor expression 
was not notably different between genotypes or treatment groups. ANOVA results were consistent 
with this impression, revealing non-significant effects of genotype (F(1,57) = 1.103, p = .298, MSE = 
0.403, η2p = 0.019) and drug (F(1,57) = 0.984, p = .325, MSE = 0.360, η2p = 0.017), and a non-
significant genotype × drug interaction (F(1,57) = 1.092, p = .301, MSE = 0.399, η2p = 0.019). Bayesian 
ANOVA results were somewhat consistent with this interpretation, though not conclusively so, 
providing unclear evidence of null genotype (BF10 = 0.427) and drug (BF10 = 0.394) effects, and less 
informative evidence regarding a genotype × drug interaction (BF10 = 0.529). 
 
5.4.3 Summary 
 Experiment 8 revealed that cortical SERT expression was raised in 19-20 month-old Tg2576 
compared with wild-type mice. However, in both the hippocampus and the cortex, the majority of 
serotonergic-related proteins did not differ between Tg2576 and wild-type mice. This absence of 
genotype difference was observed for 5HT1B and 5HT4 receptors in both the hippocampus and the 
cortex, and for SERT in the hippocampus. Bayesian analyses generally suggested these were genuine 
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null differences between Tg2576 and wild-type mice, though with the caveat that the hippocampal 
5HT4 wild-type vehicle group contained a low number of mice. Ketamine treatment had no 
discernible effect on 5HT1B, 5HT4 or SERT expression in either the hippocampus or the cortex, and 
Bayesian analyses generally supported these being null effects of ketamine. Importantly, kappa 
opioid receptor expression was increased in Tg2576 mouse cortex, as was one isoform of the mu 
opioid receptor in the hippocampus within a subset of Tg2576 and wild-type mice. In addition, there 
was a suggestion of increased mu opioid receptor expression in Tg2576 mouse cortex, though this 
was a non-significant finding, whereas cortical delta opioid receptor expression did not differ 
between genotypes. A Bayesian analysis was somewhat consistent with delta opioid receptor 
expression genuinely not differing between genotypes. Ketamine treatment had no notable effects 
on the expression of any opioid receptor, and this too was generally supported by Bayesian analyses. 
 
5.5 Experiment 9 
5.5.1 Subjects, apparatus, procedure & data analysis 
 Experiment 9 investigates whether the genotype differences revealed in Experiments 7 and 
8 are present at 4-5 months of age, in a separate cohort of Tg2576 and wild-type mice. Apparatus, 
procedure and data collection are as previously described. Synaptosomal hippocampal and cortical 
extracts were examined in 10 Tg2576 and 12 wild-type mice. 
 
5.5.2 Results 
5.5.2.1 Hippocampal NR2B-related measures 
 Inspection of panels A, B and C of Figure 5.14 indicates that at 4-5 months of age Tg2576 
mice display levels of NR2B, p-Y1472 NR2B and the p-Y1472 NR2B:total NR2B ratio, respectively, that 
are not markedly lower than in wild-type mice. Student’s t-tests were consistent with this 
impression, revealing non-significant genotype differences in NR2B (t(19) = 0.541, p = .595, d = 
0.236), p-Y1472 NR2B (t(19) = 0.913, p = .373, d = 0.399), and the p-Y1472 NR2B:total NR2B ratio 
(t(19) = 0.371, p = .714, d = 0.162). Bayesian independent samples t-tests were somewhat supportive 
of this interpretation, consistent, though not unambiguously so, with the absence of genotype 
differences for NR2B (BF10 = 0.434), p-Y1472 NR2B (BF10 = 0.525) and the p-Y1472 NR2B:total NR2B 
ratio (BF10 = 0.411). 
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Figure 5.14. Mean relative densities and representative Western blot images of NR2B (A), p-Y1472 NR2B (B), and 
the p-Y1472 NR2B:total NR2B ratio (C) in hippocampal synaptosomal extracts from 4-5 month old Tg2576 and 
wild-type mice. n = 10 Tg2576 and 11 wild-type mice. IC = internal control. 
 
 
5.5.2.2 Cortical SERT expression 
 Inspection of Figure 5.15 indicates that Tg2576 mice display a slightly raised cortical SERT 
expression compared with wild-type mice at 4-5 months of age. A Student’s t-test revealed this 
genotype difference to be non-significant (t(19) = 1.536, p = .141, d = 0.671), while a Bayesian 
independent samples t-test was not especially informative regarding the absence of a genotype 
difference (BF10 = 0.882). 
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Figure 5.15. Mean relative density and representative Western blot image of SERT in cortical synaptosomal 
extracts from 4-5 month old Tg2576 and wild-type mice. n = 10 Tg2576 and 11 wild-type mice. IC = internal 
control. 
 
 
5.5.2.3 Opioid receptors 
 Inspection of panel A of Figure 5.16 indicates that Tg2576 mice display a numerically higher, 
but not notably so, hippocampal expression of mu opioid receptor than wild-type mice at 4-5 
months of age. A Student’s t-test was consistent with this impression, revealing a non-significant 
difference between genotypes (t(19) = 1.340, p = .196, d = 0.586). A Bayesian independent samples 
t-test provided no clear evidence regarding the absence of a genotype difference (BF10 = 0.731). 
Inspection of panel B of Figure 5.16 indicates that cortical mu opioid receptor expression displays a 
similar pattern of results as in the hippocampus, with numerically greater expression in 4-5 month 
old Tg2576 mice. A Student’s t-test revealed this to be a non-significant genotype difference (t(19) = 
1.941, p = .067, d = 0.848), while a Bayesian independent samples t-test provided inconclusive 
evidence regarding the presence of a genuine genotype difference (BF10 = 1.392).  
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Figure 5.16. Mean relative densities and representative Western blot images of hippocampal (A) and cortical (B) 
mu, and cortical kappa (C), opioid receptor expression in hippocampal and cortical synaptosomal extracts from 
4-5 month old Tg2576 and wild-type mice. n = 10 Tg2576 and 11 wild-type mice. IC = internal control. 
 
 Inspection of panel C of Figure 5.16 indicates that cortical kappa opioid receptor expression 
did not materially differ between Tg2576 and wild-type mice, at 4-5 months of age. A Student’s t-
test was consistent with this impression, revealing a non-significant genotype difference (t(19) = 
0.024, p = .981, d = 0.011), and a Bayesian independent samples t-test provided evidence consistent 
with an absence of a genotype difference (BF10 = 0.391). 
 
5.5.3 Summary 
 Experiment 9 revealed that at 4-5 months of age, Tg2576 mice showed no significant 
reduction in hippocampal NR2B, p-Y1472 NR2B or the p-Y1472 NR2B:total NR2B ratio compared 
with wild-type mice. In addition, young Tg2576 mice displayed no significant increase in cortical 
SERT, hippocampal or cortical mu opioid receptor, and cortical kappa opioid receptor expression, 
compared with wild-type mice. The strongest evidence provided by Bayesian analyses for an 
absence of genotype difference was in cortical kappa opioid receptor expression and hippocampal p-
Y1472 NR2B:total NR2B expression. These results stand in contrast with those from Experiments 7 
and 8, in which older Tg2576 mice displayed a reduction in the hippocampal p-Y1472 NR2B:total 
0
0.2
0.4
0.6
0.8
1
1.2
TG WT
R
el
at
iv
e 
D
en
si
ty
Kappa opioid receptorC 
42 kDa 
                  WT   TG    WT   TG   WT    TG  WT   TG   WT   TG   WT   IC    
150 
 
NR2B ratio, and an increase in hippocampal mu opioid receptor expression (in a subset of mice), and 
cortical kappa opioid receptor and SERT expression (Table 5.1). In the case of the kappa opioid 
receptor, there is a distinct difference between aged and young Tg2576 mice, in that there was a 
significantly raised expression in older Tg2576 mice and the absence of a genotype difference in 
younger mice. A distinct difference was also seen between aged and young Tg2576 mice regarding 
the hippocampal phosphorylated:total NR2B ratio, albeit with slightly less conclusive evidence 
regarding a null genotype effect in young mice. For cortical SERT there was a significant increase in 
older Tg2576 mice, with less informative evidence supporting a null genotype effect in younger 
mice. For hippocampal mu opioid receptor expression, the Bayesian analysis provided less clear 
evidence of a null genotype effect in young Tg2576 mice. In the case of cortical mu opioid receptor 
expression, the Bayesian analysis was not particularly informative in either age group, and was not 
only in the direction of a genotype difference in both Tg2576 age groups, but was slightly stronger in 
the younger Tg2576 mice. 
 
Aged Tg2576 
biochemical difference 
Young Tg2576 
biochemical difference 
Reduced phospho:total 
NR2B ratio (HPC). 
Null. 
Increased mu opioid 
receptor (in vehicle-
treated mice) (HPC). 
Null. 
Increased mu opioid 
receptor (trend) (CTX). 
Increased mu opioid 
receptor (trend). 
Increased SERT (CTX). Null. 
Increased kappa opioid 
receptor (CTX). 
Null. 
Table 5.1. Comparison of significant biochemical results from aged (19-20 month-old) Tg2576 mice 
(Experiments 7 and 8) against young (4-5 month-old) Tg2576 mice (Experiment 9), based on the conventional 
statistical analysis. CTX = cortex, HPC = hippocampus. 
 
 
5.5.4 Chapter summary 
 Experiment 6 revealed that sub-anaesthetic ketamine treatment lowered soluble Aβ42 in 
the cortex and hippocampus of Tg2576 mice, while insoluble Aβ42, and both Aβ40 forms, were 
unaffected by this treatment in both regions. Experiment 7 demonstrated that directly following the 
T-maze test (Chapter 4, Experiment 5), 19-20 month-old Tg2576 mice showed a reduction in the 
hippocampal p-Y1472 NR2B:total NR2B ratio compared with wild-type mice. While GluR1, p-Ser845 
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GluR1 and the p-GluR1:total GluR1 ratio did not generally differ between Tg2576 and wild-type mice 
in the hippocampus and cortex, ketamine treatment did increase all three GluR1 measures across 
both genotypes in the hippocampus, with a near-significant increase in the p-GluR1:total GluR1 ratio 
in the cortex. PSD-95 expression did not differ between genotypes or drug treatment groups. 
Experiment 8 demonstrated that 5HT1B, 5HT4 and SERT expression were unaffected by ketamine 
treatment in mouse hippocampus and cortex, and did not differ between Tg2576 and wild-type 
mice, with the exception of increased SERT expression in Tg2576 cortex. Mu opioid receptor 
expression was increased in Tg2576 mouse hippocampus (when examining only vehicle-treated 
mice), with a near-significant mu receptor increase in Tg2576 cortex. Kappa opioid receptor 
expression was increased in Tg2576 cortex, while delta opioid receptor expression was not different 
to that of wild-type mice. Ketamine treatment had no apparent effect on expression of any of the 
opioid receptors. A summary of the significant and non-significant genotype differences found in 
aged Tg2576 and wild-type mice is presented in Table 5.2. As an additional note, Bonferroni 
corrections were also applied to the statistically significant results of Experiments 7 and 8, in order 
to examine whether results remained significant after having been corrected for multiple 
comparisons. While it was not immediately clear how best to organise different receptors 
investigated in different brain regions into sensible groupings to which corrections would be applied, 
an approach was taken as follows: corrected groups comprised receptors for a particular 
neurotransmitter within one brain region, for example NMDAR-related measures within the 
hippocampus, AMPAR-related measures within the cortex, 5HTergic-related measures within the 
hippocampus, opioidergic-related measures within the cortex, etc. After applying Bonferroni 
corrections in this way, the hippocampal p:total NR2B genotype difference, hippocampal mu 
receptor (within vehicle-treated mice) genotype difference and all hippocampal GluR1-related 
ketamine effects no longer reached statistical significance, while the cortical SERT and kappa 
receptor genotype differences remained statistically significant. 
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Aged Tg2576 biochemical 
difference (relative to wild-
type mice) 
Statistical significance 
NR1 (HPC). Non-significant. 
NR2B (HPC). Non-significant. 
p-NR2B Y1472 (HPC). Non-significant. 
Reduced phospho:total 
NR2B ratio (HPC). 
Significant. 
GluR1 (HPC and CTX). Non-significant. 
p-GluR1 Ser845 (HPC and 
CTX). 
Non-significant. 
Phospho:total GluR1 ratio 
(HPC and CTX). 
Non-significant. 
5HT1B receptor (HPC and 
CTX). 
Non-significant. 
5HT4 receptor (HPC and 
CTX). 
Non-significant. 
SERT HPC. Non-significant. 
Increased SERT (CTX). Significant. 
49 kDa mu opioid receptor 
(HPC). 
Non-significant. 
Increased 47 kDa mu 
opioid receptor (in vehicle-
treated mice) (HPC). 
Significant. 
Increased mu opioid 
receptor (trend) (CTX). 
Significant (trend). 
Increased kappa opioid 
receptor (CTX). 
Significant. 
Delta opioid receptor 
(CTX). 
Non-significant. 
Table 5.2. Description of significant (bolded) and non-significant (unbolded) findings from aged Tg2576 and 
wild-type mice (Experiments 7 and 8), based on conventional significance testing. 
 
 Experiment 9 served as a control test to determine whether APP overexpression per se could 
produce the biochemical differences observed between aged Tg2576 and wild-type mice, by 
examining both genotypes at a younger age (4-5 months old). While conventional significance 
testing revealed non-significant genotype differences in young mice for all receptors of interest, the 
Bayesian analysis indicated differences in the strength of evidence for null genotype effects. 
Hippocampal p-Y1472 NR2B:total NR2B ratio and the cortical kappa opioid receptor had the 
strongest Bayesian evidence for not differing between Tg2576 and wild-type mice at this age, while 
the Bayesian evidence supporting no genotype difference was less conclusive for hippocampal and 
cortical mu opioid receptor, and for cortical SERT expression. The major findings of importance for 
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this thesis are the hippocampal p-Y1472 NR2B:total NR2B ratio decrease, and the cortical SERT and 
kappa opioid receptor increases, in Tg2576 mice, discussed below. How the overall biochemical 
results relate to the hedonic and cognitive deficits displayed by Tg2576 mice in Chapters 3 and 4, 
respectively, as well as the effects and non-effects of ketamine treatment, will now be discussed. 
 
5.6 Discussion 
 Experiment 1 in Chapter 3 gave a longitudinal profile of the hedonic behaviour of Tg2576 
mice, in which they showed a hedonic deficit which emerged between 4-5 and 8 months of age. 
Experiment 2 in the same chapter revealed that sub-anaesthetic ketamine treatment did not 
improve this hedonic deficit in Tg2576 mice. Chapter 5 has examined two neurotransmitter systems 
(serotonergic and opioidergic) in order to investigate whether they showed any alterations which 
might relate to either anhedonia or the lack of a ketamine effect on anhedonia in Tg2576 mice. In 
addition, gauging the state of these transmitter systems in Tg2576 mice may suggest further 
avenues for exploration in the treatment of depression in early Alzheimer’s disease. 
  
5.6.1 5HT1B receptor expression 
 Previous research had found a decrease in hippocampal 5HT1B expression in Tg2576 mice 
(Tajeddinn et al., 2015), which this project did not replicate in either Tg2576 hippocampus or cortex. 
The study of Tajeddinn et al reported that Tg2576 mice at 2 years of age showed a reduced 
hippocampal 5HT1B expression compared with wild-type mice, however some differences between 
this earlier study and the present results of this chapter should be commented on. Firstly, Tajeddinn 
et al used only female Tg2576 mice, whereas only male Tg2576 mice were used in the experiments 
of this thesis. This is highly likely to produce differences in biochemical measurements, as the 4-5 
day oestrus cycle of rodents includes fluctuating levels of sex hormones such as oestradiol, 
progesterone and luteinising hormone (Caligioni, 2009; Goldman, Murr, & Cooper, 2007). Such 
hormonal changes could cause differences in 5HT1B receptor expression; oestradiol treatment in 
ovariectomised rats decreased 5HT1B mRNA in a subregion of the dorsal raphe nuclei, for example 
(Hiroi & Neumaier, 2009). In addition, Tajeddinn et al appear to have examined the 5HT1B receptor in 
hippocampal lysates, whereas Experiment 8 examined 5HT1B receptor expression within the 
narrower pool of synaptosomes in order to investigate synaptically-related changes. A large 
proportion of 5HT1B receptors are stored in intraneuronal vesicles (Liebmann et al., 2012), so 
divergences in findings could be due to the fact that different cellular fractions were scrutinised. 
Lastly, Tajeddinn et al appear to have used behaviourally naïve Tg2576 mice, while the Tg2576 mice 
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in this thesis experienced multiple hedonic and cognitive behavioural tests before being sacrificed 
for biochemistry. Experience-dependent alterations to 5HT1B receptor expression therefore cannot 
be ruled out in this thesis. In sum, while the 5HT1B receptor expression results shown in Experiment 
8 were not in agreement with a previous report, this could be due to a combination of sex 
differences, the precise cellular fraction being investigated and the prior experience of Tg2576 mice. 
 The 5HT1B receptor was investigated due to its presence in the nucleus accumbens and 
ventral pallidum being implicated in the antidepressant mechanism of action of ketamine (Yamanaka 
et al., 2014). As ketamine did not improve the hedonic behaviour of Tg2576 mice, whom in a 
previous report showed a reduction in hippocampal 5HT1B expression, it was thought that such a 
reduction could provide indirect evidence explaining why ketamine failed to relieve the Tg2576 
mouse hedonic deficit. As no 5HT1B reduction was observed in Tg2576 hippocampus or cortex in 
Experiment 8, the failure of ketamine may lie elsewhere biochemically, though this has not 
conclusively ruled out localised 5HT1B receptor changes in discrete Tg2576 brain structures, such as 
the nucleus accumbens or ventral pallidum. 
  
5.6.2 5HT4 receptor expression 
 5HT4 receptor expression was investigated in Tg2576 mouse hippocampus and cortex due to 
it potentially being altered by the presence of Aβ, as well as possibly contributing to Tg2576 
cognitive and/or hedonic deficits. The 5HT4 receptor has a complex relationship with Aβ, as cell 
culture and animal studies have reported that 5HT4 receptor agonism stimulates sAPPα secretion 
and lowers Aβ release (Cachard-Chastel et al., 2007; Cho & Hu, 2007), including reducing Aβ in 
Alzheimer’s disease model mice (Baranger et al., 2017; Giannoni et al., 2013; Tesseur et al., 2013). 
One possibility, therefore, is that 5HT4 receptor activation may shift APP processing towards the 
non-amyloidogenic pathway. However, chronic 5HT4 receptor activation has also been shown to 
increase sAPPβ production (Tesseur et al., 2013), meaning that its effect on APP may not be simply 
shifting APP processing away from the amyloidogenic pathway. Regardless, the fact that insoluble 
Aβ-burdened Alzheimer’s disease patients show increased brain 5HT4 receptor expression (Madsen 
et al., 2011), and that 5HT4 receptor activation decreases Aβ levels in Alzheimer’s disease model 
mice, suggested that this receptor may respond to the presence of Aβ and thus may be altered in 
Tg2576 mice. In addition, the 5HT4 receptor has been implicated in cognition and hedonics by 
pharmacological and genetic knockout rodent studies (Amigó et al., 2016; Hagena & Manahan-
Vaughan, 2017; Lucas et al., 2007), and thus could contribute to the deficits displayed by Tg2576 
mice in Chapters 3 and 4. 
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 Experiment 8 revealed no difference in 5HT4 receptor expression between Tg2576 and wild-
type mice, in either the hippocampus or cortex. While 5HT4 receptor agonists have been used in 
Alzheimer’s disease model mice, this is the first report of expression of the receptor itself in such a 
mouse model, and suggests that the 5HT4 receptor may not be synaptically altered in mouse models 
of Alzheimer’s disease. This result differs from a study of humans in an earlier stage of Alzheimer’s 
disease in which 5HT4 receptor expression was increased (Madsen et al., 2011), though in principle 
other pathological events absent in Tg2576 mice, such as tau NFTs, could also cause biochemical 
changes. Investigating 5HT4 receptor expression in Alzheimer’s disease patients with and without 
anhedonic symptoms could clarify whether a relationship exists between 5HT4-mediated signalling 
and anhedonia. Further, the 5HT4 receptor can exist in several splice variants with different C-
terminal amino acid sequences, some of which differ between mice and humans in the same splice 
variant (Claeysen, Sebben, Becamel, Bockaert, & Dumuis, 1999). If the 5HT4 receptor does react, 
whether directly or indirectly, to Aβ then species differences in C-termini or in variant expression 
could account for different 5HT4 receptor levels seen across species in which Aβ has accumulated 
(for example, if the C-termini of 5HT4 receptors react to intracellular Aβ). As 5HT4 receptor 
expression was not altered in synaptosomal extracts from 19-20 month-old Tg2576 mice in 
Experiment 8, this thesis provides no evidence suggesting this receptor may be involved in the 
hedonic and cognitive deficits revealed in Chapters 3 and 4, respectively. However, targeting this 
receptor could still prove useful as an approach for lowering Aβ levels and, given that 5HT4 receptor 
agonists have improved cognition and hedonic behaviour in mice (Hagena & Manahan-Vaughan, 
2017; Lucas et al., 2007), it would be interesting to see whether such drugs could improve the 
Tg2576 behavioural deficits seen in Chapters 3 and 4. Importantly, prior studies assessing the impact 
of 5HT4 receptor knockout and agonism on mouse hedonic behaviour have used raw sucrose 
solution intake as a hedonic index (Amigó et al., 2016; Lucas et al., 2007). Gauging the impact of 
activating 5HT4 receptors using a more appropriate technique such as lick cluster analysis would 
provide a more informative measure of hedonic responsiveness. Lastly, ketamine treatment had no 
observable effect on hippocampal or cortical 5HT4 receptor expression in either Tg2576 or wild-type 
mice. While some component of the antidepressant effect of ketamine may depend upon 
serotonergic signalling (du Jardin et al., 2016; Gigliucci et al., 2013; Pham et al., 2017; Yamanaka et 
al., 2014), the treatment itself does not appear to alter 5HT4 receptor expression. 
  
5.6.3 SERT expression 
 Experiment 8 also revealed that synaptic SERT expression was not altered in 19-20 month-
old Tg2576 hippocampus, but was elevated in Tg2576 cortex compared with wild-type mice. This 
156 
 
differs from a previous report showing reduced SERT expression in Tg2576 hippocampus (Tajeddinn 
et al., 2015), however, the same caveats mentioned above regarding differing 5HT1B receptor results 
apply. That is, the Tajeddinn et al study used all female (behaviourally naïve) Tg2576 mice, and 
appeared to examine hippocampal lysate rather than synaptosomal extracts, whereas this thesis 
used all male Tg2576 mice which had undergone multiple behavioural tests, and examined 
synaptosomal SERT expression, which could account for differences in observed hippocampal 
results. The Tg2576 elevated cortical SERT expression seen in Experiment 8 is contrary to studies in 
APP/PS1 mice, in which SERT expression is reduced in the dorsal raphe (Metaxas et al., 2018), and 
frontal and parietal cortex (Metaxas et al., 2019), however, again these were studies using 
exclusively or overwhelmingly female mice. In addition, APP/PS1 mice also display a loss of 
serotonergic axons with age in parts of the hippocampal formation, as well as in motor and barrel 
cortex (Liu et al., 2008). However, this latter study did not report the sex of mice used, and also 
examined mice only harbouring the Swedish APP mutation, expressed in Tg2576 mice, which did not 
display any abnormalities in serotonergic axonal density (Liu et al., 2008). Further, SERT expression 
has also been studied in male 3xTgAD mice, which show an increase in SERT-immunoreactive fibre 
density in the stratum molecular layer of CA1 (Noristani, Meadows, Olabarria, Verkhratsky, & 
Rodríguez, 2011; Noristani, Olabarria, Verkhratsky, & Rodríguez, 2010). The present literature on 
whether SERT expression is altered in Alzheimer’s disease mouse models is thus unclear, and 
comparisons across studies are difficult due to differences in the sex of mice used, specific mutations 
and pathology present (i.e. PS1 and tau mutations, tau or accelerated Aβ pathology), the cellular 
fraction investigated, and the technique being used (e.g. Western blotting or 
immunohistochemistry). Experiments comparing SERT expression in both Alzheimer’s disease mouse 
models and human patients, of both sexes, may resolve the apparently contradictory findings. 
 It is not immediately obvious what explains the elevated Tg2576 cortical SERT expression 
seen in this chapter. While the report of Metaxas et al using APP/PS1 mice did not report an increase 
in cortical SERT expression, their study did reveal that Aβ40 diminishes the activity of SERT in terms 
of serotonin uptake (Metaxas et al., 2019). Given that ketamine treatment in this thesis only reduced 
soluble Aβ42, not Aβ40, in Tg2576 mice, then the increased Tg2576 cortical SERT expression across 
treatment groups could represent a compensatory response to lowered SERT activity. Other 
possibilities could include a response to changes in serotonin availability or the activity of other 5HT 
receptors not investigated, though this would need to be confirmed by further study. Whether this 
SERT alteration in Tg2576 mice could relate to the hedonic deficit documented in Chapter 3 is 
unclear. There is some limited preclinical evidence potentially linking SERT with anhedonia, in that 
hippocampal SERT reduction has co-occurred with anhedonic behaviour (Tang et al., 2014, 2013), 
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and fluoxetine treatment both increased SERT and improved hedonic behaviour (measured by 
sucrose preference test) (Tang et al., 2013). However, this does not directly link SERT with anhedonia 
and involves a SERT reduction rather than elevation. Further investigations of SERT in Tg2576 mice, 
such as the functionality of SERT in this mouse model, and whether specifically targeting SERT 
improves hedonic behaviour as measured by lick cluster analysis, would be useful. 
  
5.6.4 Opioid receptor expression 
 The three major opioid receptors (mu, kappa, and delta) were also investigated in Tg2576 
mice as potential mediators of the hedonic deficit detailed in Chapter 3. While delta opioid receptor 
expression was not altered in Tg2576 mouse cortex, hippocampal mu expression was increased in 
vehicle-treated Tg2576 mice, and cortical mu expression was non-significantly elevated in Tg2576 
mice overall. Importantly, kappa opioid receptor expression was greater in Tg2576 mouse cortex. In 
general, studies of depressive behaviour in rodents have revealed that agonism of mu and delta 
opioid receptors has an anti-depressant effect, while kappa opioid receptor agonism has a pro-
depressive effect (Lutz & Kieffer, 2013). In addition, several behavioural studies have suggested that 
the kappa receptor could mediate anhedonia specifically. For example, kappa opioid receptor 
agonists increase the intra-cranial self-stimulation threshold in rats (Carlezon et al., 2006; 
Todtenkopf, Marcus, Portoghese, & Carlezon, 2004), which is taken as an indicator of anhedonia 
(Der-Avakian & Markou, 2012). Kappa receptor agonists also decrease mouse self-grooming in the 
splash test (Butelman, McElroy, Prisinzano, & Kreek, 2019), something also used as an indicator of 
anhedonia. Such behavioural changes can be prevented or diminished by the use of kappa opioid 
receptor antagonists (Butelman et al., 2019; Chartoff et al., 2012), and there is interest in the use of 
kappa opioid receptor antagonists as antidepressant and anti-anhedonic agents (Carlezon & Krystal, 
2016; Peciña et al., 2019). While these behavioural studies have not used direct measures of hedonic 
behaviour or response, there is speculation that hedonic tone is balanced on the one (positive) side 
by mu and delta opioid receptors, and on the other (negative) side by kappa opioid receptors (Bailey 
& Husbands, 2018). If this is indeed the case, then the increase in kappa opioid receptors in Tg2576 
cortex could decrease the hedonic response of Tg2576 mice, and the non-significant mu opioid 
receptor increase could potentially represent a compensatory process. Importantly, this Tg2576 
cortical kappa opioid receptor increase was not present at 4-5 months of age, an age when Tg2576 
mice show normal hedonic functioning. This is not direct proof that the elevated kappa opioid 
receptor expression seen in Tg2576 cortex mediates the hedonic deficit seen in these mice. 
However, given the linkage of the kappa opioid receptor with other, less direct, measures of 
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anhedonia, the results of this chapter are certainly suggestive that the kappa opioid receptor could 
underlie the hedonic deficit seen in Tg2576 mice. 
 Opioid receptors have not previously been investigated in Alzheimer’s disease mouse 
models, and so this is not only the first report of an altered opioid receptor system in such a mouse 
model, but also pairs the kappa receptor elevation with a hedonic deficit which it may mediate. 
However, the functional status of kappa opioid receptors in Tg2576 mice is not known, and future 
studies should measure not only receptor expression and functionality, but also the levels of the 
endogenous ligands which activate opioid receptors, such as dynorphins, enkephalins and β-
endorphin, in order to provide a full picture of the opioid system in Tg2576 mice. Investigating the 
potential mechanism underlying this kappa receptor elevation is also important, whether it be a 
direct result of Aβ accumulation, or a response to the consequences of Aβ, such as excitotoxicity or 
inflammation. A critical follow-up to this finding of increased kappa opioid receptor expression in 
Tg2576 mice would be trialling a kappa receptor antagonist in these mice, in order to ameliorate 
their hedonic deficit. It is noteworthy in this context that ketamine treatment failed to improve the 
hedonic behaviour of Tg2576 mice, and also failed to reduce kappa opioid receptor expression. 
However further work is needed to establish whether these two phenomena are directly related. 
  
5.6.5 Glutamate receptor subunits 
 The NMDAR and AMPAR profile revealed in Experiment 7 suggests that the glutamatergic 
system in these 19-20 month-old Tg2576 mice is selectively rather than generally altered. That is, 
Tg2576 mice show a reduction in the hippocampal p-Y1472 NR2B:total NR2B subunit ratio within the 
NMDAR, while the NR1 subunit, along with AMPAR subunits GluR1 and p-Ser845 GluR1, did not 
differ between genotypes. Importantly, this relative reduction in NR2B phosphorylation was not 
seen in younger (4-5 month-old) Tg2576 mice. In addition, PSD-95 expression was not disturbed in 
Tg2576 mice. Some of these findings are in keeping with previous studies while others are distinct 
from prior reports. For example, cultured cortical Tg2576 neurons have shown lowered surface NR1 
availability (Snyder et al., 2005), whereas a change in synaptic NR1 expression was not seen in 
Tg2576 hippocampal tissue in this chapter. The same study which revealed this NR1 internalisation 
also demonstrated that NR2B endocytosis and dephosphorylation at Y1472 are induced by Aβ in 
cultured neurons (Snyder et al., 2005), which is consistent with the relatively reduced NR2B 
phosphorylation observed in Tg2576 hippocampus in Experiment 7. Reductions in both NR2B and p-
Y1472 NR2B have also been observed in cortical synaptosomal fractions from 9 month-old and 12 
month-old, but not 3 month-old, Tg2576 mice (Kurup et al., 2010; Zhang et al., 2010), which 
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reinforces the finding in this chapter that synaptic NR2B (Y1472) dephosphorylation appears to be an 
age-related occurrence in Tg2576 mice. This could suggest that changes in the phosphorylation state 
of the NR2B subunit in Tg2576 mice occur gradually as Aβ accumulates, either due to Aβ acting on 
NMDARs or as a compensatory response to Aβ-induced changes. 
 These glutamatergic receptor components were primarily investigated in relation to the 
Tg2576 object-in-place deficit documented in Chapter 4. In this context it is notable that PDAPP 
mice, which develop an object-in-place deficit with age, have shown a strikingly similar profile of 
reduced p-Y1472 NR2B:total NR2B ratio in hippocampal synaptosomes, while NR1, NR2B and PSD-95 
were unaltered (Evans et al., 2019). Importantly, administration of an antibody which lowered 
soluble Aβ levels in the hippocampus, and increased NR2B phosphorylation at the Y1472 residue, 
abolished the object-in-place task deficit in PDAPP mice. The importance of the NR2B subunit in 
object-in-place task performance was confirmed in this study by a further experiment, in which a 
selective NR2B antagonist administered to wild-type mice impaired their performance in the object-
in-place task (Evans et al., 2019). The reduction in the ratio of hippocampal phosphorylated to total 
NR2B, at the tyrosine 1472 residue, could therefore account for the Tg2576 object-in-place deficit. 
NMDARs in general are thought to allow for the encoding of memories (Morris, 2013), and inhibition 
of NMDARs in the hippocampus prevents acquisition but not retrieval of object-in-place memory 
(Barker & Warburton, 2015). The NR2B subunit of the NMDAR is at least partially responsible for LTP 
induction, and is particularly important in mediating synaptic plasticity and information acquisition 
by interacting with CamKII (Shipton & Paulsen, 2014). The tyrosine 1472 residue is the major 
phosphorylation site on the NR2B subunit, and its phosphorylation promotes synaptic retention 
while dephosphorylation encourages endocytosis of the NMDAR (Prybylowski et al., 2005; Zhang, 
Edelmann, Liu, Crandall, & Morabito, 2008). A relative reduction in the availability of NMDARs, 
caused by dephosphorylation, would thus presumably mean diminished NMDAR currents, and a 
compromised facility to encode object-in-place information in Tg2576 mice. As synaptosomal 
preparations can contain endocytotic vesicles (Bai & Witzmann, 2007), the reduced hippocampal 
NR2B phosphorylation ratio in Tg2576 mice may indicate that there are less NR2B subunit-containing 
NMDARs present at the membrane surface, which would be consonant with a failure of information 
encoding in Tg2576 mice. This altered NR2B phosphorylation status could be a response to the 
accumulation of Aβ in Tg2576 mice, as Aβ can activate NMDARs both directly (Texidó et al., 2011), 
and indirectly by increasing glutamate availability (Li et al., 2009; Talantova et al., 2013). Such direct 
and indirect NMDAR activation could lead to NR2B dephosphorylation as a method of decreasing 
excitotoxicity (Liu et al., 2007). 
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 While a selective NMDAR subunit disturbance which could contribute to the Tg2576 object-
in-place deficit was found in this chapter, no reductions in synaptic GluR1, p-Ser845 GluR1 or PSD-95 
were found in Tg2576 mice. This is in contrast to other studies in which Tg2576 cultured neurons 
show reductions in GluR1 and PSD-95 (Almeida et al., 2005), and Tg2576 mouse hippocampus shows 
trafficking of GluR1 away from the synapse and an overall reduction in p-Ser845 GluR1 (D’Amelio et 
al., 2011). The fact that these changes were not found in the present results could be explained by 
the fact that the GluR1 and p-Ser845 GluR1 changes were found in young Tg2576 mice, meaning 
that GluR1 levels could potentially readjust over time. Another difference is the extensive 
behavioural testing schedule all aged mice went through in this thesis, which could in and of itself 
produce biochemical changes. For example, Tg2576 mice exposed to only 6 days of water maze 
training show an increased presence of GluR1 and PSD-95 in the hippocampus, while NR2B remained 
unaffected (Jiang et al., 2015). Therefore there could potentially be some contribution of GluR1 
and/or PSD-95 to the Tg2576 object-in-place deficit under ‘typical’ conditions, and the use of 
repeated cognitive testing may obscure their impact. 
 While the use of sub-anaesthetic ketamine treatment reduced soluble Aβ42 levels, it did not 
alter NR2B phosphorylation and failed to improve Tg2576 performance in the object-in-place task. 
As the current, broadly accepted hypothesis of Alzheimer’s disease is that Aβ is the beginning of a 
pathogenic cascade (Selkoe & Hardy, 2016), one interpretation of these possible incongruities is 
simply that by 19-20 months of age the pathological cascade in Tg2576 mice is well established, with 
a number of neuronal insults being long-present and unaffected by Aβ reduction by this point. If this 
is the case, an earlier intervention with ketamine, coupled with a longer treatment duration, could 
be a more sensible intervention. Other possible interpretations include there being an Aβ threshold 
for cognitive (and hedonic) impairments (both in terms of behaviour and underlying biochemistry), 
below which ketamine treatment did not push the Aβ concentration. There could also possibly be 
roles for Aβ40, which was not reduced by ketamine, and Aβ plaques (as insoluble Aβ was not 
reduced) which can act as reservoirs of soluble Aβ. It is possible that in older Alzheimer’s disease 
model mice, which have already accrued a number of behavioural deficits, treatments that either 
specifically target precise neurotransmitter systems, or have this targeted effect alongside an Aβ-
lowering approach, may be the most effective. For example, the study of Evans et al found that an 
antibody aimed at lowering Aβ production reduced both soluble Aβ40 and increased NR2B 
phosphorylation in PDAPP mouse hippocampus, and rescued performance in the object-in-place task 
(Evans et al., 2019). This distinction in terms of affecting or not affecting NR2B phosphorylation may 
explain the difference in behavioural effects of these two Aβ-lowering agents. Potentially Aβ was for 
some reason more sensitive to the effects of ketamine than was the NR2B subunit, or a higher 
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ketamine dose may have been needed to alter NR2B phosphorylation. While ketamine treatment 
did, however, generally increase both GluR1 and p-Ser845 GluR1 in Tg2576 (and wild-type) mice, it is 
not surprising that this did not improve object-in-place performance, as the Tg2576 deficit may be a 
specific result of an NR2B-containing NMDAR deficiency in the hippocampus. 
 In sum, the results of this chapter reveal specific disturbances to the glutamatergic, 
opioidergic and serotonergic neurotransmitter systems in 19-20 month-old Tg2576 mice. Namely, 
these are a relative decrease in hippocampal NR2B Y1472 phosphorylation, and increased expression 
of cortical kappa opioid receptor, hippocampal mu opioid receptor (in a subset of mice), and cortical 
SERT. The kappa and mu opioid receptor changes may indicate an unbalanced hedonic tone which is 
weighted towards anhedonia, and the NR2B dephosphorylation may relate to a failure to encode 
object-location associations. The effect of the cortical SERT increase, however, is unclear. While 
these changes may be the result of a protracted period of Aβ accumulation, reducing Aβ levels with 
ketamine did not relieve these behavioural problems. This suggests either more targeted treatments 
or alternative ketamine regimens should be trialled in future behavioural studies. Further 
interpretations of the results of this chapter, along with the broader implications of this thesis as a 
whole, will be considered next.
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Chapter 6: General Discussion 
 
6.1 Summary of results 
 The aims of this thesis were to profile hedonic and cognitive behaviour in Tg2576 mice, using 
lick cluster analysis and the object-in-place task, respectively. A longitudinal approach was used in 
these tasks, as age-related deteriorations would be consistent with chronic Aβ accumulation rather 
than APP overexpression per se. Further, ketamine treatment and the biochemistry potentially 
underlying the behavioural deficits were investigated, including a young cohort analysed to control 
for the simple presence of APP overexpression. In Chapter 3, Experiment 1 revealed an age-
dependent decrease in lick cluster size in Tg2576 mice, consistent with a hedonic deficit, although 
the age by genotype interaction was only found to be significant in a secondary statistical analysis. 
The absence of this hedonic deficit in Tg2576 mice at 4-5 months of age was consistent with it being 
an Aβ-related impairment, rather than being attributable to APP overexpression per se. Experiment 
2 in Chapter 3 revealed that sub-anaesthetic ketamine, at a dose generally beneficial in alleviating 
depressive behaviour in other rodent studies, failed to improve hedonic responsiveness in Tg2576 
mice at 19 months of age. 
 The cognitive ability of Tg2576 mice was examined longitudinally in Chapter 4, using the 
object-in-place task. Experiment 3 did not directly establish an age-dependent cognitive deficit in 
Tg2576 mice using this task, which may have been due to lower object contact times with repeated 
testing interfering with task performance. Nonetheless, a cognitive deficit in this task was present in 
Tg2576 mice at 16-17 months of age, but not at any previous time points. In Experiment 4 of Chapter 
4, sub-anaesthetic ketamine treatment also had no impact on object-in-place task performance at 
19-20 months of age, which remained deficient in Tg2576 mice. A T-maze task examining spatial 
novelty preference (Experiment 5) was introduced at this final time point, in order to investigate 
cognition in a task not reliant upon object contact, which found that Tg2576 mice were not impaired 
in spatial novelty preference, suggesting a profound spatial memory deficit was not present. As was 
discussed in Chapters 2 and 4, studies of object recognition in Tg2576 mice have revealed what 
appears to be a selective deficit in object-in-place memory, in that memory for other object 
manipulations, such as object location novelty, remains intact (Good & Hale, 2007). It therefore 
seems reasonable to infer that this dissociation reflects the fact that binding specific object-location 
configurations and recognising objects in novel locations depend upon different memory processes. 
The T-maze data from Experiment 5, in which spatial novelty detection appears intact, or at the very 
least not obviously impaired, in Tg2576 mice with an object-in-place memory deficit, would seem to 
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be in keeping with this observation. However, object location novelty and T-maze spatial novelty 
testing are not perfectly matched tasks, and so a simple difference between the two in task 
sensitivity cannot be ruled out. 
 Despite not improving Tg2576 mouse behavioural performance, ketamine treatment was 
associated with reduced soluble Aβ42 in both hippocampus and cortex, in Experiment 6 of Chapter 
5. Insoluble Aβ42, and both forms of Aβ40, however, were not decreased by ketamine treatment. 
Experiment 7 (Chapter 5) revealed that many of the glutamate receptor subunits examined (NR1, 
NR2B, p-NR2B, GluR1, p-GluR1 and phosphorylated:total GluR1) were generally unaltered in 
synaptosomal extracts from Tg2576 mice, while phosphorylated:total NR2B (Y1472) expression was 
reduced in Tg2576 hippocampus, consistent with a failure of NMDAR-enabled encoding in the 
object-in-place task. Despite not improving task performance, ketamine treatment did increase 
expression of all GluR1 measures in Tg2576 mouse hippocampus. 
 When transmitter systems related to depression were investigated, Experiment 8 in Chapter 
5 demonstrated that the hippocampal and cortical synaptosomal profile of 5HT1B, 5HT4 and SERT 
expression was generally similar between Tg2576 and wild-type mice, with the exception of Tg2576 
mice possessing elevated cortical SERT expression. Further, examination of the opioidergic system in 
Experiment 8 revealed that Tg2576 mice displayed elevated kappa receptor expression in the cortex, 
and an elevation of one mu receptor isoform in the hippocampus. While there was a suggestion of 
elevated cortical mu in Tg2576 mouse cortex, delta receptor expression was not meaningfully 
different between Tg2576 and wild-type mouse cortex. While the relevance of elevated cortical SERT 
in Tg2576 mice was uncertain, increased kappa receptor expression was proposed to mediate a 
negative hedonic tone, accounting for the Tg2576 hedonic dysfunction seen in Chapter 3. Elevated 
hippocampal mu opioid receptor in a subset of Tg2576 mice, and the suggestion of a mu increase in 
Tg2576 cortex, could represent a compensatory process. However, there was also the suggestion of 
elevated cortical mu opioid receptor expression in young Tg2576 mice, and therefore this particular 
observation may be unrelated to aging and Aβ. Ketamine treatment had no observable impact on 
any of the serotonergic or opioidergic receptors investigated. Importantly, Experiment 9 in Chapter 5 
revealed that at 4-5 months of age, when no Tg2576 hedonic or cognitive deficit was present, none 
of the biochemical measures in which aged Tg2576 mice differed from wild-type mice (hippocampal 
phosphorylated:total NR2B ratio, cortical kappa, hippocampal mu, cortical SERT) were significantly 
different between genotypes. This supported the view that these biochemical changes were a result 
of, or downstream from, Aβ accumulation, rather than being caused by APP overexpression per se. 
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 Taken together, the results of these experiments provide tentative answers to several 
questions posed by this thesis. Firstly, the fact that an age-related hedonic deficit was profiled in 
Tg2576 mice suggests that Aβ pathology is sufficient to produce anhedonic behaviour, though the 
precise mechanisms by which this could occur, and the brain regions this may take place within, 
require further investigation. Importantly, this does not discount tau species or neurodegeneration 
as other salient pathological events which could disrupt hedonic functioning in the course of 
Alzheimer’s disease. This does, however, suggest that depressive symptoms such as anhedonia could 
be an early (that is, pre-clinical) manifestation of Alzheimer’s disease. In addition, the biochemical 
results of this thesis indicate that the opioid system in Tg2576 mice may be altered as a result of Aβ 
accumulation, and that elevated kappa opioid receptor expression may represent an imbalance in 
hedonic tone which skews reward processing towards anhedonia. However, the route by which Aβ 
might be causing this disturbance is not known, though some speculation will be offered in Section 
6.2. In addition, though a clear and fully informative cognitive profile in aging Tg2576 mice could not 
be obtained due to the effects of repeated testing, this thesis did confirm the presence of a Tg2576 
object-in-place deficit from 16-17 months of age onwards. This memory impairment being present in 
aged Tg2576 mice, but absent in younger mice, is consistent with it being due to Aβ pathology. 
Examination of synaptic receptor-driven mechanisms which could account for this cognitive deficit 
suggested that this is an NMDAR-related dysfunction, consistent with a failure to encode specific 
object-location memories. However, owing to the longitudinal experimental design, impairments in 
AMPAR function that may disrupt object-in-place performance in Tg2576 mice could have been 
obscured, and therefore cannot be entirely ruled out. Lastly, one aim of the thesis was to investigate 
the use of a novel treatment for alleviating these hedonic and cognitive deficits, to which end sub-
anaesthetic ketamine was trialled. While the particular dose and regimen used did not improve 
either of these impairments in Tg2576 mice, broad and firm conclusions should not be drawn from 
these null results, and this will be commented on further in Section 6.5. 
 
6.2 Outstanding considerations relating to Tg2576 behavioural deficits 
 The view presented in this thesis thus far is that the hedonic deficit which develops in 
Tg2576 mice could be attributed to an altered opioidergic system, represented by an increase in 
cortical kappa receptor expression. In addition, the cognitive deficit that eventually manifested in 
Tg2576 mice has been understood in terms of a disturbed synaptic NMDAR function. However, there 
are other biological systems or events which could, individually or through interplay with one 
another, also contribute to the Tg2576 behavioural deficits documented in this thesis. In particular, 
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inflammation, the glutamatergic system and reduced synaptic or functional connectivity could also 
underlie hedonic dysfunction, while the opioidergic and cholinergic systems could contribute to 
impaired cognition, all of which may be caused by Aβ accumulation. These additional processes, and 
how they might relate to the results reported in this thesis, will be considered in turn. 
 
6.2.1 Inflammation and anhedonia 
 Studies in both rodents and humans demonstrate that anhedonia may feature an 
inflammatory component. In otherwise healthy individuals who were administered an inflammation-
inducing endotoxin, left ventral striatum activity when anticipating a monetary reward was reduced, 
which also mediated the relationship between endotoxin challenge and an increase in observer-
rated depressed mood (Eisenberger et al., 2010). In rodents, inflammatory mediators such as IL-1β 
and TNF-α, and the inflammation-inducing agent lipopolysaccharide (LPS), diminish the consumption 
of, or preference for, palatable solutions in rodents (Brebner, Hayley, Zacharko, Merali, & Anisman, 
2000; Henry et al., 2008). Taken together, such studies suggest that inflammation can be sufficient 
to disrupt hedonic functioning. Of note here is that Aβ activates multiple aspects of the innate 
immune system (Salminen, Ojala, Kauppinen, Kaarniranta, & Suuronen, 2009), and several studies 
have reported that Tg2576 mice exhibit neuroinflammation and a profile of elevated pro-
inflammatory cytokines (Abbas et al., 2002; Apelt & Schliebs, 2001; Benzing et al., 1999; Sly et al., 
2001). Therefore the hedonic deficit which develops in Tg2576 mice could contain an inflammatory 
component, resulting from gradual Aβ accumulation. 
 One specific consequence of neuroinflammation in Tg2576 mice which could produce 
anhedonia is activation of the kynurenine pathway. Pro-inflammatory cytokines induce the 
expression of indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme in the 
conversion of tryptophan to kynurenine (Swardfager, Rosenblat, Benlamri, & McIntyre, 2016). 
Following the metabolism of tryptophan to kynurenine by IDO and other enzymes, kynurenine is 
then further metabolised to damaging compounds such as 3-hydroxy-kynurenine (3-HK), 3-hydroxy-
anthranilic acid (3-HAA) and quinolinic acid (Schwarcz, Bruno, Muchowski, & Wu, 2012). While 3-HK 
and 3-HAA induce oxidative stress by generating free radicals, quinolinic acid is an NMDAR agonist 
and excitotoxin, revealing an overlap between inflammation and NMDARs (Schwarcz et al., 2012; 
Swardfager et al., 2016). The kynurenine pathway, specifically IDO activity, has been correlated with 
anhedonia scores in both major depressive disorder and combined depressed and non-depressed 
adolescents (Gabbay, Ely, Babb, & Liebes, 2012). Further, the ratio of serum kynurenic acid to 
quinolinic acid negatively correlates with anhedonia severity in patients with major depressive 
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disorder (Savitz et al., 2015). This suggests that redirection of the kynurenine pathway away from 
kynurenic acid and towards quinolinic acid production may be important in inflammation-induced 
anhedonia. These studies thus reveal a route by which Aβ-provoked inflammation could 
theoretically disrupt hedonic functioning in Tg2576 mice, with the stimulation of pro-inflammatory 
cytokines inducing IDO expression, activating the kynurenine pathway and then increasing 
production of quinolinic acid relative to kynurenic acid. In fact, studies using Alzheimer’s disease 
brain, transgenic mice, and cultured cells lend support to the notion that Aβ could have such an 
effect. 
 Post mortem investigation of Alzheimer’s disease brain has revealed that in the 
hippocampus, microglia and astrocytes express the greatest amount of IDO and quinolinic acid in the 
vicinity of Aβ senile plaques (Guillemin, Brew, Noonan, Takikawa, & Cullen, 2005), suggesting a 
stimulatory effect of Aβ on the kynurenine pathway, mediated by neuroinflammation. Further, 
3xTgAD mice display an increase in hippocampal quinolinic acid production with age (Wu et al., 
2013), consistent with, though not direct proof of, a role of Aβ. The role of Aβ has, however, been 
directly demonstrated in a cell culture study, which revealed that application of Aβ induces IDO 
expression and quinolinic acid production in human primary macrophages and microglia (Guillemin, 
Smythe, Veas, Takikawa, & Brew, 2003). The kynurenine system has been indirectly examined in 
Tg2576 mice, in which IDO expression was measured (Akimoto, Yamada, & Takikawa, 2007). While 
this study found no difference between 8-11 month old Tg2576 and wild-type mice in brain IDO 
expression, this used a relatively small number of mice and only investigated whole brain activity 
rather than activity in discrete brain regions. However, even with these limitations, this study did 
reveal that once Tg2576 mice have been exposed to a pro-inflammatory insult (LPS), IDO activity was 
greatly increased, suggesting to the authors that microglia in Tg2576 mice are primed to ‘overreact’ 
to an inflammatory challenge. While nothing conclusive can be stated from this one result, taken 
together with the broader literature, this does suggest that pro-inflammatory cytokines activating 
the kynurenine pathway could potentially bear upon hedonic dysfunction in Tg2576 mice, as a result 
of Aβ activity. 
 A broader related point about inflammation and anhedonia in the context of Alzheimer’s 
disease is that inflammation itself could represent a common pathway partially accounting for 
anhedonia occurring alongside Alzheimer’s disease. For example, variants of CD33 and TREM2, both 
of which genes are associated with inflammatory activity, have been identified as genetic risk factors 
for Alzheimer’s disease (Jonsson et al., 2013, Naj et al., 2011). As inflammation may represent one 
risk factor underlying Alzheimer’s disease, and because there may also be an inflammatory 
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component of anhedonia, it is possible that one mechanism by which anhedonia occurs in 
Alzheimer’s disease is through inflammatory activity which contributes to both phenomena. 
 
6.2.2 Glutamate and anhedonia 
 In addition to inflammation, altered glutamate signalling or availability also appears to 
contribute to anhedonia. In major depressive disorder patients, both glutamate concentrations and 
negative blood oxygenation level-dependent (BOLD) responses to emotional stimulation in the 
pregenual ACC correlated with emotional intensity ratings, which was used as a surrogate measure 
of anhedonia (Walter et al., 2009). A more recent study has reported that glutamate concentration 
in the basal ganglia positively correlated with self-reported anhedonia subscale score (Haroon et al., 
2016), suggesting that altered glutamate levels or glutamatergic signalling may be a component of 
anhedonia. Similarly, preventing the uptake of glutamate by astrocytes, thus increasing its 
availability, results in increased ICSS thresholds in rodents (Bechtholt-Gompf et al., 2010; John et al., 
2012), a behaviour typically interpreted as anhedonic. Cell culture experimentation has shown that 
Aβ stimulates the release of glutamate from both rat and human astrocytes (Talantova et al., 2013), 
and that Aβ42 prolongs the availability of extracellular glutamate by reducing surface expression of 
the glutamate transporter GLT-1 in mouse astrocytes (Scimemi et al., 2013). While this thesis did not 
examine glutamate concentration, an Aβ-induced increase in either glutamate concentration or time 
available at the synapse could be a contributor to hedonic dysfunction in Tg2576 mice. This 
possibility is supported by the fact that in Tg2576 hippocampal slices, transient astrocytic internal 
Ca2+ elevations occurred with greater frequency, and NMDAR-mediated slow inward currents were 
enhanced in CA1 neurons, when compared with slices from wild-type littermates (Pirttimaki et al., 
2013). These findings are consistent with enhanced astrocytic glutamate release due to Aβ 
(Pirttimaki et al., 2013). Whether this does in fact pertain to hedonic behaviour in Tg2576 mice, 
however, requires investigation. 
 Alongside disturbances in synaptic concentration or availability of glutamate itself, specific 
alterations in glutamate receptor subunits may also disrupt hedonic functioning. For example, mice 
in which the GluR1 serine 831 phosphorylation site has been mutated to alanine, preventing its 
phosphorylation by CamKII, display a reduced sucrose preference (Cai et al., 2013), suggesting that 
impaired glutamate signalling and synaptic plasticity may lead to anhedonia in rodents. Such a view 
seems to be further validated by the fact that GluR1 knockout mice display anhedonic behaviour 
when lick cluster size in response to palatable fluids is investigated (Austen et al., 2017). Taken 
together, such studies may suggest that the glutamate transmitter system is involved in hedonic 
168 
 
behaviour or experience, with normal hedonic functioning mediated at least in part by tightly 
regulated glutamate activity. Hedonic dysfunction may arise if glutamatergic signalling becomes 
deregulated, either by being dampened down (as in loss of GluR1-containing AMPARs) or excessively 
activated (e.g. an overabundance of glutamate). Interestingly, this thesis has documented hedonic 
dysfunction in Tg2576 mice in which GluR1 was not diminished in synaptosomal extracts. One 
possibility may be that there are multiple biochemical pathways which can diminish or interrupt 
hedonic processing. Within such a view, GluR1 absence may lead to anhedonia, but so equally might 
an imbalance in hedonic tone caused by increased kappa opioid receptor expression, as might an 
increase in pro-inflammatory cytokines and subsequent activation of the kynurenine pathway. 
Therefore the fact that this thesis reported a hedonic deficit whilst not revealing a GluR1 deficiency 
is not necessarily surprising. In addition, while this thesis found that phosphorylation of the Ser845 
GluR1 site in Tg2576 mice was generally similar to that of wild-type mice, it did not investigate the 
Ser831 site, and so cannot speak to the possibility that this site could be involved in a Tg2576 
hedonic deficit. Further, while this thesis did not find a GluR1 deficiency in Tg2576 mice, it did reveal 
a reduction in the hippocampal phosphorylated:total NR2B ratio at the Y1472 residue. Therefore 
another possibility is that glutamate receptor dysfunction is an important facet of anhedonia, but 
that multiple receptors within the glutamate system can mediate hedonic dysfunction, something 
which will be revisited in the next section. 
 
6.2.3 Reduced synaptic and/or functional connectivity and anhedonia 
 One further consideration in how the effects of Aβ, either directly by synapse loss or 
indirectly by other means, could produce anhedonia is in terms of loss of synaptic or functional 
connectivity. Impaired connectivity in the brain’s reward network has been linked to anhedonia, in 
adolescent depressive patients for example (Gabbay et al., 2013). In these patients, anhedonia 
severity negatively correlated with functional connectivity between the left nucleus accumbens and 
subgenual ACC and caudate, and right nucleus accumbens and occipital fusiform cortex (Gabbay et 
al., 2013). In addition, disturbed corticostriatal functional connectivity has been reported in people 
with social anhedonia (Wang et al., 2016). In patients with major depression, C-reactive protein (a 
general inflammatory marker) positively correlates with decreased ventral striatum and 
ventromedial PFC connectivity, and this decreased connectivity correlates with greater anhedonia 
(Felger et al., 2016). Such losses of connectivity and potential subsequent anhedonia could be 
produced by Aβ, as in both clinically normal and mild cognitive impairment patients, the presence of 
Aβ is associated with degraded functional connectivity between cortical structures (Drzezga et al., 
2011; Hedden et al., 2009). The fact that these connective interruptions can be seen in clinically 
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normal and MCI patients suggests that they may be an early Aβ-related event in Alzheimer’s disease, 
and could plausibly contribute to hedonic dysfunction in Tg2576 mice. 
 A recent hypothesis which may explain the link between connectivity and hedonic function 
is the ‘excitatory synapse hypothesis’ of depression (Thompson et al., 2015). This posits that when 
specific subsets of excitatory (that is, glutamatergic) synapses within the brain’s reward network 
become weakened, the resulting diminished activity in reward circuitry, for example, can lead to 
depressive symptoms such as anhedonia. In such a light, antidepressant treatments such as SSRIs, 
electroconvulsive therapy and ketamine are thought to owe their effectiveness to their ability to 
strengthen excitatory synapses. As Aβ is known to reversibly reduce synapse number by interacting 
with NMDARs, which are expressed at excitatory synapses (Shankar et al., 2007), as well as disrupt 
synapse function (Mucke & Selkoe, 2012), then the degradative effects of Aβ at excitatory synapses 
could possibly disrupt connectivity between nodes in the reward system. Such an effect could be 
sufficient to produce anhedonia in Tg2576 mice. The finding in this thesis that aged Tg2576 mice 
show a reduction in hippocampal NR2B Y1472 phosphorylation, relative to total NR2B expression, 
may indicate a diminished availability of active NMDARs and thus impaired excitatory synaptic 
transmission. If this state exists in reward-related brain regions in Tg2576 mice, then this impaired 
system may disrupt hedonic processing, consistent with the ‘excitatory synapse hypothesis’. 
 
6.2.4 Summary of Tg2576 hedonic deficit interpretations 
 The above remarks make the point that hedonic dysfunction in Tg2576 mice could 
potentially be the result of multiple aberrations, all of which may be caused by Aβ accumulation. 
While possibly the most compelling explanation found in this thesis is an increase in kappa opioid 
receptor expression in Tg2576 mice, and possible resultant imbalance in hedonic tone, a role of 
NMDARs, glutamate more broadly, and inflammation as concomitant insults is also possible. 
Interestingly, a subtype of depression characterised by inflammation, elevated glutamate, 
anhedonia and loss of network integrity has been proposed (Haroon et al., 2018). Given that Aβ can 
activate multiple aspects of the innate immune system (Salminen et al., 2009), increase glutamate 
availability and/or neuronal sensitivity to glutamate (Li et al., 2009; Mattson et al., 1992; Talantova 
et al., 2013), and reduce synapse function and number (Mucke & Selkoe, 2012; Shankar et al., 2007), 
then it could lie at the centre of such a syndrome. The fact that Tg2576 mice have shown in this 
thesis a behavioural state consistent with anhedonia, while other studies have reported Tg2576 mice 
showing elevated pro-inflammatory cytokines (Abbas et al., 2002; Apelt & Schliebs, 2001; Benzing et 
al., 1999; Sly et al., 2001), and neuronal activity consistent with increased astrocytic glutamate 
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release (Pirttimaki et al., 2013), suggests that such a depressive phenotype may be present in this 
mouse model, though this requires demonstrating. A further possibility is that the elevated kappa 
opioid receptor expression in Tg2576 mice shown in this thesis could be provoked by elevated 
glutamate levels, or the prolonged synaptic presence of glutamate. Kappa opioid receptors inhibit 
glutamate release in the nucleus accumbens (Hjelmstad & Fields, 2001, 2003), one site in the brain’s 
reward network, for example. Therefore changes in the opioidergic system in Tg2576 mice could 
represent a compensatory response to excitotoxicity, whether due to glutamate directly or to other 
molecules such as quinolinic acid. Taken together, these possibilities reveal that there is a rich and 
possibly interconnected repertoire of signalling events which may interact to produce anhedonia in 
Tg2576 mice, or alternatively may simply represent additive insults. Whichever of these possibilities 
may be the case, there would seem to be ample biological targets which future investigations of 
anhedonia and its treatment in Tg2576 mice could investigate. Such investigations could both reveal 
additional mechanisms underlying this hedonic deficit, and suggest further therapeutic approaches. 
 
6.2.5 Opioid receptors and cognition  
 While the Tg2576 object-in-place memory deficit has largely been discussed thus far as 
representing an NMDAR-mediated dysfunction, there are other transmitter systems which could 
also be considered. For example, while the opioidergic transmitter system has primarily been 
discussed in this thesis as a regulator of hedonic tone, opioid signalling also contributes to memory 
performance in a variety of tasks. Antagonising mu opioid receptors in the CA3 region of the 
hippocampus impairs spatial learning in the Morris water maze, and mu receptor knockout mice 
show impaired learning in both the Morris water maze and radial maze while kappa receptor 
knockout mice were unimpaired (Daumas et al., 2007; Jamot, Matthes, Simonin, Kieffer, & Roder, 
2003). The mu receptor increase seen in Tg2576 hippocampus (and possibly the suggestion of the 
same in the cortex) could therefore potentially be a compensatory process linked to both 
rebalancing hedonic tone and improving mnemonic ability. In addition, in mice exposed to forced 
swim stress, kappa opioid receptor stimulation by dynorphin appears to contribute to the stress-
induced impairment in novel object recognition (Carey, Lyons, Shay, Dunton, & McLaughlin, 2009). 
However, procedural issues with how the authors ran the object novelty experiments meant that 
object novelty was combined with relative location unfamiliarity, thus it is currently unclear how 
kappa receptors relate to either object or location processing. While no experiments in this thesis 
involved exposing mice to forced swim stress, and did not examine novel object recognition memory 
in Tg2576 mice, the possibility of a disrupted opioidergic system contributing to the Tg2576 object-
in-place memory deficit cannot be ruled out. The precise brain region and the manner in which 
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opioid receptors or their neurotransmitters could perturb object-in-place memory would require 
investigating. This thesis, for example, did not examine kappa opioid receptor expression in the 
hippocampus, and the perirhinal cortex and medial prefrontal cortex are other regions which it 
would be sensible to scrutinise, all of which contribute to object-in-place performance. 
 
6.2.6 Cholinergic receptors and cognition 
 The importance of the cholinergic system in cognition has been recognised for some time 
(Hasselmo, 2006; Warburton et al., 2003), including in studies of recognition memory in rodents 
(Barker & Warburton, 2009; Winters & Bussey, 2005), though cholinergic transmission was not 
examined in this thesis. Interrupted cholinergic signalling due to Aβ accumulation, in particular 
disturbances to nicotinic cholinergic receptors, may be an additional component of the Tg2576 
object-in-place memory deficit. Nicotinic cholinergic receptors are present on some percentage of 
hippocampal glutamatergic neurons, and increase the likelihood of LTP induction via both 
membrane depolarisation and providing a supplementary calcium influx (Dani & Bertrand, 2007), 
thus contributing to learning and memory processes. There are a number of nicotinic cholinergic 
receptors, and Aβ is known to bind to the α7nAchR with high affinity (Cecon et al., 2019; Wang, Lee, 
D’Andrea, et al., 2000; Wang, Lee, Davis, & Shank, 2000), and this binding appears to lead to the 
neuronal internalisation of both Aβ and α7nAchRs (Nagele, D’Andrea, Anderson, & Wang, 2002). The 
α7nAchR may be neuroprotective, at least earlier in the course of Alzheimer’s disease, as crossing 
Tg2576 mice with α7nAchR knockout mice results in a number of changes at 5 months of age, 
including a more severe cognitive impairment and a reduction of cholinergic markers and 
functionality in the hippocampus (Hernandez, Kayed, Zheng, Sweatt, & Dineley, 2010). This possible 
neuroprotective ability may explain why the α7nAchR is upregulated in Tg2576 mouse brain from a 
relatively young through to older age, including in the hippocampus (Bednar et al., 2002; Dineley et 
al., 2001), representing a potential compensatory response to Aβ. However, in both APP/PS1 mouse 
and human Alzheimer’s disease brain the α7nAchR appears to lose functionality in certain brain 
regions (Søderman et al., 2008; Wang et al., 2009), and because dissociating Aβ-α7nAchR complexes 
improves their functioning (Wang et al., 2009), this seems to be due to the binding of Aβ. Despite 
the observed upregulation of α7nAchR in Tg2576 mouse brain, therefore, the functionality of this 
receptor in Tg2576 mice may be compromised. The importance of this is that α7nAchRs in the 
medial prefrontal cortex are required for successful encoding by rodents in the object-in-place task 
(Sabec et al., 2018), and as such they could be another means by which task performance is impaired 
in Tg2576 mice. However, this has only been demonstrated at the longer delay period of 24 hours, 
whereas a short delay of 2 minutes was used in this thesis. Given the importance of the α7nAchR in 
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object-in-place task performance, and the fact that its functionality may be diminished in Tg2576 
mice, the cholinergic system may also contribute to cognitive impairment in Tg2576 mice. 
 
6.2.7 Summary of Tg2576 cognitive deficit interpretations 
 While this thesis has focused on hippocampal NMDARs and AMPARs as receptors of interest 
in the Tg2576 object-in-place deficit, a more nuanced understanding that multiple transmitter 
systems could feed into this deficit should be brought to bear upon future studies. There could 
potentially be a role for the opioidergic system in impaired object-in-place performance in Tg2576 
mice, as well as the cholinergic system, in particular the α7nAchR. As with the understanding of the 
Tg2576 hedonic deficit, impaired cognition in Tg2576 mice could be the result of multiple and 
potentially interlinked disturbances, all of which may be directly or indirectly due to Aβ activity. For 
example, some degree of hippocampal NMDAR disruption by Aβ could be mediated through the 
α7nAchR; the α7nAchR can form a complex with NMDARs (Li, Li, Pei, Le, & Liu, 2012), interruption of 
which interferes with the ability of cholinergic transmission to strengthen NMDAR currents and 
enhance LTP, and impairs novel object recognition (Li, Nai, Lipina, Roder, & Liu, 2013). Importantly, 
disruption of the α7nAchR-NMDAR complex can be caused by Aβ42 oligomers (Elnagar et al., 2017), 
and if Aβ oligomers have such an effect in Tg2576 mice, then this could interfere with object-in-place 
task performance, depending on the brain region such an effect occurred in. In addition, changes in 
functional connectivity, mentioned in Section 6.2.3, could be another event which degrades 
cognitive ability in Tg2576 mice, and Aβ-driven neuroinflammation may contribute to this 
disconnectivity. For instance, in patients with MCI or probable Alzheimer’s disease, higher 
neuroinflammation was associated with an altered functional connectivity profile which included 
diminished connectivity within the default mode network, though connectivity within important 
structures such as the hippocampus was not examined (Passamonti et al., 2019). Further, the 
stronger the association between inflammation and connectivity, the worse the cognition of 
patients, suggesting that the relationship between inflammation and altered connectivity could 
impair memory performance (Passamonti et al., 2019). While the relationship between 
neuroinflammation and connectivity does not appear to have been investigated in Tg2576 mice, 
impaired resting-state connectivity in this mouse model has been reported in the hippocampal 
network (Shah et al., 2016), and default mode network (Belloy et al., 2018). Given the documented 
neuroinflammation in Tg2576 mice and the ability of Aβ to provoke neuroinflammation, detailed in 
Section 6.2.1, an inflammatory response to Aβ could damage functional connectivity and thereby 
impair cognition in Tg2576 mice. In sum, the object-in-place memory deficit displayed by Tg2576 
mice could be the result of multiple events, including impaired NMDAR signalling, loss of α7nAchR 
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function, neuroinflammation and degraded connectivity, as well as potentially altered opioid 
signalling. Disentangling the relevance and timing of these multiple derangements in relation to 
Tg2576 object-in-place performance will be an important goal of future studies. 
 
6.3 Caveats concerning APP overexpressing transgenic mice 
 While APP overexpressing transgenic mice have historically been the most commonly used 
mouse models of Alzheimer’s disease, their nature confers certain limitations upon them. APP 
overexpression itself could induce behavioural or biochemical changes not directly related to Aβ 
accumulation; expressing APP at supra-physiological levels and thus over-producing other APP 
fragments, for example, can potentially induce artefactual phenotypes (Saito et al., 2016). This thesis 
has attempted to rule out the overexpression of APP per se underlying behavioural or biochemical 
changes, by both longitudinally testing mice behaviourally, and including a young cohort for 
biochemical analysis. In Tg2576 mice, levels of the APP protein itself appear to be consistently 
elevated from 2 months of age onwards (Hsiao et al., 1996; Kawarabayashi et al., 2001). The fact 
that the Tg2576 behavioural deficits profiled in Chapters 3 and 4, and the major biochemical changes 
in Chapter 5, were both absent in younger mice (4-5 months of age) but present in older mice is 
consistent with their being due to the accumulation of Aβ. However, the involvement of other APP 
fragments in these changes cannot be conclusively ruled out in this thesis. In addition to APP 
overexpression itself, other limitations of these mouse models include the use of different 
promoters, APP constructs, and specific APP mutations, which complicates the comparison of results 
across different models (Sasaguri et al., 2017).  
 A more sophisticated approach to modelling Alzheimer’s disease in mice has recently been 
established, based on the cross-breeding of mouse lines harbouring different human APP mutations, 
and the humanising of the murine Aβ sequence (Saito et al., 2014). The benefit of this approach is 
that it avoids the need for expressing APP at supra-physiological levels, thus reducing the likelihood 
of creating certain artefactual phenotypes (Saito et al., 2016). This technique has produced models 
such as NL-F and NL-G-F mice, which display Aβ accumulation, Aβ plaque deposition with associated 
inflammatory response, a reduction in synaptic markers, and cognitive deficits (Saito et al., 2014). 
This ‘knock-in’ approach thus allows for a ‘cleaner’ mouse model of early or pre-clinical Alzheimer’s 
disease, which should provide results which are more straightforward to interpret, though these 
models still have limitations of their own (Sasaguri et al., 2017). While more sophisticated, this 
approach to modelling Alzheimer’s disease is relatively new. The various neuropathological features 
and behavioural deficits these mice display require further investigation, and validation across 
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multiple laboratories, which is now beginning to occur (Masuda et al., 2016; Mehla et al., 2019). 
Whilst the future of modelling Alzheimer’s disease in mice may lie in APP knock-in mice, at the 
current juncture they remain relatively new and are still being validated; the Tg2576 mouse was 
therefore an appropriate choice of model for this thesis, due to it being much more established at 
the beginning of this thesis, more widely used, and more well-characterised in terms of 
neuropathology and behaviour. 
 
6.4 Do Alzheimer’s disease mouse models capture neuropsychiatric symptoms? 
 Putting the caveats surrounding APP overexpressing mice to one side, the fact that a 
hedonic deficit was discovered in Tg2576 mice, and that anhedonia is present in patients with mild 
cognitive impairment and early Alzheimer’s disease (Kumar, Jorm, Parslow, & Sachdev, 2006; Lopez 
et al., 2003), suggests that Alzheimer’s disease mouse models could capture the neuropsychiatric, as 
well as cognitive, symptoms of the disease. This collection of neuropsychiatric symptoms, also 
known as BPSD, includes depression, anxiety, agitation and aggression, and disturbed sleep and 
appetite (Haupt, Kurz, & Jänner, 2000; Mirakhur, Craig, Hart, McLlroy, & Passmore, 2004; Petrovic et 
al., 2007). Notably, many of these non-cognitive disturbances seen in Alzheimer’s disease are also 
observed in Alzheimer’s disease mouse models. As has been mentioned in Chapter 1, depression is a 
fairly common symptom of Alzheimer’s disease (Chi et al., 2015), and many Alzheimer’s disease 
mouse models display some type of depressive behaviour, (Abdel-Hafiz et al., 2018; Filali et al., 
2009; Iascone et al., 2013; Romano et al., 2015), although there are certain issues with the 
behavioural tests generally used (discussed in Chapters 2 and 3). Outside of depressive behaviour, 
certain disturbances in sleep and/or circadian activity have been reported in Tg2576 (Wisor et al., 
2005), and APP/PS1 knock-in (Duncan et al., 2012), mice. Further, male Tg2576 mice display more 
aggressive behaviour than their wild-type littermates in the resident-intruder test (Alexander et al., 
2011). 3xTgAD mice consistently display an elevated food intake from an early age, and in later life 
also have a reduced body weight compared against their wild-type counterparts (Knight, 
Verkhratsky, Luckman, Allan, & Lawrence, 2012). After a 12 hour fast, 3xTgAD mice also consume a 
greater amount of food than wild-type mice, and spend more time feeding (Adebakin, Bradley, 
Gümüsgöz, Waters, & Lawrence, 2012). This profile of elevated consumption alongside eventual 
reduced body weight is similar to the consumption and body weight profile of Tg2576 mice shown in 
Chapter 3, both of which are similar to reports of weight loss and hyperphagia in Alzheimer’s disease 
(Aziz et al., 2008; Ikeda, Brown, Holland, Fukuhara, & Hodges, 2002; Morris, Hope, & Fairburn, 1989). 
Taken together, such results suggest that Alzheimer’s disease mouse models could capture a range 
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of BPSD, although care should be taken when interpreting results, again due to differences in 
mutations, promoters, genetic backgrounds, and the use of APP overexpression. Nonetheless, if the 
presence of such non-cognitive symptoms of Alzheimer’s disease is validated through multiple 
studies, including in APP knock-in mice, then it would suggest a basis for investigating the 
relationship between Aβ and BPSD more broadly, and for using such mouse models as a platform for 
testing therapies which target BPSD. 
 
6.5 Future directions 
 The novel findings of this thesis largely related to the Tg2576 hedonic deficit profiled in 
Chapter 3, and the possible biochemical underpinnings of it (e.g. an elevated kappa opioid receptor 
expression). Therefore the future directions which could follow will place more weight on this aspect 
of the empirical data, though consideration will also be given to following up on other results from 
this thesis. These latter points will be covered first, followed by an exploration of how the more 
theoretically consequential findings could be further expanded upon. 
 Profiling cognitive decline in Tg2576 mice, using the object-in-place task, was in practice 
complicated by decreasing object contact times after the first testing period, particularly for Tg2576 
mice. In addition, the repeated cognitive testing in and of itself could also influence biochemical 
changes that may ordinarily occur with age in Tg2576 mice, as well as potentially delay the cognitive 
deficit itself. This effectively means that comparing the emergence of the hedonic and cognitive 
deficits in Tg2576 mice in this thesis is unlikely to be informative. In hindsight the longitudinal 
within-subjects use of an object exploration-dependent test in Tg2576 mice was not the most 
appropriate methodological choice. Future experiments investigating cognition and age in Tg2576 
mice may benefit from a cross-sectional rather than longitudinal design, especially if using tasks 
which rely upon object exploration. Further, a re-examination of the glutamate system in Tg2576 
mice using such a cross-sectional approach should provide biochemical results unaltered by 
repeated testing, and may suggest further therapeutic approaches to improving cognition. As it 
stands, based on the results of this thesis, agents which precisely modulate NMDAR function, in 
particular the NR2B subunit, in such a way as to alleviate memory impairment under pathological 
conditions but not interfere with functionality under ‘typical’ physiological conditions, may merit 
investigation. However, other changes to the glutamate system, such as in scaffolding proteins such 
as PSD-95 or AMPAR subunits cannot be definitively ruled out in Tg2576 mice, owing to the nature 
of repeated testing that was employed in this thesis (Jiang et al., 2015). This will be a matter for 
future studies to confirm or disconfirm. 
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 Chapters 3 and 5 demonstrated that the particular sub-anaesthetic ketamine dosage regime 
selected failed to improve both the Tg2576 hedonic deficit, and the receptor-based changes which 
could underlie the deficit (e.g. elevated kappa opioid receptor expression). However, because this 
thesis was both aiming to capture an age profile and test a therapeutic agent in the same cohorts of 
mice, this necessarily involved trialling an antidepressant agent once the hedonic deficit had been 
present for some time (roughly 11-12 months from its first clear emergence). Therefore future 
experiments going beyond this work could include initiating ketamine treatment at a much earlier 
time (e.g. prior to the deficit appearing), or using a longer treatment period, as well as selecting a 
different dose. In addition, the utility of other potential anti-depressant agents, such as kappa opioid 
receptor antagonists, would be useful to investigate in Tg2576 mice. Importantly, given that 
inflammation and the kynurenine pathway may be non-opioid related routes by which anhedonia 
arises in Tg2576 mice, anti-inflammatory drugs or agents which modulate the kynurenine system 
also merit investigation. 
 Chapter 3 detailed the age-related hedonic deficit displayed by Tg2576 mice, the first major 
finding of consequence in this thesis. While an important finding, the profiling of this deficit is the 
first time lick cluster size has been examined over time in an Alzheimer’s disease mouse model, and 
thus this can be followed up in a number of ways. This hedonic deficit was seen when 4% and 16% 
sucrose solutions were used; a basic expansion upon these experiments would be to replicate the 
Tg2576 hedonic deficit, but across a larger and more comprehensive range of sucrose solutions, in 
order to fully capture the hedonic capacity of Tg2576 mice. In addition, the age-dependency of the 
Tg2576 hedonic dysfunction was only confirmed when grouping the results into 4-5 months of age 
compared against the lick cluster size values averaged across all later time points. Thus the precise 
age of emergence and trajectory could be better profiled in future experiments, by a more judicious 
choice of time points at which to examine lick cluster size. It would also be of interest to compare 
the Tg2576 lick cluster size deficit against other common mouse models of depression, e.g. the 
chronic unpredictable mild stress or olfactory bulbectomy models (Song & Leonard, 2005; Willner et 
al., 1987). Such a comparison would allow for a qualitative evaluation of the Tg2576 hedonic 
dysfunction relative to other ‘standard’ rodent depression models; that is, the questions of how 
similar they might look in terms of hedonic behaviour, and how treatable Tg2576 mice are compared 
to these other models, could be answered. Answering these questions would provide more 
information about the precise nature of Aβ-induced anhedonic behaviour. Given the caveats about 
APP overexpressing mouse models, it would be useful to examine hedonic behaviour in other 
Alzheimer’s disease mouse models, both different APP overexpressing lines and APP knock-in mice, 
in order to better assess the view that this anhedonia is an Aβ-caused event. While the age-related 
177 
 
Tg2576 hedonic deficit is consistent with a causative role for Aβ, whether any particular Aβ species is 
the most salient requires further examination. Soluble Aβ dimers, trimers and dodecamers have all 
emerged as important pathological species in disrupting cognitive processes (Klyubin et al., 2008; 
Lesné et al., 2006; Shankar et al., 2008; Townsend et al., 2006), but whether these are particularly 
important in mediating anhedonia remains unaddressed. As a final suggestion for further 
investigations into the nature of hedonic dysfunction in Tg2576 mice, it should be noted that this 
thesis has only examined lick cluster size in direct response to the consumption of palatable 
solutions. That is, what has been reported is a deficit of consummatory anhedonia. However, 
anhedonia can be fractionated into distinct aspects, including anticipatory anhedonia, motivational 
anhedonia, and reward-related learning (Berridge, Robinson, & Aldridge, 2009; Rømer Thomsen, 
Whybrow, & Kringelbach, 2015; Treadway & Zald, 2011). This thesis was in part a preliminary 
investigation into hedonic behaviour in Tg2576 mice, and as such focused on one aspect of 
anhedonia, direct (consummatory) hedonic response. What would be especially informative is if 
future studies investigated the full repertoire of hedonic processes, in both Tg2576 mice specifically, 
and other Alzheimer’s disease mouse models. Such a set of experiments could reveal whether Aβ 
pathology interacts with multiple components of the hedonic system in mice.
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